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Nerve growth factor (NGF) is a known factor in the development of persistent pain, a condition 
which affects approx. 20% of the UK population. Current therapeutics available for pain exhibit 
limited effectiveness and therefore better targeted and more effective therapeutics are 
essential. Clinical trials using anti-NGF have been successful in consistently alleviating pain of 
patients suffering from chronic pain however the main mechanism of action of NGF is 
unknown. The main aim of this PhD was to investigate the role for TrkA and p75 receptors for 
NGF in the development of persistent pain, specifically targeted to primary sensory afferents. 
The first aim was to determine whether NGF acts directly or indirectly (via other cell types 
reported to express receptors for NGF) on sensory neurons in the development of pain. To 
address this we optimised and characterised a protocol for purifying sensory neuronal cultures 
from dorsal root ganglia (DRG) using magnetic assisted cell sorting (MACS), a method we found 
to reliably produce viable 95% pure neuronal cultures. The second major question surrounding 
the mechanism of NGF is whether NGF acts mainly through the TrkA or the p75 receptor, or do 
the two receptors work in synergy. In order to address this we used two different methods. 
First, we chose to use an approach using viral vectors, both lenti and adeno-associated virus, 
to introduce Cre recombinase into DRG neurons with floxed regions of the NTRK1 and NGFR 
genes to knockout expression of TrkA or p75 respectively. Secondly, we bred a new transgenic 
mouse lines for conditional knockout of TrkA or p75 under the control of tamoxifen by crossing 
the above mentioned floxed mouse lines with an Advillin CreERT2 transgenic mouse, where 
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Chapter 1: General Introduction  
Pain according to the definition provided by the international association for the study of pain 
(IASP) is “an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage” (IASP 2017). For the majority of people 
pain is a protective mechanism which can be described as nociceptive, inflammatory or 
neuropathic (Woolf 2010). Following injury the site of injury becomes inflamed and 
hypersensitive to non-noxious stimuli thereby triggering a drive to protect the injury site from 
further damage, thus allowing the injury to heal (Dubin and Patapoutian 2010; Woolf and Ma 
2007). However, in some cases, following repair of the injury, pain persists and becomes 
chronic, the reasons for which are unclear. Pain itself can also be described as an emotional 
response driven by prior experiences (Smith and Lewin 2009). In this way two people with 
similar injuries can experience different levels of pain. Environmental factors impacting on a 
person’s emotional state can also play a role. For example, a study performed using soldiers 
from world war two found that even patients with severe injuries such as penetrating wounds 
of the torso or abdomen or extensive soft tissue injuries, refused to take more morphine 
stating that they felt either little or no pain. This lack of pain was attributed to the emotional 
turmoil associated with conditions on the fighting front line where the relief of being away 
from the fighting was enough to override the pain from injuries (Beecher 1946). Therefore, 
pain can be described as a complex state.  
Generally, painful stimuli are detected by sensory neurons that innervate peripheral tissues. 
Two thirds of sensory neurons are known as nociceptors. The term nociceptor, first described 
by Sherrington, describes a population of neurons that respond to high threshold painful 




Patapoutian 2010; Woolf and Ma 2007). Following the induction of a painful stimuli 
nociceptors project into the dorsal horn of the spinal cord, where the information is integrated 
and passed up the spinal cord via projection neurons into the brainstem, where the signal is 
passed to cortical regions of the brain, processed, and pain is perceived (Kuner 2010; Kelleher, 
Tewari, and McMahon 2016) (Fig 1.1). During the acute phase of pain, peripheral and central 
sensitisation of the pain pathway occurs, a process in which neurotrophins and other 
inflammatory mediators play a role. However, in some cases following the resolution of injury, 
pain becomes chronic.  
 
Figure 1.1 Schematic outlining the major anatomical pathways involved in pain processing. 
Noxious stimulus is detected in the periphery and transduced into an action potential in a 
nociceptive neuron. Signal is then transmitted to the dorsal horn of the spinal cord where it 
may undergo descending or local modulation. Finally, it is transmitted up through ascending 





The prevalence of chronic pain is a worldwide issue with an estimated 6-8% of the UK 
population alone predicted to suffer from neuropathic pain (Hall et al. 2013; Bouhassira et al. 
2008). Worldwide, estimates of the prevalence of all types of chronic pain have risen by 20% 
(van Hecke, Torrance, and Smith 2013; Breivik et al. 2006) which results in a significant 
economic burden (The national acamedies press 2011) since treatment is expensive. Chronic 
pain additionally has a devastating impact on the quality of life in affected individuals. Current 
treatments for pain are unsuitable for long term use with some analgesic treatments such as 
opioids having negative side effects including addiction (Z. Y. Wang et al. 2015). However, 
there are currently a number of phase II and III clinical trials in place to develop novel 
therapeutics (Rice et al. 2014; Schwertner et al. 2013; M. T. Brown et al. 2012; Ford 2012) 
including anti-NGF monoclonal antibodies. Despite success of such alternative therapeutics, a 
number of side effects have been reported (Hertz and Fields 2012) leading to a need for 
further research in the field. We therefore investigate in this study the detailed role of NGF 
signalling in pain.  
1.1 NGF, TrkA and p75 
Nerve growth factor (NGF) is a member of the neurotrophin (NT) family of growth factors (GFs) 
which also include brain derived neurotrophin factor (BDNF), neurotrophin-3 and 4/5 (NT-3 
and NT-4/5). It was first discovered in 1948 by Elmer Bueker, confirmed by Rita Levi-Montalcini 
(Cohen, Levi-Montalcini, and Hamburger 1954; Levi-montalcini 1987) and then later isolated by 
Stanley Cohen in 1960 from the submandibular gland in mice (Cohen 1960). NGF was the first 
member of the NT family to be positively identified, with BDNF and NT-3 isolated 
subsequently. Over the past 60 years our understanding of this molecule and its role in disease 




NGF signals via two receptors, the high affinity TrkA receptor and a lower affinity p75 
neurotrophin receptor (p75).  
 
Figure 1.2 Schematic showing the structure of the NGF receptors TrkA and p75 a- Overview of 
TrkA receptor and b- overview of p75 receptor. 
 
TrkA is a member of the tropomyosin family of tyrosine receptor kinases, encoded on 
chromosome 3 and consisting of 17 exons. It is a transmembrane protein with a highly 
conserved tyrosine kinase domain in the intracellular region, a helical transmembrane domain 
and a leucine/cysteine rich extracellular domain containing an IgG-C2 domain (Chao, 




member of the NT family where TrkA is selective for NGF, (with some activation by NT-3). TrkB 
is selective for BDNF and NT-4/5 and TrkC is selective for NT-3. In the presence of NGF the TrkA 
receptor monomers dimerise and the intracellular part of the receptor becomes 
autophosphorylated which leads to the activation of a number of growth and survival 
downstream signalling pathways including MAPK, AKT and PLCγ (Pezet and McMahon 2006; 
Kiris et al. 2014; Wiesmann et al. 1999). Phosphorylation of TrkA at Y490 residue permits 
interaction of TrkA with Shc which in turn activates the MAPK and Ras pathway via Grb-SOS  
(Capsoni et al., 2011). Y785 phosphorylation however has been shown to facilitate the binding 
of proteins containing the SH2 domain such as PI3K (Capsoni et al. 2011), CHK1 and PLCγ. 
Interaction of TrkA with CRK (adaptor protein) has also been reported to activate ERK 
signalling (W J Friedman and Greene 1999) (Fig 1.3).  
P75 is a member of the tumour necrosis factor receptor 1 (TNFR1) superfamily and is described 
as a promiscuous receptor as it is capable of interacting with all members of the NT family 
(Capsoni and Cattaneo 2006; K. F. Lee et al. 1992). It is encoded on chromosome 11 and 
contains 6 exons. Like the Trk receptors, p75 is also a transmembrane protein consisting of a 
helical transmembrane domain. However, the extracellular domain contains four cysteine rich 
repeat regions and there is a highly conserved unique intracellular domain which includes a 
death domain region (Chao, Hempstead, and Barbara 1995) (Fig 1.2b). Therefore, signalling of 
NGF via the p75 has been described to activate apoptotic pathways and exert its effect via ERK, 
JNK and NF-κB via activation of the IL-1 receptor associated kinase (IRAK). However, when co-
expressed with TrkA it can promote growth (Meeker and Williams 2014; He and Garcia 2004; 
W J Friedman and Greene 1999; Mamidipudi, Li, and Wooten 2002) (Fig 1.3).  
The distinction of NGF signalling via TrkA for growth and survival and via p75 for activation of 




investigation and greater understanding of NGF signalling has thus far uncovered a more 
complex signalling process.  
 
Figure 1.3 NGF exerts its biological effects via TrkA and p75. NGF signalling via TrkA activates 
the PI3K-Akt, ERK and PLCγ signalling pathways. TrkA is capable of interacting with p75 and 
there is some evidence of transactivation of TrkA from G-protein coupled receptors. Activation 
of p75 signals apoptosis through the JNK pathway, however, in the presence of TrkA p75 can 
activate survival pathways. P75 is capable of interactions with the sortilin, which can act as a 
co-receptor for proNGF signalling through p75. In addition, there is some evidence that p75 is 





NGF is transcribed as a pro-form (proNGF). Following cleavage of the pre NGF signal (pre-
proNGF) on entry into the endoplasmic reticulum, proNGF is stored in the Golgi body. This 
proNGF is then cleaved further by furin to release mature NGF. This mature NGF is stored in 
vesicles and transported to the nerve terminals while the pro domain of NGF is recycled 
(D’Onofrio et al. 2011). It has been shown that both the proNGF and mature NGF can be 
released by cells, particularly following injury, where the pro-form appears to be a selective 
agonist for p75 (Hempstead 2009; Bruno and Cuello 2006). In addition, a number of other 
receptors have been identified which modulate NGF signalling. Sortilin for example, a receptor 
mainly associated with endosomes can control the trafficking of receptors such as TrkA to the 
cell surface, but in addition, has also been shown to interact with the p75 as a co-receptor for 
proNGF signalling (Capsoni and Cattaneo 2006; Meeker and Williams 2014). Other studies 
suggest that the Nogo receptor interacts with the p75 receptor and is able to modulate its 
signalling, or that activation of G-protein coupled receptors can transactivate TrkA in the 
absence of NGF (Meeker and Williams 2014). Finally, despite the two receptors controlling 
opposing signalling pathways there is evidence that TrkA and p75 can interact and modulate 
downstream signalling (Meeker and Williams 2014).  There is evidence that cells co-expressing 
TrkA and p75 are more specific for NGF and bind NGF with a faster association rate (Chao, 
Hempstead, and Barbara 1995; Canossa et al. 1996). Hence, NGF signalling is complex, and 
depends on the presence of both NGF forms and the pattern of different receptors. What is 
clear however is that many of the biological actions of NGF depend on signalling through both 
NGF receptors ( a Patapoutian and Reichardt 2001) (Fig 1.3).  
In the adult nervous system, TrkA is expressed on peptidergic C fibres, sympathetic post-
ganglionic neurons and small populations of CNS neurons (Usoskin et al. 2014; Thakur et al. 
2014; Richner et al. 2014). There is also evidence that TrkA is expressed in the cortex and 




cells are believed to express TrkA including mast cells, macrophages, satellite glial cells (SGC), T 
and B cells (Aloe et al. 2012; Chan et al. 2004). However, expression of TrkA on immune cells is 
mostly  not supported by recent RNA sequencing studies (Gosselin et al. 2014; Lavin et al. 
2014; Mo et al. 2015). 
 P75 has a more widespread expression pattern, it is co-expressed with TrkA on peptidergic 
nociceptors but is also present on other sensory neurons including some non-peptidergic 
neurons, and in moderate amounts on other cells types, including sympathetic post-ganglionic 
neurons, neutrophil granulocytes, macrophages (Richner et al. 2014; Aloe et al. 2012) and 
Schwann cells surrounding sensory axons bundles of C fibres (Ebenezer et al. 2007; Aloe et al. 
2012) . Surprisingly, there is little expression in the CNS and, as with TrkA,  expression on 
immune cells is not well supported in recent genome wide sequencing studies (Gosselin et al. 
2014; Lavin et al. 2014; Mo et al. 2015). 
1.2 Role of NGF in development  
NGF is essential for the development and survival of sensory and sympathetic neurons (Patel 
et al. 2003; Delree et al. 1989). Knockout of NGF in mice showed that despite survival in utero, 
knockouts do not survive past weaning with a maximum lifespan of 28 days. Compared to 
littermates, NGF null mice display developmental delays in hair growth and ptosis and a 
marked insensitivity to noxious stimuli. In addition, they exhibit a severe loss of cells in the 
superior cervical ganglia (SCG) and a 70% loss of neurons in the dorsal  root ganglia (DRG), 
specifically small diameter neurons (Crowley et al. 1994).  TrkA knockout mice show a similar 
phenotype to the NGF knockout mice. As with the NGF knockout mice, TrkA knockouts are 
viable in utero surviving to a maximum of 55 days post-natal. Sensory defects as measured by a 
failure to detect deep pinpricks in whisker pads and rear paws and thermal hyposensitivity are 




mutilation (Smeyne et al. 1994). These mice also show a loss of neurons in the SCG and a 70-
90% loss of DRG neurons, preferentially small diameter neurons (Smeyne et al. 1994). In 
contrast, mice lacking the p75 are born physically normal and are fertile. Mice are observed to 
exhibit a loss of epidermal nerve fibres including those positive for calcitonin gene-related 
peptide (CGRP) (K. F. Lee et al. 1992; Bergmann et al. 1997) and have a deficit in thermal 
sensitivity (K. F. Lee et al. 1992) and mechanical sensitivity (Bergmann et al. 1997) with some 
evidence of self-mutilation in hind paws by 4 months of age (K. F. Lee et al. 1992). Although 
there is no indication of any effect in SCG (K. F. Lee et al. 1992), DRGs appear noticeably 
smaller however there is no significant loss in a particular population of neurons (Bergmann et 
al. 1997). Overall, this suggests that NGF signalling via the TrkA and p75 receptors plays a 
dominant role in development.  
Evidence from human studies further suggests a role for NGF in development. Hereditary 
sensory and autonomic neuropathy (HSAN) IV and V patients exhibit insensitivity to pain as a 
result of an improper nervous system development. HSAN IV (also known as CIPA – chronic 
insensitivity to pain with anhydrosis) is an autosomal recessive disease which arises from a 
mutation in the NTRK1 gene encoding the TrkA receptor. It was first described in 1996 when 
testing of multiple families of CIPA patients showed mutations resulting in a frameshift or an 
alternate splice site in exons 1-3 (Yasuhiro Indo et al. 1996). Since then multiple mutations 
have been discovered across the 17 exons of TrkA (for review see (Y Indo 2012)). As previously 
described, NGF is a key regulator during the development of the sensory and sympathetic 
nervous system and in maintenance of the cholinergic neurons in the basal forebrain (Capsoni 
and Cattaneo 2006). As a result patients with HSAN IV show symptoms of insensitivity to pain 
which can result in self-mutilation and serious injuries such as fractures and mental retardation 
(Yasuhiro Indo et al. 1996) in addition to other symptoms including anhydrosis (inability to 




an autosomal recessive disease where patients exhibit  insensitivity to pain without anhydrosis 
or mental retardation as a result of a mutation in the NGFB gene encoding NGF (Capsoni et al. 
2011). The R100W mutation in NGFβ in HSAN V has been labelled as a “painless” NGF 
mutation (insensitivity to pain) which results in an inability for cleavage of proNGF to mature 
NGF and a decreased ability for this proNGF mutant to bind to p75. Interestingly, in a 
preclinical model, behavioural tests using a similar mutation, R100E, showed a decreased 
sensitivity to pain compared to wild type NGF treated animals (Capsoni et al. 2011). 
Investigation of common signalling pathways showed that R1000W and R100E mutations 
resulted in a loss of phosphorylation of TrkA residues Y490 and Y785 (Capsoni et al. 2011) 
which suggests that TrkA downstream signalling plays an important role in the development of 
hyperalgesia. However, a mutation in the NGFB gene has recently been reported in a Bedouin 
family which results in a frameshift in the NGFB gene. These patients exhibit signs of a HSAN IV 
phenotype despite not carrying a mutation in the NTRK1 gene (Carvalho et al. 2011). 
The effects observed in global knockout rodent models and HSAN IV and V patients are both 
linked to mutations in the NGF signalling pathway (Yasuhiro Indo et al. 1996; Einarsdottir et al. 
2004; K. F. Lee et al. 1992; Bergmann et al. 1997; Crowley et al. 1994; Smeyne et al. 1994). The 
chronic insensitivity to pain in these genetic diseases is the consequence of deficient NGF 
signalling early in development where sensory and sympathetic neurons are NGF dependent 
(Crowley et al., 1994). NGF secreted from peripheral tissue binds to the peripheral terminals of 
axons branching out from the DRG which is then retrogradely transported back to the cell 
soma, as shown in experiments using labelled NGF. Furthermore, these experiments showed 
that following axotomy, neurons underwent apoptosis as a result of reduced NGF signalling 
from the peripheral terminals (Levi-montalcini, 1987). Therefore, in NGF or TrkA knockout 
mice or human patients with HSAN IV or V, the failure of NGF to either be secreted in the 




hyposensitivity to mechanical and thermal noxious stimuli arises. Since this effect is limited to 
TrkA expressing C fibres all other DRG sensory neurons develop normally, therefore, there is 
no loss in proprioception for example which is controlled by large diameter fibres (Hudspith, 
Siddall, and Munglani 2006).  
1.3 Changing role of NGF postnatal 
The role of NGF in development changes abruptly in the post-natal animal. It has been 
described that from P3 to P14 there is a downregulation in TrkA expression from 80% of DRG 
neurons to 40-50% of neurons, which correlates with an increase in the expression of Isolectin 
B4 (IB4) positive neurons – a marker of non-peptidergic C fibres (Bennett et al. 1996). This 
change in NGF dependence and differentiation to peptidergic/non-peptidergic C fibres from 
early developmental events hinges on Runx1 expression which acts as a molecular switch and 
is only expressed in non-petidergic fibres (Lallemend and Ernfors 2012; Wainger et al. 2014; 
Blanchard et al. 2014). Fully differentiated neurons which are NGF independent (for survival) 
are established by P14 in rodents.  
In the post-natal brain, NGF has been implicated in Alzheimer’s disease (AD). Although it is not 
essential in early development (Crowley et al. 1994) of cholinergic neurons it has been well 
established to have an essential role in the maintenance of these neurons in the basal 
forebrain through retrograde transport of NGF through them from the cortex and 
hippocampus to the basal forebrain, a process which is disrupted in AD leading to the 
apoptosis of cholinergic neurons. Studies in AD11 transgenic mice (a model of AD) showed 
intranasal application of NGF rescued loss of cholinergic neurons and cognitive defects. 
Furthermore in AD12 mice (a model of AD) where NGF is neutralised and p75 is knocked out 
there is absence of β-amyloid deposits or plagues suggesting that there is a complex role for 




1.4 Functional role of NGF in the adult nociceptive system  
In the adult the most well described role for NGF is in the development of persistent pain. This 
is supported by a number of animal studies using pharmacological methods to targeting the 
NGF/TrkA pathway. A number of peripheral cells have been shown to secrete NGF in response 
to injury including immune cells, fibroblasts, neurons, smooth muscle cells and epithelial cells 
(Richner et al. 2014). Andreev et al showed that injection of NGF subcutaneously into the hind-
paw of rats at doses as low as 250ng could elicit a sustained thermal hyperalgesia that lasted 
for several hours (Andreev et al. 1995). This was confirmed by Lewin et al, 1993, who showed 
that injection of exogenous NGF into the paw resulted in hyperalgesia as seen by a reduced 
threshold to mechanical and thermal stimuli (Lewin, Ritter, and Mendell 1993). Furthermore, it 
has been reported that treatment of mice or rats with anti-NGF or a TrkA blocker results in an 
attenuation of thermal and mechanical allodynia in a wide range of animal models of 
persistent pain (Bennett et al. 1998; McMahon et al. 1995; Woolf et al. 1994; Lewin, Ritter, 
and Mendell 1993). Woolf et al, 1994, tested an anti-NGF antibody in rats injected with 
complete Freud’s adjuvant (CFA), an inflammatory model which induces mechanical and 
thermal hyperalgesia. Compared to CFA treated control animals, animals treated with anti-NGF 
monoclonal antibody showed a significant decrease in thermal and mechanical hyperalgesia 
following CFA treatment (Woolf et al. 1994). McMahon et al, 1995, used intra-plantar pumps 
in the hind paws of rats to deliver a TrkA-IgG fusion molecule which blocks signalling of NGF 
through the TrkA receptor. They observed that rats treated with TrkA-IgG and capsaicin, which 
induces inflammatory pain,  exhibited reduced thermal hypersensitivity compared to animals 
treated with capsaicin alone (McMahon et al. 1995). In regards to human diseases NGF has 
been linked to a number of different persistent pain conditions including osteoarthritis (OA), 
lower back pain (LBP), diabetic peripheral neuropathy (DPN), bladder pain syndrome (BPS), 




al. 2012; Capsoni and Cattaneo 2006; McCaffrey et al. 2014; Alvarez and Levine 2014; Jiang, 
Liu, and Kuo 2014).   
NGF plays an important role in the development and maintenance of chronic pain in adult 
animals (Fig 1.4). Firstly, NGF has a role in the development of peripheral sensitivity. Following 
peripheral injury or inflammation, there is recruitment of immune cells to the injury site to 
which the body responds by secreting multiple factors including growth factors (e.g. NGF), 
cytokines and chemokines as part of an “inflammatory soup”. Upon nerve injury neurons 
immediately release chemokine ligand 1 (CXCL1) and CCL2 which recruit early inflammatory 
responders – the resident macrophages. Once activated these resident macrophages secrete 
pro-inflammatory mediators such as NGF, cytokines and chemokines at the site of injury 
(Barouch et al. 2001; Zhuang et al. 2007). Neutrophil granulocytes attracted by NGF and CXCL1 
migrate into the site and secrete further inflammatory mediators (Perkins and Tracey 2000) 
which in combination with macrophages result in the migration of further macrophages and 
monocytes (immature macrophages activated to become mature macrophages) to the injury 
site. Schwann cells secreting NGF and GDNF (glial derived neurotrophin factor) act to sensitise 
neurons which results in secretion of pro-inflammatory mediators, such as substance P 
(O’Connor et al. 2004), CGRP, bradykinin and nitric oxide (NO) which vasodilates blood vessels 
resulting in swelling and oedema. In addition to Schwann cells releasing NGF to sensitise 
neurons, in inflammation Schwann cells can activate resident macrophages, neutrophil 
granulocytes and mast cells stimulating further release of pro-inflammatory mediators such as 
prostaglandin and TNFα (Tofaris et al. 2002). TNFα bound to macrophages further signals the 
release of pro-inflammatory mediators via the MAPK pathway. NGF bound to macrophages 
can stimulate further release of TNFα. Altogether, this results in the injury site being bathed in 
an “inflammatory soup” of NGF, cytokines and chemokines with positive feedback loops in 





Figure 1.4 Mechanisms of NGF in persistent pain – peripheral sensitisation, central 
sensitisation and hyper-innervation a- Schematic of peripheral sensitisation. Injury or 




NGF, bradykinin and PGE2 which bind to receptors on peripheral terminals of nociceptors. This 
results in various processes including receptor modulation, channel modulation and gene 
expression which all contribute to the process of peripheral sensitisation. b- Schematic of 
central sensitisation. Noxious stimuli can also be amplified by processes within the CNS. The 
pharmacology is best understood at a spinal level, where the NMDA receptor plays a pivotal 
role. This form of modulation is often referred to as central sensitisation. c- Evidence of 
nociceptor sprouting in some models of persistent pain. This data shows sections of bone 
immunostained for CGRP+ sensory nerve fibres in (i) normal mice and (ii) mice with tumours 
implanted into intramedullary space, and (iii) mice with tumours but treated with anti-NGF. 
Note the NGF-dependent increase in innervation in this model. However, following anti-NGF 
treatment in tumour implanted mice hyper-innervation was attenuated (Jimenez-Andrade et al, 
2011) (taken from Kelleher et al, 2016). 
 
including microglia (Clark et al. 2007). Neurons alone have receptors for substance P, TNFα, 
prostaglandin E2 (PGE2), bradykinin and NGF which all function to sensitise the neuron via the 
insertion of TRPVI channels into peripheral terminals (A. Patapoutian, Tate, and Woolf 2009). 
Binding of NGF, and other sensitising compound present in the “inflammatory soup”, 
(Bradykinin, PGE2, TNFα and endothelin to name a few), to receptors on peripheral 
nociceptors induces rapid sensitisation of the nociceptive response (A. Patapoutian, Tate, and 
Woolf 2009; Dubin and Patapoutian 2010). NGF (unlike Bradykinin or other sensitising 
molecules) is also retrograde transported to the cell soma. Increased NGF in the soma results 
in a phenotypic switch and induces rapid transcription of many pain related genes including 
TRPV1, which then signals for insertion of this capsaicin sensitive ion channel into the 
peripheral terminal, thus increasing the sensitivity of the neuron to depolarisation and the 




Woolf 2009; Basbaum et al. 2009). This has been confirmed in vitro where NGF has been 
shown to be important in sensitisation of DRG neurons. Neurons were desensitised following 
repeated exposure to capsaicin to activate TRPV1 ion channel, however, following treatment 
of neurons with NGF, they were found to be sensitised and responsive to further exposure to 
capsaicin (Bonnington and McNaughton 2003). Other pain related genes, such as BDNF, are 
packed into dense core vesicles and released in response to activity from central processes on 
nociceptors, contributing to central sensitisation.   
Intrathecal injection of NGF has been shown to increase the expression of BDNF in TrkA 
positive DRG neurons to almost 85% neurons expressing BDNF (compared to 21% in controls), 
compared to a minimal increase in BDNF expression in TrkB or C positive DRG neurons (Kerr et 
al. 1999; Michael et al. 1997). In addition, intrathecal NGF results in an increase in the number 
of axons expressing BDNF in the spinal cord (Michael et al. 1997; Kerr et al. 1999), projecting 
into laminae I and II from dorsal roots, which also appear to co-express CGRP, another typical 
marker of TrkA positive neurons (Michael et al. 1997).  Further to this, BDNF has been shown 
to enhance the effect of NMDA receptor on central sensitisation in a model where rats were 
treated with NGF prior to injection with a TrkB-IgG antibody, after which a reduction in the 
second phase response to the formalin test was observed, which is also linked to the process 
of central sensitisation (Kerr et al. 1999).  
Another potential mechanism is that NGF causes pain by promoting sprouting of nociceptive 
fibres in peripheral tissues.  NGF has a well-established role in promoting growth of sensory 
and sympathetic neurons in vitro and in vivo. In several pain states, for example bone cancer 
pain, there is an apparent effect for NGF to promote the sprouting of axon terminals of 
nociceptive neurons resulting in a hyper-innervation of peripheral tissue. It is unclear what 
functional consequence this has on the nociceptors, but it could result in an increased 




for example sprouting of CGPR positive fibres can be blocked by early treatment with anti-NGF 
(Jimenez-Andrade et al. 2011). In addition, anti-NGF treatment in a mouse model of bone 
cancer pain resulted in an attenuated guarding and flinching behaviour in anti-NGF treated 
mice compared tumour only controls (Sevcik et al. 2005; Jimenez-Andrade et al. 2011; 
McCaffrey et al. 2014). This was accompanied by a reduction in markers of peripheral 
sensitisation – ATF-3 and CD-68 positive macrophages in the DRG – and central sensitisation – 
dynorphin-IR and c-fos in deep laminae of the spinal cord (Sevcik et al. 2005).  
Overall, treatment with anti-NGF compounds showed an attenuation of pain related 
behaviours in accordance with a reduction in peripheral and central sensitisation markers and 
reversal of hyper-innervation of peripheral tissues suggesting that NGF plays a diverse role in 
the adult nociceptive system.  
1.5 Therapeutic potential of anti-NGF treatment in experimental 
and clinical studies  
Given the range of biological effects of NGF on the nociceptive system, it is not surprising that 
multiple studies have explored the importance of this factor as a pain mediator in a variety of 
experimental pain models. These studies began in the 1990’s and are still being performed 
today.  The early preclinical studies focussed on inflammatory models induced for instance by 
carrageenan or CFA (e.g. (Woolf et al. 1994; McMahon et al. 1995).  Over the years the range 
of models tested has increased dramatically and one of the striking features of this literature is 
the consistency of anti-NGF effects. There is good preclinical evidence for targeting the NGF 
signalling as an effect analgesic in a number of pain states including acute burn injury, UV 





Following these findings in preclinical models a number of anti-NGF therapies developed for 
the clinic have progressed into phase III clinical trials, mainly in osteoarthritis (OA) patients. 
Multiple anti-NGF monoclonal antibodies are currently in phase III trials including tanezumab 
(Pfizer), fasinumab (Regeneron) and fulranumab (Janssen and Regeneron). Typically, anti-NGF 
treatment in clinical trials is administered as part of a combined therapeutic approach with a 
non-steroidal anti-inflammatory drug (NSAID), the current recommended treatment for OA 
patients. However, due to an increase in the number of side effects reported, including cases 
of rapidly accelerated OA (RPOA) and osteonecrosis in both affected and unaffected joints of 
OA patients clinical trials were put on hold in 2010 by the FDA, and re-evaluated in 2012 (Hertz 
and Fields 2012; Holmes 2012; Chang et al. 2016). As of March 2015 the hold on clinical trials 
was lifted on most of the OA trials under the condition of better screening for adverse effects 
including the autonomic nervous system (Mullard 2015). The incidence of rapidly progressing 
OA seems to be associated with the combined use of anti-NGF and NSAID treatment so the 
new trials will focus on anti-NGF monotherapies. However, there was a success in a recent 
clinical trial where tanezumab and NSAID such as diclofenac was combined. This therapy 
resulted in a reduction in pain in OA patients with no adverse side effects observed (Balanescu 
et al. 2014).  
Osteonecrosis in joints following treatment could be explained by an increase in weight 
bearing on affected joints following pain relief however in a number of cases osteonecrosis 
was also seen in non-weight bearing joints and while weight bearing may be a factor in 
accelerating degeneration, it may not be the underlying cause (Seidel and Lane 2012). 
Fasinumab, developed by Regeneron, is also a monoclonal antibody specific for NGF 
extensively tested in OA patients. Treatment with this drug resulted in a 50% reduction in pain 
as measured by the WOMAC score measuring joint pain, stiffness and function. As success in 




been declared effective in these clinical trials. Side effects from Fasinumab ranged from mild to 
moderate with increasing dosage. The most severe symptoms included joint pain and swelling 
predominately (Tiseo et al. 2014). 
Despite side effects, results from clinical trials have shown a robust reduction in pain 
compared to placebo in patients in a variety of conditions. Tanezumab has been most widely 
tested, showing a striking dose dependent effect on reducing pain in OA, with a reduction in 
pain scores  from 20-50% with increasing doses (Lane et al. 2010). This striking effect has been 
repeated in a number of other subsequent trials. In addition to OA, there have also been 
beneficial effects of anti-NGF observed in lower back pain (LBP), diabetic peripheral 
neuropathy (DPN) and bladder pain syndrome in animal models and clinical trials (Bannwarth 
and Kostine 2014; Capsoni and Cattaneo 2006; Aloe et al. 2012).  This includes fulranumab 
treatment in patients with DPN, which showed a dose dependent alleviation of pain despite 
early termination of the phase II clinical trial in response to the FDA hold (H. Wang et al. 2014). 
A meta-analysis of anti-NGF treatment in LBP patients indicated that anti-NGF has a beneficial 
role in alleviation of pain and functional recovery (mainly tanezumab), although after 
screening over a thousand studies, only 4 randomised controlled trials were analysed, which 
further implicates a need for deeper research into the effects of anti-NGF (Leite et al. 2014).  
There have also been unsuccessful clinical trials with anti-NGF agents. These include chronic 
pancreatitis, endometriosis and painful intervertebral discs (for review see (Pezet and 
McMahon 2006)). Of course, it is not known if these negative findings are the result of patient 
heterogeneity, poor trial design or due to NGF not being an important pain mediator in these 
conditions. The range of effect sizes observed in different anti-NGF trials suggests that other 
important pain mediators beyond NGF contribute to clinical pain states. Further clinical trials 




Overall, both animal models and clinical trials show anti-NGF to be a highly effective as an 
analgesic therapeutic (Bannwarth and Kostine 2014). It is not yet a licenced product, and the 
adverse effects reported may frustrate full development of anti-NGF. However, since there are 
multiple opportunities to interfere with NGF signalling it is likely that some of these will be 
explored for potential analgesic effects, hopefully eliciting less side effects.   
1.6 Current questions in the NGF field 
Despite an extensive amount of research into functional and pharmacological effects of NGF 
there are still a number of unanswered questions that need to be addressed.  
Although it has been established that there is a role for NGF in pain through a number of 
mechanisms, it is still unclear what the relative importance of these are. As described above, 
various cells in the PNS and CNS express TrkA and/or p75 and secrete NGF and/or other 
sensitising components of the “inflammatory soup”. Therefore, it is reasonable to question 
whether NGF sensitisation of sensory neurons is a direct effect of NGF on the neurons 
themselves, or if it is an indirect effect via another cell type. In addition, there is some debate 
as to how NGF signals through its two different receptors. From a simplified view, NGF 
signalling via TrkA promotes survival and growth and signalling through p75 promotes 
apoptosis. However, almost 60 years after the discovery of NGF, the picture became more and 
more complicated with more potential contributions and subtle alterations to the signalling 
pathway coming from a number of different sources as described above (chapter 1.1). It is 
possible that either TrkA or p75 has an overpowering effect or there could be subtle 
modulation of signalling between the two receptors. Finally, the contribution of proNGF versus 
the mature NGF form in the NGF signalling pathway is unclear.   
It has been well established that OA patients treated with anti-NGF have a beneficial effect in 




multiple clinical trials the effectiveness and mechanism of anti-NGF is still undergoing testing 
due to a number of unexplained side effects. Questions such as what is causing these 
underlying adverse side effects and the suggested impact on the autonomic nervous system 
require further investigation. It is also not known why anti-NGF treatments are so effective. 
There are a number of other components of the “inflammatory soup” that could be a useful 
target for chronic pain therapies, however, they are as yet undiscovered, in the early testing 
phases, and might not have as much potential as anti-NGF therapies. The effect might be 
explained with a multi-action effect on peripheral and central sensitisation and, in the case of 
bone cancer pain, in some cases reversal of hyper-innervation of tissue?   
In conclusion, over 60 years of research has shown that NGF is essential in development of 
sensory and sympathetic neurons and nociceptive pain in the adult organism. Animal models 
and more recently clinical trials have shown that treatment with anti-NGF is highly effective in 
the alleviation of pain, specifically in OA, over and above currently prescribed treatments. If 
the side effect profile of anti-NGF can be overcome or mitigated, it is likely that this treatment 
could become an important addition to analgesic armoury for patient use.    
1.7 Aims of the study 
As described above there is great potential for the use of anti-NGF therapies in pain however 
there are a number of unanswered questions surrounding the role of NGF in pain. In this study 
we aimed to address two of these questions. First, we investigated whether NGF signals 
directly onto neurons, or indirectly via non-neuronal cells. We did so by optimising and 
characterising a method for purifying neuronal cultures from adult DRG using magnetic 
assisted cell sorting (MACS). Second, we aimed to investigate whether one or both of the NGF 
receptors, TrkA and p75, play a role in the development of hyperalgesia. To address this, we 




the adult mouse using the Cre-LoxP system. The first approach involves the use of viral vectors 
including both lenti and adeno-associated viruses to deliver Cre into the DRG both in culture 
and in the animal. The second approach involves the breeding of new conditional inducible 
knockout mouse line for both the TrkA and the p75 receptor, where knockout of either the 














Chapter 2: MACS purification as a 
method to generate pure neuronal 
cultures from DRG 
2.1 Introduction: 
As described in the previous chapter (chapter 1.4) there is increasing evidence for the role of a 
neuroimmune interaction in the processing of acute and chronic pain. It is known that 
following injury a number of growth factors, inflammatory mediators, chemokines, and 
cytokines including NGF, bradykinin and prostaglandin E2 (PGE2) to name a few are secreted 
as components of the “inflammatory soup”. However, the mechanism of action of these 
factors, including NGF, is not fully known e.g. whether the factors bind directly to the 
peripheral terminals of sensory neurons or there if they act indirectly via non-neuronal cells 
expressing the ligand receptors of the inflammatory soup. One way to decipher the 
mechanism of action is purifying specific cell types, such as neurons, for which in vitro 
experiments of individual cell types or co-culture systems can be treated with specific 
components of the “inflammatory soup”, such as NGF. 
2.1.1 Current methods of generating pure neuronal and non-neuronal cultures 
A number of methods have been described in the literature to purify specific cell types from 




immunopanning, fluorescence-associated cell sorting (FACS) and depletion of other cell types 
using chemical reagents.  
A BSA cushion is used in order to remove a variable proportion of satellite glial cells (SGC) from 
a DRG cell culture preparation. However, this method is only valid to reduce the number of 
SGCs does not fully purify the neuronal culture, it merely enriches the number of neurons in 
the culture (de Luca, Faroni, and Reid 2015). Following digestion, dissociation and titration of 
DRG cells they are filtered and then pipetted carefully onto the top of a 15% BSA cushion and 
centrifuged to pellet cells to the bottom of the tube through the cushion. Using this method, a 
proportion of the SGCs within the single cell suspension are retained in the BSA cushion and 
therefore removed with the supernatant. Passing single cell suspensions through a percoll 
gradient can also be used to clean up and enrich cultures by removing myelin and large 
aggregates of cells for a number of tissues (Delree et al. 1989). Delree et al  for example used a 
percoll gradient to clean myelin from adult DRG cell suspensions before isolating neurons 
through a small filter of 10 µm which allows the passage of smaller non-neuronal cells and 
neuronal cells were retained on the filter itself whereas Nguyen et al used a percoll gradient to 
clean up tissue samples digested from the dorsolateral caudal neocortex (V. Nguyen and 
McQuillen 2010; Delree et al. 1989). 
 Performing immunopanning requires a single cell suspension firstly placed onto a negative 
panning plate coated with antibodies against a cell type to be removed from the suspension 
for 45 minutes. This step can be repeated with the same or a different negative panning plate 
before the cell suspension is placed onto a positive panning plate coated with an antibody 
against the cell type of interest. After incubation for 45 minutes, all unbound cells are removed 
with the supernatant. Trypsin is added to the positive panning plate and cells are collected and 
plated as recommended for the cell type of interest (Winzeler and Wang 2013). Zhang et al 




was an effective and robust method for isolating RGCs while maintaining the cells neuronal 
morphology and expression of well-known marker proteins such as Thy-1. Approximately 70% 
of RGC attached and survived post plating, and cultures could be maintained for up to 1 month 
at which point there were only 30% RGC remaining. This 2 step protocol involved 2 rounds of 
incubation on the negative panning plate coated in goat anti-mouse IgG, on top of which the 
single cell suspension was placed after incubation with a mouse anti-rat macrophage 
antiserum to tag all of the macrophages in the culture. Following this the cell suspension was 
then plated onto the positive panning plate coated in anti-Thy-1 antibody to capture the RGC 
(X.-M. Zhang et al. 2010).  
FACS utilises a panel of antibodies to isolate specific cell types. It has been widely used in the 
immunology field for many years. Recently, with increasing interest in neuroimmune 
interactions, it is also increasingly used in the pain field. This includes studies like Zhang et al 
which investigated the recruitment of macrophages in the PNS and the CNS after injury. They 
took bone marrow transplants from a bone marrow chimeric mouse line which have a GFP 
tagged cells and injected this into irradiated wildtype C57Bl mice 3 weeks before a dorsal root 
ganglionectomy was performed. FACS was then used to isolate GFP vs non GFP expressing 
macrophages to ask whether circulating macrophages were limited to the PNS or if they were 
also recruited into the CNS as part of a repair mechanism (G. Zhang, Hoffman, and Sheikh 
2014). Other studies using FACS have used this method to separate populations of neurons 
that have been injected with tracers. For example, Reinhold et al injected Fluoroemerald (FE) 
into a nerve proximal to the site of a chronic constriction injury and 1-dioctadecyl-3,3,3,3-
tetramethylindocarbocyanine perchlorate (Dil) into the plantar skin of the hindpaw in order to 





Some methods purifying neurons involve the depletion of non-neuronal cells using chemical 
reagents. Kar et al collected superior cervical ganglia and despite using MACS technology to 
dissociate cells, neurons were enriched by treating cultures with 5-fluoro-2’-deoxyuridine, an 
anti-mitotic inhibitor, to prevent the growth of non-neuronal cells in the culture (Kar et al. 
2013). This same technique has also been used by Ross et al after treatment of DRG cultures 
for 3 weeks (Ross et al. 2001). When using fluorodeoxyuridine for neuronal enrichment of DRG 
cultures three treatments within two weeks were needed and even then the achieved 
enrichment did not reach the experimental requirements for purity. Therefore, this method 
has later been improved with a treatment of Ara-C (R. Liu, Lin, and Xu 2013). Using Ara-C it was 
found that a single high dose treatment of anti-mitotic inhibitors flurorodeoxyuridine and Ara-
C for 72 hours was enough to obtain 99% neuronal purity from DRG cultures after only one 
week in culture. Even though non neuronal cells survived and proliferated in culture post 24 
hours, a large scale death of these cells was found with no or minimal toxic effect observed on 
the survival of neuronal cells (R. Liu, Lin, and Xu 2013).  
A different approach to the above methods which involves the isolation of the cell of interest 
from tissue with subsequent purification is the generation of new cell line models which are 
able to replicate the behaviour and responses of a particular cell type in vitro. Although there 
are a number of cell lines that have been used in the past to study neurons, including PC12 and 
SH-SY5Y cell lines, recently there has been work describing a new method for reprogramming 
fibroblasts to differentiate into neurons. Wainger et al describes how a mixture of five 
transcription factors can be used to re-programme fibroblasts into nociceptors. The advantage 
of this method being that it is easier to isolate and collect large numbers of fibroblasts which 
can proliferate in culture compared to neuronal cultures. Fibroblasts treated with this mixture 
of transcription factors, express protein and ion channels similar to those found in terminally 




neuropathy as observed by an increase in the expression of TRPV1 following the treatment of 
cultures with the inflammatory mediator prostaglandin E2 and oxaliplatin respectively 
(Wainger et al. 2014).  
In addition to reprogramming fibroblasts, new cell lines of sensory neurons have been 
obtained using the immortimouse model, a transgenic mouse line which can be used to isolate 
immortal cell lines. The benefit of this technique being large numbers of nociceptors for in 
vitro studies can be obtained without the need for large numbers of animals. Doran et al, 2015 
collected E12.5 embryos and DRG were isolated with the aim to collect and clone sensory 
neuron progenitor cells. E12.5 embryos were used as it is known that at E12.5 proprioceptor 
and low threshold mechanoreceptors are terminally differentiated, whereas the nociceptors 
are still dividing. This study found that the newly isolated MED17.11 cell line was capable of 
undergoing neurite outgrowth and correlated best to sensory neuron progenitors as testing 
showed their cytochemical and pharmacological properties to be consistent with nociceptive 
lineage neurons. However, these cell types also had markers for mechanoreceptors and 
proprioceptors suggesting that they may have multimodal potential and could be targeted to a 
more specific lineage using a targeted differentiation medium for example with specific growth 
factors for a subtype of nociceptors (Doran et al. 2015).   
2.1.2 MACS has been used to purify a number of neuronal and non-neuronal cell 
types 
Recently, Miltenyi produced a commercially available method which allows magnetic assisted 
cell sorting (MACS) of cell suspensions through the process of positive or negative selection. 
Originally, this method was developed for use in the immunology field and was first used to 
separate B cells from peripheral blood samples (Abts et al. 1989). It was developed as a more 




methods such as FACS which is time consuming and laborious (Miltenyi et al. 1990). Recently 
however, MACS technology has developed and begun branching out into other fields such as 
neuroscience. 
Currently, in the neuroscience field MACS is being used to isolate a number of cell types 
including retinal ganglionic cells (RGC), neurons, astrocytes, microglia and macrophages (for 
neuroimmune interactions) to name a few. 
Haraguchi et al used MACS purification to isolate microglia, macrophages and neutrophils in 
order to better understand the neuroimmune interactions, specifically investigating the role of 
transient receptor potential melastatin 2 (TRPM2), a nonselective calcium permeable cation 
channel, in neuropathic and inflammatory pain. They incubated plantar skin and lumbar cord 
tissue samples either with PE-labelled anti-CD11b antibodies for microglia, PE-labelled rat anti-
F4/80 antibody for macrophages or biotin-labelled rat anti-Gr-1 for neutrophils. Anti-PE 
microbeads or anti-biotin microbeads were then added to the respective solutions to isolate 
either microglia, macrophages or neutrophils from the sample (Haraguchi et al. 2012). A 
number of other studies have used these antibodies. This includes the isolation of microglia 
using MACS anti-CD11b antibodies to investigate activation of microglia (J. Lee et al. 2008) and 
isolation of CD11b/c positive cells from sections of the hippocampus (Williamson et al. 2011). 
However, in this study the preparation of tissue from the hippocampus in this study involved a 
two-step use of MACS technology. First anti-myelin microbeads were used to remove myelin 
from the single cell suspension and the suspension was run through a MACS LD column before 
the cell suspension from the flow-through was incubated with PE-conjugated mouse anti-rat 
CD11b/c antibody and anti-PE microbeads. Following this second incubation the cell 
suspension was then passed through a MACS LS column (Williamson et al. 2011). In addition to 
this, MACS purification has also been used to isolate retinal ganglion cells (RGCs). It has been 




streptavidin microbeads can effectively enrich RGC from 0.55% to 31% after passing through 
the MACS column (Shoge et al. 1999). Also, Cizkova et al have used MACS technology to 
generate oligodendrocyte cultures in vitro. They used specific A2B5 antibody labelled 
microbeads to isolate neural stem cells from E16 spinal cord samples, which differentiated in 
culture. They found that this method was effective in enriching oligodendrocyte cultures from 
6-8% before to 58-61% following MACS and contained a mixture of both oligodendrocyte 
precursors and mature oligodendrocyte cells as observed by specific cell markers (Cizkova et 
al. 2009).  
Vroemen et al described the use of MACS to purify p75 positive Schwann cells from peripheral 
nerve biopsies with the aim to use these Schwann cell cultures in the future to investigate 
regeneration, axon repair and remyelination. They described two different methods of MACS 
purification to enrich Schwann cells. First they used anti-p75 monoclonal antibodies, similar to 
the technique previously described which has been reported to take 3-6 weeks to enrich 
Schwann cell cultures (Tuszynski et al. 1998). Instead they used here this anti-p75 monoclonal 
antibody with microbead linked rat anti-mouse IgG1 to tag all p75 positive Schwann cells 
before passing the cells through the MACS MS+ column within the miniMACS magnet to collect 
tagged cells and isolate them using positive selection. In the second method anti-Thy-1 IgG1 
with microbead linked rat anti-mouse IgG1 antibodies were used to tag fibroblasts in the single 
cell suspension and deplete them using the MACS MS+ column within the miniMACS magnet. 
In this way, Schwann cells of interest were collected by negative selection where tagged 
fibroblasts were retained in the column and Schwann cells passed through the MACS column 
and were collected in the flow through. The first method resulted in a better enrichment of 
p75 positive Schwann cells than the second. However, the second method showed weakness 
when used with adult tissue, but it worked better when tested with neonatal tissue. Overall, 




after collection of peripheral nerve biopsies cultures were purified. (Vroemen and Weidner 
2003).   
Finally, MACS has been used to purify neural precursors from the ventricular zone of brains 
from human foetuses. Tissue was homogenised and incubated with PE-conjugated anti-
CD133+ antibodies and anti-PE magnetic beads and run through a MACS MS column in the 
miniMACS separator. FACS and immunocytochemistry was used to assess the enrichment after 
MACS purification. It was found that the cell suspension post MACS contained 85% neural 
precursor cells compared to 6-8% directly after dissection, with no change in the viability of 
the cells (Yu et al. 2004).  
Using a non-neuronal antibody cocktail, neurons can be isolated from tissues by negative 
selection using MACS technology, as used in my work/ the current study. Briefly, this 
commercially available technique involves the incubation of dissociated and triturated DRG 
samples with firstly a cocktail of non-neuronal antibodies with biotin tag against astrocytes, 
oligodendrocytes, microglia, fibroblasts and endothelium cells to tag all non-neuronal cells. An 
anti-biotin secondary antibody with a microbead tag is then added to the cell suspension 
which gives cells a magnetic charge. Cell suspensions are then run through a LD column 
containing ferromagnetic spheres which in combination with a large magnet amplifies the 
magnetic field within the column. This holds all non-neuronal tagged cells in suspension in the 









Figure 2.1 Schematic of MACS purification (Miltenyi biotech).  a- Schematic showing the 
anatomical location of DRG neurons containing the cell bodies of sensory primary afferent 
neurons. All DRG from cervical to lumbar regions collected. Red crosses indicate the parts of the 
sensory nerve fibres cut either side of the DRG. b i- collagenase digestion and trituration to 
single cell suspension ii-incubation with cocktail of non-neuronal biotin conjugated primary 
antibodies. Cocktail contains a mixture of antibodies against astrocytes, oligodendrocytes, 
microglia, endothelial cells and fibroblasts.   iii-incubation with an Anti-biotin micro beads 
conjugated secondary antibody c LD columns are held in a strong magnetic bar. Ferromagnetic 
spheres in LD columns amplify the magnetic field within the column and hold micro bead 
tagged non-neuronal cells in suspension. Untagged neuronal cells flow through the column and 
are collected in the eluate through negative selection.  
 
2.1.3 Aim of the chapter  
The overall project aims at deciphering the mechanism of action of NGF in pain. Neurons and 
non-neuronal cells have been reported to express the NGF receptors TrkA and p75 (Usoskin et 
al. 2014; Thakur et al. 2014; Aloe et al. 2012; Richner et al. 2014; Ebenezer et al. 2007). It is 
unknown whether NGF signals peripheral sensitivity following injury via direct binding to 
neurons or an indirect effect from non-neuronal cells. In order to distinguish these two 
possibilities, it is essential to have purified neuronal cultures. The aim of this part of the project 
is therefore, to optimise a method to purify sensory neurons from dorsal root ganglia (DRG) 
which contain the cell bodies of sensory neurons innervating the periphery. We decided to use 
MACS technology with the non-neuronal antibody cocktails to isolate neurons by the process 
of negative selection. Since this protocol had not previously been used to isolate sensory 




2.2 Methods:  
2.2.1 Animals 
All animals were obtained from Charles river and housed in a designated facility and 
maintained in accordance with ASPA and Home Office regulations. Animals were kept in a 12hr 
light dark cycle and fed ad libitum. All animals were sacrificed using schedule 1.  
2.2.2 DRG cultures 
All (or most) dorsal root ganglia were collected from adult C57Bl mice, incubated at 37°C for 45 
minutes and dissociated using an enzyme mixture of 3 mg/ml dispase (Roche, 04942078001), 
0.1% collagenase (Sigma Aldrich, C9891) and 200 U/ml DNAseI (Roche, 10104159001) in F12 
medium (Life Technologies, 21765029). Cells were centrifuged for 15 seconds at 800 rpm and 
the supernatant discarded. The cell pellet was then gently triturated in 1 ml of F12 medium 
before brief 15 second centrifugation at 800 rpm. Supernatant was then collected and the 
titration procedure of pellet resuspension and supernatant collection was repeated 4 times. 
Supernatant was then filtered through a 70 μm filter and centrifuged for 8 minutes at 1000 
rpm. Supernatant was discarded and cell pellet re-suspended in 200μl of plating medium prior 
to counting and plating. DRG cultures were plated at a density of approximately 3000 neurons 
in a 70 – 80 µl volume per well of 4 well plates containing 13mm diameter coverslips. 
Coverslips/ plates were pre-coated with 1:10 poly-L-lysine (PLL) (Sigma Aldrich, P4707) in dH2O 
overnight at 4°C and 1:10 growth factor reduced (GFR) matrigel (BD bioscience, 356230) in F12 
for 2 hrs at room temperature (RT). Plates were left with the added cells at room temperature 
for 5 min to allow cells to settle before being placed in the incubator (37⁰C 5% CO2) for 1 hour 
to allow cells to attach prior to addition of 400 µl of plating medium. For DRG cultures without 




supplement (Life technologies, 17502-048), 1x PenStrep (Sigma Aldrich, P4333) in Ham’s F12 
with L-Glut (Life technologies, 21765029)). Cells were fixed 24 hours after plating.  
2.2.3 Magnetic-assisted cell sorting (MACS) 
Following dissociation and titration (as described above) cells were centrifuged for 8 minutes 
at 1000 rpm and supernatant discarded. The cell pellet was re-suspended in 2 ml of DPBS 
(Gibco, 14190144) and centrifuged at 1000 rpm for 7 minutes. Supernatant was discarded and 
cells were re-suspended in 130 µl of 0.5% w/v BSA in MACS buffer (wash buffer used 
throughout protocol) and 30 µl of the non-neuronal biotin antibody cocktail (commercially 
available) against astrocytes, oligodendrocytes, microglia, fibroblasts and endothelium was 
added and incubated at 4°C for 5 minutes (Miltenyi biotec, 130-098-752). Cell suspension was 
topped up to 2 ml final volume with MACS buffer and centrifuged at 1000 rpm for 7 minutes. 
Supernatant was discarded, and cells re-suspended in 130 µl of MACS buffer and 30 µl of anti-
biotin microbeads (Miltenyi biotec, 130-098-752). Cells were incubated at 4°C for 10 minutes 
before topping up to 500 µl with MACS buffer. For neuronal separation this protocol utilises LD 
columns from Miltenyi Biotech to purify neurons by negative selection, see Fig 2.1 for 
schematic. LD columns were primed with 2 ml MACS buffer in the QuadroMACS separator 
before 500 µl of the cell suspension was added to the column. Meanwhile, 1 ml of MACS 
buffer was added to the tube previously containing the cell suspension to wash out any 
remaining cells and added to the column once the cell suspension had run into the column, 
followed by a washing through with 1.5 ml MACS buffer added directly to the column. Eluate 
was centrifuged at 1000 rpm for 8 minutes and cell pellet re-suspended in plating medium. The 
content of the plating medium varied depending on the experiment: Ham’s F12 with L-Glut, BS 
(described above) or B27 supplemented (2% B27 supplement (Life technologies, 17504-044) 
and 1xPenStrep in F12 medium). Approximately 3000 cells per well were seeded and left at 




prior to addition of 400 µl of plating medium. For experiments involving NGF treatment, 
control conditions were plated in B27 medium and the experimental conditions contained 
different dilution of 100 µg/ml NGF in 0.1% BSA in HBSS (Cambridge Bioscience, GFM11-1000) 
diluted in B27. Cultures were left in the incubator for 24 – 48 hours. Cultures that were left 
more than 24 hours, media was changed after 24 hours.  
2.2.4 Percol purification  
DRGs were dissociated, titrated, filtered and centrifuged for 8 mins at 1000 rpm as mentioned 
previously. While cells were centrifuging, the percoll gradient is prepared. In duplicate, 
prepare 28% percol (GE Healthcare, 17-0891-01) in F12 medium (no additives) and add 4ml to 
each tube. In a separate tube prepare 12.5% percol in HBSS (Gibco, 14025-050) and gently 
layer 4ml over the 28% percol layer already in your prepared tubes. Once the cell suspension 
has been centrifuged, remove the supernatant and re-suspend the cell pellet in 1 ml of HBSS. 
Carefully add 0.5 ml of cell suspension over the percoll gradient and centrifuge for 10 min at 
1300 rpm, slow the centrifuge using the soft break for this step. Cells will pass through the 
gradient to the bottom of the tube and the debris and myelin will collect at the percoll 
interface. Discard the top 4.5 ml including the debris and add 4ml of F12 medium to the 
remaining solution in the tube. Centrifuge for 6 min at 1000 rpm.  Remove the supernatant 
and re-suspend in BS plating medium and plated onto glass coverslips coated in PLL and 
laminin. Coverslips/ plates were pre-coated with 1:10 PLL (Sigma Aldrich, P4707) in dH2O 
overnight at 4°C and 1:100 laminin (Sigma, L2020) in F12 for 2 hrs at 37⁰C. Plates were left with 
the added cells at room temperature for 5 min to allow cells to settle before being placed in 
the incubator (37⁰C 5% CO2) for 1 hour to allow cells to attach prior to addition of 400 µl of 





Equal volume of warm (37⁰C) 4% PFA was added to culture medium (final concentration 2% 
PFA) on PLL and matrigel coated coverslips (described above) and cells were incubated for 
20min at 37oC. Coverslips were then washed twice with 1xPBS and stored at 4oC in 1xPBS prior 
to immunostaining. Coverslips were blocked with 10% normal donkey serum (NDS) (Abcam, 
ab1666643) in PBS-Triton X-100 (0.2% triton-100 and 0.1% sodium azide in 1xPBS) for 1 hour at 
RT. Blocking solution was then removed and replaced with primary antibody solution (antibody 
in 0.2% PBS-Triton X-100; please see antibody dilutions below) and left for 1 hour at RT. Cells 
were then washed 3 x 5min with 1xPBS before secondary antibodies diluted 1:1000 in 0.2% 
PBS-Triton X-100 were added and incubated for 1 hour at RT in the dark before washing 3x 
5min with 1xPBS. Coverslips were then mounted onto microscope slides using hard set 
mounting media with DAPI (vector laboratories, H-1500). 
 Primary antibodies were diluted as follows: 1:1000 anti-β-III tubulin mAb (Promega, G712A) 
for all experiments except for 1:1000 anti-β-III tubulin rabbit polyclonal (Abcam, ab18207) 
used as a counterstain for Isolectin B4, 1:1000 anti-glutamine synthetase (GS) Rb pAb (Abcam, 
ab49873) and 1:500 Isolectin B4 biotin conjugate (Sigma Aldrich, L2140). 
The following secondary antibodies were used: donkey anti-mouse IgG (H+L) Alexa Fluor® 488 
(ThermoFisher, A21202) and donkey anti-rabbit IgG (H+L) Alexa Fluor® 546 (ThermoFisher, 
A10040). In experiments with percoll purification, MACS vs flow-through and plunger and β-III 
counterstain for IB4 donkey anti-rabbit IgG (H+L) Alexa Fluor® 568 (ThermoFisher, A10042) and 
streptavidin, Alexa Fluor® 488 conjugate (ThermoFisher, S32354) was used. 
2.2.6 Viability assay  
Viability assays of DRG cultures were carried out using Live/dead ® reduced biohazard 




protocol for staining adherent cells on coverslips. Coverslips were mounted using hard set 
mounting media with DAPI (vector laboratories, H-1500). This kit uses a highly membrane 
permeant SYTO® 10 green fluorescent nucleic acid stain which labels all cells and membrane 
impermeant DEAD Red™ red fluorescent stain which only labels cells with a compromised cell 
membrane. 
2.2.7 Imaging and analysis:  
Mosaic images were acquired at 200x using Carl Zeiss microscope and Axiovision software. 
Percentages of cell proportions were measured in Fiji using the cell counter plugin across a 
minimum of three fields for each individual experiment. Viability was also measured using the 
Fiji cell counter plugin where a minimum of 50 neurons (based on the size and shape of the 
cell) were counted across a minimum of two fields for each experimental replicate. Finally, cell 
size distribution was measured by circling the perimeter of neurons and calculating the Feret 
diameter from the soma area.  
Neurite outgrowth assay was optimised and 40 neurons (20 per technical replicate) per 
experimental replicate were traced using Fiji. All individual neurites were traced along each 
neurite projecting from the soma to their longest branch point and data used to measure the 
longest and shortest, the mean length, number of neurites and the total neurite outgrowth 
from each of the longest branches. Following this, all remaining branches were traced and 
from this the overall neurite outgrowth was calculated and the overall neurite outgrowth 
normalised to the number of neurites (see Fig 2.6a).  
2.2.8 Statistics  
Graphs were plotted and statistical tests performed using GraphPad Prism 7 software. One and 
two-way ANOVA were performed to analyse cell size distribution and neurite outgrowth 




hoc test where appropriate. Finally, linear regression analysis was performed to compare 
neurite outgrowth parameters. 
2.3 Results  
2.3.1 Purification of DRG cultures using a percoll gradient does not remove 
satellite glial cells 
Passing dissociated DRG neurons through a percoll gradient is a commonly used method to 
clean up and purify DRG cultures. Therefore, we first tested percoll gradients as a method to 
purify DRG neurons. Following dissociation and titration, DRG cell suspensions were passed 
through a percoll gradient and then cultured for 24 hours in vitro. Percoll purified cultures 
although being free of debris and myelin were found to be 20.1% (±2.1%) neuronal, 71.1% 
(±3.2%) satellite glial cells (SGC) and 8.7% (±1.4%) other nuclei (Fig 2.2a and b). Measuring the 
cell size distribution showed a loss in the medium and large diameter neuronal population 
compared to the small diameter neurons where small diameter neurons are defined as <30um, 
medium diameter 30-40um and large diameter neurons are >40um. Small diameter neurons vs 
medium diameter neurons p=0.0029 and small diameter neurons vs large diameter neurons 





Figure 2.2 Passing DRG neurons through a percoll gradient prior to plating is not sufficient to 
purify DRG neurons in culture. a- representative immunocytochemistry (ICC) images of 
dissociated DRG passed through a percoll gradient. Staining with β-III tubulin for neuronal cells, 
glutamine synthatase (GS) for SGC cells and DAPI for nuclei. b- quantification of percentage of 
neurons (20.1% ± 2.1%) and SGC (71.1% ± 3.2%) in percoll purified cultures, n=3 independent 
cultures.  c- cell size distribution of neurons. One-way ANOVA with Tukey post hoc test.  Small 
diameter vs medium diameter p=0.0029, small diameter vs large diameter p=0.0014.  
 
2.3.2 Optimisation of Magnetic-Activated Cell Sorting 
Magnetic-Activated Cell Sorting (MACS) has been increasingly used in the neuroscience field to 
isolate specific cell populations. We decided to use this technology to isolate sensory neurons 




DRG samples with firstly a commercially available kit with a cocktail of non-neuronal 
antibodies with biotin tag against astrocytes, oligodendrocytes, microglia, fibroblasts and 
endothelium cells to tag all non-neuronal cells and then an anti-biotin secondary antibody with 
a microbead tag which gives cells a magnetic charge (Fig 2.1). Please note that as a 
commercially available kit there are no details on the antibodies used to target specific 
populations in this kit. In addition there is no mention from the company about this kit 
targeting satellite glial cells however, there is evidence from this study that these cells are also 
targeted. Neurons are then collected by negative selection after the cell suspension is run 
through an LD column held in a magnetic field. Standard DRG cultures are normally grown on 
poly-L-lysine(PLL) coated coverslips secondarily coated in laminin at a concentration of 1:100 in 
F12 medium for 2 hours at 37⁰C. Cells grown on laminin were fixed with 4% PFA for 10 minutes 
at room temperature. However, growing MACS purified neurons on laminin and fixing in 4% 
PFA was not optimal for MACS purified cultures as MACS purified neurons did not adhere well 
to glass coverslips coated with PLL and laminin. In order to address this a number of coating 
substrates were tested including ConcanavalinA, collagen and martigel (Table 2.1) A thin layer 
of 1:10 matrigel incubated for at least 1 hour at RT on PLL coated coverslips was found to be 
the optimal substrate for purified neurons to be adherent in culture, however, during the 
fixing of cells with 4% PFA for 10 min at room temperature a loss of cells was observed. 
Matrigel is a temperature sensitive regent that is liquid between 4⁰C and 21⁰C and solidifies 
below 4oC and above 21oC. We hypothesised that fixation of the cells at RT could have lowered 
the temperature of the culture allowing the matrigel to liquefy prior to the cells becoming 
adequately fixed. In addition, high concentrations of PFA have been found to destabilise the 
matrigel matrix. Therefore, the fixing protocol was altered until an optimal fixation of warm 2% 










2.3.3 MACS LD column alone is not sufficient to purify neurons and has no 
negative effect on cell survival  
In order to determine what effect the MACS LD column alone has on the purity and the 
viability of neurons, DRGs were taken and dissociated as described in the methods, then the 
MACS protocol was carried out in the absence of the MACS antibodies. In substitution of the 
non-neuronal cocktail and the biotin conjugated antibodies, cells were resuspended in 150µl of 
MACS buffer as opposed to 130µl and then run through the MACS LD column and referred to 
here as “mock MACS”. Cells were fixed after 2 days in culture and the number of neurons 
counted at this point. Mock MACS cultures were found to be 8.3% (±4.8%) neuronal, 54% 
(±9.2%) SGC and 37.7% (±5.9%) containing other cells (other nuclei) (Fig 2.3a and c). The 
neurons in these culture were found to be 98.2% (±0.6%) viable using a live dead viability kit 
(Fig 2.3b and e). Measurement of cell size distribution showed an approximately normal 
distribution of small, medium and large diameter neurons with a trend towards a reduction in 
the number of large diameter neurons compared to a standard DRG cultures. There was no 
significant difference between groups as measured by one-way ANOVA with Bonferroni’s post-
hoc test (Fig 2.3d).  Taken together, this suggests that the MACS LD column alone is not 





Figure 2.3 The LD column alone is not sufficient to purify neuronal cells and does not induce 
cell death. a- representative ICC of DRG neurons purified through a mock MACS through the LD 
column in the absence of non-neuronal biotin conjugated primary and anti-biotin micro bead 
conjugated secondary antibodies. Stained with β-III tubulin for neurons and GS for SGC.  b- 
representative ICC of mock MACS purified DRG stained with viability dyes SYTO® 10 live dye and 
DEAD Red™. c- Quantification of percentage of neuronal cells (8.3% ± 4.8%) and SGC (54% ± 
9.2%) following mock MACS purification. d- cell size distribution for mock MACS. e- 





2.3.4 MACS purification enriches viable neuronal cultures  
To see if MACS purification can effectively purify sensory neuron cultures from DRGs we first 
compared the percentage of neurons in both non-MACS and MACS purified cultures left for 24 
hours in BS medium. DRG cultures without purification were found to be 11.9% (±0.5%) 
neuronal, 38.1% (±0.5%) SGC and 50% (±0%) other cells. MACS purified cultures however were 
90.1% (±1.4%) neuronal, 0.5% (±0.8%) SGC and 9.4% (±0.8%) other cells (Fig 2.4a, d and f). 
Measurement of cell viability using a live dead kit showed no significant difference in viability 
of MACS purified neurons compared to non-MACS purified neurons, one-way ANOVA with 
Tukey post-hoc test. After 48 hours in culture, DRG cultures without MACS purification were 
seen to be 92.6% (±3.2%) viable cells compared to an average 93.5% (±2.7%) viability for MACS 
purified cultures, cultured for short-term (1 or 2 hours) or long-term (24, 48 or 72 hours) 
period of time (Fig 2.4b and c).  
2.3.5 MACS purified cultures contain mainly small diameter neurons 
When performing MACS purification, from my own observation, the cell yield was greatly 
reduced compared to the yield from a DRG culture not purified. To investigate if the cell loss 
was widespread or limited to one specific population we measured the cell size distribution of 
neurons after 24 hours in culture. Compared to non-MACS DRG cultures (Fig 2.4e) we 
observed that MACS purified neurons showed a shift towards small diameter neurons, the 
result of a significant loss in medium and large diameter neurons (Fig 2.4g). Small diameter 
neurons vs medium diameter neurons p=0.006 and small diameter neurons vs large diameter 
neurons p=0.004, one-way ANOVA with Bonferroni’s post-hoc (Fig 2.4fg). To assess whether 
the MACS column is selective for one subset of small diameter neurons MACS purified 








Figure 2.4 MACS purification results in pure neuronal cultures which are viable and consist 
mainly of small diameter neurons. a- representative immunocytochemistry (ICC) of DRG 
cultures with and without MACS (MACS and non-MACS) purification, stained with β-III tubulin 
for neurons and GS for SGC 24 hours in vitro. b- Representative ICC for cell viability using SYTO® 
10 live dye and DEAD Red™ 3 days following MACS purification. c- quantification of neuron 
viability for MACS purification at 1, 2, 24, 48 and 72 hours post MACS (average 93.5% live ± 
2.7%) compared to non-MACS purification 48 hours in culture (92.6% live ± 3.2%), n=2-4 
independent cultures. One-way ANOVA with Tukey multiple comparison. d and f- quantification 
of representative percentage of neurons and SGC following d non-MACS purification (neurons 
11.9% ± 0.5%, SGC 38.1% ± 0.5%) or f MACS purification (neurons 90.1% ± 1.4%, SGC 0.5% ± 
0.8%) n=3 independent cultures. Cell size distribution for e non-MACS and g MACS purified DRG 
neurons show MACS purified cultures to contain mainly small diameter neurons, n=3 
independent cultures.  One-way ANOVA, Bonferroni’s post hoc for MACS cultures small 
diameter vs medium diameter p=0.006 and small diameter vs large diameter p=0.004. h- 
Representative ICC for MACS purified neurons stained for IB4 marker for non-peptidergic c-fibre 
neurons and pan-neuronal marker β-III tubulin 24 hours post MACS purification. i- 
Quantification of IB4 positive neurons (38.2% ± 7.9%), n=3 independent experiments.   
 
neurons. MACS purified neurons were found to be 38.2% positive for IB4 (± 7.9%) suggesting 
that there is no small diameter neuron population bias (Fig 2.4 h and i).  
MACS LD columns have a pore size of 40µm therefore we hypothesised that the large and 
medium diameter neurons could be retained in the LD column. We investigated this by 
collecting three different fractions from the MACS LD column. This included MACS purified 
neurons, “flow through” from the column collected by releasing the LD column from the 




fraction where a syringe plunger was used to force through any remaining cells. Each of the 
fractions were cultured for 24 hours. Firstly, we counted the percentage of neurons that were 
being collected in each of the fractions. The MACS fraction was found to be 90.6% (±3.2%) 
neuronal, 5.3% (±1.3%) SGC and 4.1% (±1.9%) other cells compared to the flow through 
fraction 3.4% (±0.7%) neuronal, 88.5% (±3.5%) SGC and 8.1% (±4.2%) other cells and the 
plunger fraction 6.9% (±4.1%) neuronal, 80.6% (±5.0%) SGC and 12.6% (±0.9%) other cells. If 
this is split into cell types we found that neurons represented 76.8% (±1.0%) of the MACS 
fraction, 18.0% (±1.8%) flow through and 5.2% (±2.8%) plunger. SGC represented 0.8% (±0.4%) 
of the MACS fraction, 84.1% (±11.4%) flow through and 15.1% (±11.7%) plunger. Other cells 
represented 9.2% (±10.1%) of the MACS fraction, 71.1% (±9.4%) flow through and 19.7% 
(±12.5%) plunger fractions (Fig 2.5a and b). Cell size distribution for each of these fractions 
showed that as with MACS purification there is a shift towards small diameter neurons in the 
flow through and the plunger fractions, and corresponding with the percentages of neurons 
found in each of the fraction a significant decrease in the number of neurons of certain size. 
10µm MACS vs flow through and plunger p<0.0001, 15µm MACS vs flow through and plunger 









Figure 2.5 A small percentage of neurons are retained in the MACS LD column during 
purification. a- Representative immunocytochemistry of neurons and SGC collected within the 
MACS, flow through and plunger released fractions from the MACS column, cells stained with 
β-III tubulin pan-neuronal marker and GS for SGC. b- Quantification for representative 
population of neurons and SGC in the MACS cultures (90.6% ± 3.2% neurons, 5.3% ± 1.3% SGC), 
flow through (3.4% ± 0.7% neurons, 88.5% ± 3.5% SGC) and plunger (6.9% ± 4.1% neurons, 
80.6% ± 5.0% SGC) fractions from the MACS LD column. c- Cell size distribution for MACS, flow 
through and plunger fractions. Two-way ANOVA, Tukey post hoc **** p<0.0001, * p= 0.0256. 
All n=3 independent cultures.  
 
2.3.6 MACS purified neurons exhibit a delay in neurite outgrowth 
Since we established that MACS cultures were viable the next step was to determine whether 
the neurons showed similar neurite outgrowth compared to non-MACS DRG neurons. We 
developed a neurite outgrowth assay and investigated neurite outgrowth 24 and 48 hours 
post-MACS purification. The neurite outgrowth assay involved firstly the tracing of all neurites 
from a cell body to the furthest point, this gives longest, shortest and mean neurite lengths, 
number of neurites and the total neurite length of the longest neurite branches from each 
neurite from the soma. Secondarily, the remaining branches of the neuron are traced to 
estimate the overall neurite outgrowth and the overall neurite outgrowth normalised to the 
number of neurites (Fig 2.6a).  We compared each of these neurite outgrowth parameters to 
the other measurements for all neurons analysed in this chapter and found that there was a 
correlation between the parameters, some of which were found to be significant.  For 
example, mean neurite length vs longest neurite (R2=0.974), total neurite length from the 
longest branch vs total neurite outgrowth (R2=0.9578) and longest neurite vs overall total 




significance across multiple neurite outgrowth parameters, particularly highly correlated 
measurements, in various experiments adds weight to observations as being more biologically 
relevant (Supplementary Fig 2.1 and Supplementary Table 2.1).  
 
Figure 2.6 MACS purified neurons exhibit a delayed onset for neurite outgrowth compared to 
standard DRG cultures. a- representative immunocytochemistry of non-MACS DRG culture left 
for 1 day in BS medium stained with β-III tubulin pan-neuronal marker and GS (left) and 
example traces for neurite outgrowth measurements tracing first all neurites to furthest point 




MACS purified DRG neurons plated in F12, BS or B27 supplemented medium for 1 or 2 days. c- 
Total neurite outgrowth quantification for MACS purified neurons compared to no MACS 
purification for different plating mediums. One-way ANOVA, Tukey post hoc, p<0.0001. d- 
quantification of the percentage of cells with no neurites 1 and 2 days post MACS purification 
and plating in different culture mediums.  Two-way ANOVA, Tukey post hoc p≤0.002. All n=3 
independent cultures.  
 
From personal observation, we observed a significant reduction in the total neurite outgrowth 
in MACS purified neurons compared to non-MACS purified neurons after 24 hours in culture. 
We investigated the neurite outgrowth of MACS purified neurons further by culturing purified 
neurons in three different growth mediums and measuring neurite outgrowth after 24 and 48 
hours post-MACS. Compared to non-MACS purified neurons cultured in standard BS medium 
(1958 ± 420 µm), there was a significant reduction in the neurite outgrowth of MACS purified 
neurons with F12 (4 ± 4 µm), BS (87 ± 84 µm) and B27 (39 ± 25 µm) medium (average taken 
from all neurons measured per condition). Non-MACS purified BS vs MACS purified F12, BS and 
B27 all p<0.0001, one-way ANOVA with Tukey post-hoc (Fig 2.6a, b and c). Furthermore, we 
found that a large percentage of neurons 24 hours post-MACS purification don’t show any 
neurite outgrowth (F12 93% ± 9%, BS 59% ± 12% and B27 78% ± 8%) compared to the non-
MACS purified neurons cultured for 24 hours (23% ± 9%) p≤0.002, two-way ANOVA with Tukey 
post-hoc (Fig 2.6d).  
Also we found a significant increase in neurite outgrowth 48 hours post -MACS purification 
(F12 823 ± 238 µm, BS 1220 ± 272 µm and B27 1495 ± 446 µm) compared to 24 hours post-
MACS purification, which correlates with a decrease in the percentage of neurons with no 
neurites (F12 18% ± 10%, BS 10% ± 3% and B27 8% ± 3%). However, there was no significant 




F12, BS or B27 mediums 24 or 48 hours post-MACS purification (Fig 2.6c and d). This 
observation is supported by additional neurite outgrowth measurements of the longest, 
shortest and mean neurite length, number of neurons, total neurite outgrowth from the 
longest branch at overall neurite outgrowth normalised to number of neurites with only minor 
exceptions. There is a significant difference in the length of the longest neurite between MACS 
purified neurons grown in F12 and B27 mediums after 48 hours in culture (p=0.0028), the total 
length from longest branch (p=0.014) and total neurite outgrowth (p=0.049). Interestingly, 
there is also a significant difference in the number of neurites in MACS purified neurons grown 
in F12 and BS medium for 24 hours (p=0.0139) (supplementary Fig 2.2). 
The observed delay in neurite outgrowth after 24 hours in culture between MACS and non-
MACS purified neurons (Fig 2.6c) made us question if this was caused by the absence of non-
neuronal cells and secreted factors or whether the cells were stressed and in a sort of 
“recovery” period. To test this conditioned medium (CM) was taken from a non-MACS culture 
at 24 hours and used to culture MACS purified cultures which were analysed for neurite 
outgrowth at 24 and 48 hours. First, to ensure that CM does not affect the purity of MACS 
purified cultures, the percentage of neurons and SGC were counted. MACS purified cells grown 
in CM were 91.8% (5.6%) neuronal, 0.2% (0.3%) SGC, 8% (5.3%) other cells (Fig 2.7a and b). 
Compared to MACS purified neurons grown for 24 hours in BS control medium (51 ± 69 µm) 
there was a significant increase in the overall neurite outgrowth in MACS purified cultures 
grown in CM (779 ± 74 µm) for 24 hours p=0.0082, one-way ANOVA with Tukey post-hoc. 
However, there was no significant difference in the neurite outgrowth between these 
conditions after 48 hours in culture post-MACS, (BS control 1308 ± 231 µm and CM 1803 ± 301 
µm), (Fig 2.7a and c). This trend holds for most of the additional neurite outgrowth 




overall neurite outgrowth normalised to number of neurites (p=0.0002) which show a 
significant increase between BS and CM after 48 hours in culture (Supplementary Fig 2.3).  
 
Figure 2.7 MACS purified DRG cultures respond to conditional medium (CM) taken from non-
MACS purified cultures. a- representative ICC of MACS purified neurons plated in BS or CM 
taken from non-MACS purified DRG cultures for 1 or 2 days. Stained with β-III pan-neuronal 
marker and glutamine synthetase (GS). b- Quantification of percentage of neurons (91.8% ± 
5.6%) and SGC (0.2% ± 0.3%) in MACS purified cultures plated in CM. c- Total neurite outgrowth 





2.3.7 MACS purified neurons are responsive to NGF 
Based on the CM experiments MACS purified neurons are responsive to secreted factors, one 
of the growth factors that neuronal and non-neuronal cells are known to secrete is NGF.  
Therefore, we further investigated whether MACS purified cells response to NGF specifically. 
Purified neurons were exposed to increasing NGF concentrations and neurite outgrowth was 
measured. Compared to B27 control medium treatment with 10 (p=0.004), 50 (p<0.0001) and 
100ng/ml (p=0.005) NGF showed a significant increase in neurite outgrowth, one-way ANOVA 
with Tukey post-hoc. B27 control 19 ± 9µm, 1ng/ml NGF 82 ± 7µm, 5ng/ml NGF 389 ± 226 µm, 
10ng/ml NGF 824 ± 131 µm, 50ng/ml NGF 977 ± 229 µm and 100ng/ml NGF 800 ± 28 µm (Fig 
2.8a and b).  From this an optimal concentration of 10ng/ml was derived and used in all 
further experiments involving NGF treatment. Additional neurite outgrowth measurements 
showed the same trend with minor exceptions. The number of neurites per neuron (p=0.0192) 
and the total length of neurites from the longest neurite branch (p=0.0332) also showed a 
significant increase with 5ng/ml NGF and treatment of MACS purified neurons with 50ng/ml 






Figure 2.8 MACS purified neurons respond to NGF in a dose dependent manner. a- 
Representative ICC of MACS purified neurons treated with increasing concentrations of NGF. 
Neurons are stained with pan-neuronal marker β-III tubulin. b- Quantification of total neurite 
outgrowth for cells treated with NGF and dose response curve of total neurite outgrowth in 
response to NGF. One-way ANOVA with Tukey post hoc, B27 vs 10ng/ml NGF p=0.004 B27 vs 






2.4.1 Benefits of MACS compared to other methods of purification 
As described MACS purification is efficient in enriching and purifying cultures of both non-
neuronal cell cultures and neuronal cultures. Compared to other methods such as 
immunopanning or FACS, MACS purification is a faster method taking only a few hours from 
tissue to culture compared to days of preparation like immunopanning for which plates for 
negative and positive panning are prepared one day in advance plus at least a day to grow the 
culture or several hours of processing time to isolate specific cells using FACS (Miltenyi et al. 
1990). In some cases, faster methods require the use of less reagents such as buffers and 
culture medium and so have the advantage of being cheaper and less labour intensive. 
Immunopanning, for example, requires a large amount of antibodies to coat the panning 
plates in addition to buffers and culture medium making this experiment costlier than MACS 
purification. However, we found that when using MACS purification of DRGs that there is one 
confounding element which makes this method less cost effective. Due to the loss of medium 
and large diameter neurons there was a decrease in the yield of total neurons which therefore 
for larger experiments results in the need for a greater number of animals to collect DRGs 
from, which is more expensive.  
The advantage of the MACS technology amongst others is that it is an adaptive technique. For 
example, Schwarz et al used the MACS LD column with anti-myelin beads in order to clean up 
hippocampal tissue samples analysing it by FACS (Schwarz and Bilbo 2013). Lee et al  also used 
MACS as a prior step to FACS in order to purify CD11b/c positive cells from brain tissue before 
FACS analysis (J. Lee et al. 2008). Furthermore, development of MACS purification has been 
inspired by some of the more traditional purification methods such as immunopanning. 




been commonly used in immunopanning, in combination with MACS microbeads and ran 
samples of neocortex through the MACS column to purify p75 positive cells. In this study, two 
separate populations of cells from the neocortex were collected, flow through from the MACS 
column contained all p75 negative cells (cortical plate cells) and cells washed off the column 
contained the p75 positive fraction of cells (subplate neurons) (V. Nguyen and McQuillen 
2010).  
Feldmann et al describes a novel protocol adapting MACS technology to purify multiple cell 
types from the same tissue sample, an improvement on the current methods which would 
require a separate tissue sample for the isolation of each specific cell population of interest. 
Brain samples from postnatal mice were collected, digested and then dissociated using MACS 
dissociation enzymes and gentleMACS dissociator followed by the removal of myelin using 
anti-myelin microbeads. An anti-ACSA-2 antibody was then used to tag astrocytes in the cell 
suspension before running it through a MACS LS column. Astrocytes were washed off the 
column and used for culturing. However, the flow through from the column was incubated 
with the non-neuronal cell antibody cocktail and anti-biotin microbeads in order to deplete 
non-neuronal cells by running the sample through a MACS MS column. Using this method, 
cultures of 92% astrocytes and 86% neurons were obtained (Feldmann et al. 2014).  This study 
is an excellent example for how versatile this technique is.  
In conclusion, there are many techniques that can be used to purify cells that is beneficial for 
the investigation of mechanisms and the roles specific cell types play in a specific disease state, 
such as pain. Here, we have shown that MACS purification of DRG cultures can effectively be 
used to further investigate specific behaviours and responses of sensory neurons. Our group 
already published a successful application of the MACS technique where DRG neurons were 
purified using MACS and RNA was isolated and prepared for RNA sequencing. This study 




(Thakur et al. 2014). However, there are limitations associated with this technique, such as the 
inability to measure changes in cell surface markers, which the use of MACS purified cultures 
may be better suited to address.  
2.4.2 MACS purification effectively generates 90% pure sensory neuron cultures 
from whole DRG 
Magnetic assisted cell sorting (MACS) has been widely used in the immunology field to isolate 
specific populations of immune cells. However, it is now also being used in the neuroscience 
field. Here we used MACS technology from Miltenyi biotech to isolate pure neuronal cultures 
from DRG and established that MACS purification of DRG results in viable cultures of 90% 
neuronal cells, a greater purity of neurons compared to other methods of purification such as 
immunopanning (X.-M. Zhang et al. 2010). However, contrary to non-MACS purified cultures, 
MACS purified neurons fail to adhere to coverslips coated in PLL and laminin. They also don’t 
adhere to coverslips coated with collagen or concanavallin A. Our work shows that the optimal 
coating is a thin layer of matrigel on PLL coated glass coverslips or the plastic of 4-well plates.  
It has previously been shown that different coatings result in different growth responses for 
neurons, fibroblasts and Schwann cells indicating that there could be a preference for a certain 
glycoprotein in the extracellular matrix (ECM) for each cell type. The ECM in the periphery, 
particularly during regeneration following injury is known to contain a number of components 
including laminin, fibronectin, collagen and other growth promoting elements (Ma et al. 2013). 
Evercooren et al tested the growth promoting role of laminin, fibronectin and collagen in DRG 
cultures from 9-10 week old human foetuses. They found that with collagen, the addition of 
NGF increased the success of adhesion of explants to coated plates. Compared to collagen, 
explants plated onto either fibronectin or laminin promoted a greater degree of neurite 




different patterns of neurite outgrowth: collagen showed a radial pattern and earlier migration 
of fibroblasts compared to Schwann cells, fibronectin enabled neurons to rapidly grow with 
more lateral branching patterns onto heavy layers of fibroblasts and more extensive Schwann 
cell migration and finally laminin showed no major radial bundles and instead exhibited an 
intricate branching pattern in all directions. Contrary to the other coatings, fibroblast 
migration was reduced although Schwann cells were still able to migrate (Baron-Van 
Evercooren et al. 1982). Differences between the neurite outgrowth has also been observed 
between central and peripheral neurons on different coatings. Compared to PLL coating there 
was rapid elongation of neurites from both peripheral and central neurons grown on laminin, 
however only peripheral neurons were shown to exhibit neurite elongation on fibronectin 
(Rogers et al. 1983). McGarvey et al describes how different coating affect the growth of 
Schwann cells.  Schwann cells are known to release components of the extracellular matrix 
including fibronectin, laminin and collagen in culture, and despite the fact that the addition of 
fibronectin enhances the growth of Schwann cells, Schwann cells grown on collagen coated 
coverslips in the presence of laminin grew with a 2-6 fold higher adhesion rate compared to 
fibronectin (McGarvey et al. 1984). It is also known that there are a number of integrin 
receptors expressed on neuronal and non-neuronal cells which facilitate binding to 
glycoproteins. Neurons have been shown to express for instance tissue specific integrins, such 
as α7β1 integrin, which is laminin binding and predominately expressed in DRGs and α5β1 as 
well as α4β1, which is fibronectin binding and expressed in sensory neurons (Tomaselli et al. 
1993). Since different cell types bind and grow with different affinities to different 
glycoproteins it is reasonable to assume that that different coatings will preferentially bind 
different cell types.  
It is unknown whether the reason that MACS neurons do not bind to laminin or other tested 




as they are passed down the MACS LD column or if it is the result of the lack of the non-
neuronal cells. Preferential binding of a non-neuronal cell type such as a SGC for example 
could act as an anchor point for the adhesion of neuronal cells. A study by Ng et al that 
described a method of purifying cultures of SGC which takes advantage of a loose association 
of neurons in culture. DRG cultures were plated onto poly-DL-ornithine overnight after which 
the loosely attached neurons in suspension were removed and re-plated, leaving the more 
strongly attached SGCs attached to the base of the plate. Purity of the neurons was said to be 
70% neuronal (Ng et al. 2013). This method supports the hypothesis that SGC binding first in 
culture could act as an anchor point for neuronal cells which are found in close association 
with SGC in culture (Ng et al. 2013) as culturing overnight allows the SGC to bind before 
neurons attach at a later time point e.g. after 24 hours in culture.  
Mock MACS purification of DRG neurons showed that the MACS LD column itself did not purify 
or cause any cell death. It produced cultures that had a normal distribution of small, medium 
and large cell diameter neurons. However, following MACS purification we observed that there 
was a loss in medium and large diameter neurons compared to non-MACS purified DRG 
cultures. We hypothesised that this was due to neurons being retained in the MACS LD column 
which has a pore size of 40 µm, and so we tested this by collecting three different fractions off 
the column including the MACS purified neurons, flow-through from the column where the 
MACS LD column was released from the magnetic field and the plunger fraction where any 
remaining cells were released using the plunger. As expected the majority of neurons were 
present in the MACS fraction and the flow-through and plunger fractions contained mainly 
SGCs. Surprisingly, the flow-through and plunger fraction combined accounted for only 23% of 
the total number of neurons collected from all fractions. Cell size distribution analysis revealed 
a shift towards small diameter neurons in neurons from the flow-through and the plunger 




these larger cells being caught in the MACS LD column. However, we excluded this option 
when mock MACS purification showed no change in cell size distribution. The only difference 
between the mock MACS purification and the MACS purification procedure was the presence 
of MACS antibodies. We therefore believe that the complexed by the primary and secondary 
antibodies clog up the pores of the MACS LD column and restrict the passage of large 
diameter. Experience in the lab showed that no more than the DRGs of two adult mice can be 
passed through the MACS LD column otherwise there is a detrimental impact on the yield of 
neurons, where the purification of DRGs from 3 adult mice has a similar yield of neurons as the 
DRGs from 2 adult mice. Another reason for the lack of medium and large diameter neurons in 
the MACS cultures could be due to insufficient dissociation of neurons from SGCs which results 
in large aggregates. SGC greatly outnumber neuronal cells in the DRG and are known to remain 
associated with neurons in culture leading to various problems when enriching neuronal 
cultures (Ng et al. 2013). Medium and large diameter neurons have a higher probability to be 
associated with SGCs and therefore more likely to be insufficiently dissociated due to their 
increased surface area that binds a larger number of SGC compared to small diameter 
neurons.  
One approach to test this hypothesis and potentially improve the purification is to use a 
stronger enzyme mix than the dispase and collagenase mix that we have been using. One 
possible enzyme, which is stronger than collagenase, is papain (Worthington Biochemical 
Corporation 2017). However, over-digestion bears the risk to kill the cells or destroy the 
epitopes that are needed for the binding of the antibodies that are used in the non-neuronal 
antibody cocktail for MACS purification. One other possibility would be to utilise the gentle 
MACS dissociator, which homogenises tissues using a set programme that is specific for each 
tissue. The MACS dissociator is used in a number of studies that also use MACS to 




In addition to neurons being trapped in the MACS LD column, it is possible that decreased 
numbers of cells in the plunger fraction collected could also have been the result of a neurons 
being shredded when forced through the pores of the MACS LD column. There are a number of 
other DAPI positive nuclei in cultures following MACS purification and in cultures from flow-
through and plunger fractions. Typically, MACS purified cultures contain a negliable number of 
SGCs, however, there is DAPI staining in these cultures which does not associate with neuronal 
markers. These other nuclei may be those of other cell types such as Schwann cells, however 
we rather believe that they are the nuclei of destroyed medium and large diameter neurons 
which might have been shredded in either the MACS LD column (particularly in the plunger 
fraction) or during the dissociation and titration procedure. Combined with the MACS protocol, 
the dissociation and titration could be too stressful for the larger neurons. This hypothesis 
could be tested by apoptotic assays, such as TUNEL staining which stains for DNA fragments.  
The same observation of DAPI stained nuclei present in post-MACS purified cultures that do 
not associate with markers for their cell type was made by Feldmann et al where after 
purifying astrocytes or neurons they observed evidence of contamination of DAPI stained 
nuclei that did not stain positive for neurons or astrocytes nor for other cell markers GFAP or 
MAP2 (Feldmann et al. 2014). 
After establishing that MACS purification was effective in generating pure neuronal cultures 
we then used a neurite outgrowth assay to establish if these cultures behaved in a similar 
manner to non-MACS purified cultures. We observed that MACS purified neurons exhibited a 
delay in neurite outgrowth after 24 hours in culture compared to non-MACS purified cultures. 
However, after 48 hours there was a significant increase in neurite outgrowth in MACS purified 
cultures compared to 24 hours where the neurite outgrowth in MACS purified cultures after 48 
hours was similar to neurite outgrowth of non-MACS purified cultures after 24 hours in 




significant increase in neurite outgrowth after 48 hours in culture was also observed in 
cultures grown in different culture mediums as there was no significant difference in neurite 
outgrowth with different mediums at either 24 or 48 hours in culture. We hypothesised that 
MACS purified cultures are initially inhibited for neurite outgrowth since there is a lack of cell 
contact or secreted factors from non-neuronal cells. Our experiments with the conditioned 
medium of non-MACS purified cultures on MACS purified cultures showed that MACS purified 
neurons are responsive to secreted factors in the conditioned medium, supporting the 
hypothesis that the lag in neurite outgrowth is due to the lack of secreted factors from non-
neuronal cells. This lag in neurite outgrowth following purification has also been observed by 
Ng et al. Here, DRG neurons were purified by repeated plating; the dissociated DRG cell 
suspension without purification is plated and left to adhere overnight before the loosely 
attached neurons are removed from the culture and re-plated the next day. This results in an 
enrichment to 70% neurons in the culture. Subpopulations of neurons were then isolated using 
MACS. First, IB4 (non-peptidergic nociceptors) cells were tagged and retained in the MACS 
column and IB4 negative cells were collected in the eluate, along with any remaining non-
neuronal cells. Both IB4 positive and negative fractions were cultured. Cultures of IB4 negative 
neurons plus non-neuronal cells were tested for neurite outgrowth after 24 hours in culture 
and cultures of IB4 positive neurons were tested for neurite outgrowth after 48 hours in 
culture. Both cultures showed the same amount of neurite outgrowth suggesting that in the 
absence of non-neuronal cells there is a delay in neurite outgrowth (Ng et al. 2013).  
 Knowing that MACS purified neurons responded to secreted factors we further showed that 
they also specifically responded to NGF which was able to induce neurite outgrowth by itself.  
Our results show that the optimal dose is 50 ng/ml of NGF. 10 ng/ml did induce neurite 
outgrowth, but not to the extent that 50 ng/ml did. 100 ng/ml NGF also induced neurite 




ng/ml. This might indicate saturation of the receptors; however, this would not fully explain a 
decrease in neurite outgrowth following 100 ng/ml compared to 50 ng/ml. It is possible that 
high concentrations of NGF are toxic to cultures, this could be tested by increasing the 
concentration of NGF used to treat MACS purified cultures. One other explanation could be 
that the vehicle used for NGF is toxic in large doses. This can be tested by treating MACS 
purified with vehicle alone, however this is unlikely to be the case as NGF vehicle used contains 
0.1% BSA in HBSS which is diluted 1:10 000 in culture medium prior to plating for 10 ng/ml 
NGF. As already described (chapter 1.1) the high affinity NGF receptor TrkA binds NGF in its 
monomeric form via its extracellular ligand binding domain before it then forms a dimer with 
another unbound TrkA. Higher NGF concentrations could result in all TrkA monomers binding 
NGF and no empty monomers available for dimerization which leads to saturation. The effect 
of 10 ng/ml NGF proved itself valuable to us since it increases neurite outgrowth, however, it 
allowed room for improvement. Therefore, for all subsequent experiments we used 10 ng/ml 
NGF  10 ng/ml NGF, which is close to 0.1 nM, the EC50 for NGF as tested in PC12 cells 
(Mahapatra et al. 2009), as a positive control for producing significant neurite outgrowth 
compared to MACS purified cultures cultured in the absence of NGF for 24 hours which exhibit 
little or no neurite outgrowth.   
2.4.3 Neurite outgrowth as a measurement of neuronal responses  
Neurite outgrowth is a commonly used assay in order to measure neuronal responses to 
treatment with growth factors in vitro (Rogers et al. 1983). We adapted this in our study and 
optimised a neurite outgrowth assay to study the effect of MACS purification on neurons. 
There have been a number of methods created to semi-automate or automate this technique, 
all of them related to ImageJ, such as the an automated plugin NeuriteTracer (Pool et al. 2008), 
the Neurite-J plugin which can be used to measure neurite outgrowth from organotypic 




2014) and the semi-automated plugin NeuronJ. Upon testing both the NeuronJ and the 
NeuriteJ plugin, we found that they both rely on specific immunostaining of neurons. Also, 
upon closer observation of the created images, we noticed that for a significant proportion of 
neurons there are small neurites branching off from the main branches which these plugins 
are not sensitive enough to detect. Furthermore, in cultures treated with NGF for 24 or 48 
hours or longer there were many neurites which crossed over in areas where neuronal bodies 
grew in patches which the plugins were not able to separate in single neurites or neuronal 
bodies. We therefore chose not to use the time saving ImageJ plugin. The initial 
characterisation was performed by manual tracing neurites of the neurites using Fiji – an 
updated version of ImageJ. Using this method also allowed the freedom to acquire a number 
of different growth parameters for each neuron analysed. 
In conclusion, we have characterised here a method for purifying DRG neuronal cultures using 
MACS. This method can be used for a number of potential applications ranging from the use of 
isolated neuronal cultures, to the introduction of purified neurons into co-cultures. Co-cultures 
can be then used to study the interaction of neurons with other cells such as immune cells in 
neuroimmune interactions. Isolated neuronal cultures however have the benefit of being able 
to be used to distinguish the direct effect of pain mediators, such as NGF, on the neurons 
directly vs the indirect of NGF via other cells present in non-MACS cultures. This distinction 
between the direct vs the indirect effect of pain mediators is a confound in a significant 









Supplementary figure 2.1 Linear regression comparison of neurite outgrowth measurements. 
R2 value is calculated from the line of best fit (solid blue line) and indicated for each 






Supplementary table 2.1 Comparison of different neurite outgrowth parameters. Highlighted 








Supplementary figure 2.2 Additional neurite outgrowth measurements of MACS purified 
neurons cultured for 1-2 days in different growth mediums. a longest (p=0.0028) b shortest 
and c mean neurite length, d number of neurites (p=0.0139), e total neurite outgrowth from 
longest branch (p=0.014), f total neurite outgrowth (p=0.049) and g overall neurite outgrowth 










Supplementary figure 2.3 Additional neurite outgrowth measurements of MACS purified 
neurons treated with CM from non-MACS purified DRG cultures. a longest (1d p=0.0011, 2d 
p=0.0240) b shortest (1d p=0.0103, 2d p=0.0216) and c mean neurite length (p<0.0001), d 
number of neurites (p=0.0013), e total neurite outgrowth from longest branch (p=0.0014) and f 
overall neurite outgrowth normalised to number of neurites (1d p=0.0003, 2d p=0.0002). One-







Supplementary figure 2.4 Additional neurite outgrowth measurements for MACS purified 
neurons stimulated with increasing concentrations of NGF. a longest (B27 vs 10ng/ml NGF 
p=0.0124, 50ng/ml NGF p=0.0226, 100ng/ml NGF p=0.0446) b shortest (B27 vs 10ng/ml NGF 
p=0.0156, 100ng/ml NGF p=0.0375) and c mean neurite length (B27 vs 10ng/ml NGF p=0.0081, 




p=0.0192, 10ng/ml NGF p=0.0121, 50ng/ml NGF p=0.0019, 100ng/ml NGF p=0.0008), e total 
neurite outgrowth from longest branch (B27 vs 5ng/ml NGF p=0.0332, 10ng/ml NGF p=0.0001, 
50ng/ml NGF p<0.0001, 100ng/ml NGF p=0.0006) and f overall neurite outgrowth normalised 
to number of neurites (B27 vs 10ng/ml NGF p=0.0019, 50ng/ml NGF p=0.0020, 100ng/ml NGF 












Chapter 3: Knockout of TrkA or p75 
using viral vectors 
3.1 Introduction  
As discussed previously (chapter 1.2), investigations into the role of NGF in pain have 
previously used global knockout mice for either NGF, TrkA or p75. These mice have defects in 
the development of sensory neurons and are hyposensitive to thermal and mechanical stimuli 
in addition to a shortened lifespan; global TrkA and NGF knockout mice do not survive past 
weaning (Bergmann et al. 1997; K. F. Lee et al. 1992; Crowley et al. 1994; Smeyne et al. 1994).  
In order to circumvent  these survival issues we obtained from the international mouse 
phenotyping consortium (IMPC) (IMPC 2017c; Bradley et al. 2012) floxed mouse lines for the 
conditional knockout of the NTRK1 and NGFR genes, encoding the NGF receptors TrkA and 
p75, respectively. The IMPC aims to generate commercially available mouse lines with 
mutations for targeted knockout of 20 000 known mouse genes and the NTRK1 and NGFR 
floxed mice are two of them (Bradley et al. 2012; IMPC 2017c). My hope was that these two 
lines when used in combination with the previously described MACS purification (chapter 2) 
would shed light on the role of NGF on neurons alone in vitro.   
3.1.1 Floxed NTRK1 or NGFR animals for targeted knockout of NGF receptors 
The NTRK1 fl/fl and NGFR fl/fl mouse lines were generated using embryonic stem (ES) cell 
clones. Bradley et al described the protocol that was used. LoxP sites flank the critical region of 




as being within the first 50% of the coding gene where deletion of the floxed regions results in 
a frame shift generating a truncated non-functional protein or mutant mRNA that likely to be 
degraded (Bradley et al. 2012; Hofker and van Deursen 2011). Targeting vectors used 
contained a lacZ reporter gene linked to an internal ribosome entry site (IRES) which allows 
independent transcription of the marker protein upstream of a neomycin cassette under the 
control of the hbactP promoter, the autonomous human β-actin promoter. This whole 
complex of the lacZ reporter and neomycin cassette were flanked by flippase recognition 
target (FRT) sites and followed by Lox P sites located in intron regions upstream and 
downstream of a critical exon region from the gene of interest (Fig 3.1) (Skarnes et al. 2011). 
For Cre mediated excision the LoxP sites are usually placed 250 base pairs (bp) away from the 
exons to avoid interference with the splicing process (Hofker and van Deursen 2011; Skarnes 
et al. 2011). Targeting vectors are then transfected into the ES cells using electroporation 
where the wildtype copy of the allele is replaced by the targeting vector via homologous 
recombination. ES cells are then screened for successful recombination via neomycin 
resistance. Selected ES cells were then injected into blastocytes and implanted into surrogate 
mothers that generate mutant offspring (Bradley et al. 2012; Hofker and van Deursen 2011; 
Branda and Dymecki 2004). These offspring, born within the IMPC project were then bred in 
order to obtain different knockout strains (Fig 3.1) (Skarnes et al. 2011). The first litter of mice 
are referred to as the tm1a strain which contain the targeting vector and therefore are 
reporter tagged mice (lacZ) with conditional potential for gene knockout.  Crossing of tm1a 
mice with a Cre line results in excision of the loxP flanked region and therefore knockout of the 
gene of interest, however expression of the lacZ reporter remains in the resulting tm1b line. 
The tm1c line can also be generated from the original tm1a mice through crossing of this line 
with a Flp mouse line which results in excision of the targeting vector region between the FRT 




knockout mouse line without the lacZ reporter. Crossing of the tm1c line with a Cre line results 
in the tm1d line which exhibit knockout of the gene of interest in the absence of the lacZ 
reporter (Skarnes et al. 2011; IMPC 2017c).  
 
Figure 3.1 Schematic showing the generation of conditional knockout mouse lines from the 
IMPC. Schematic taken from Skarnes et al describes generation of floxed mice of specific genes 
starting from tm1a conditional knockout mouse lines with a lacZ reporter. Mice are crossed 
either with a Cre recombinase mouse to generate tm1b knockout mice with a reporter gene or 
generate tm1c conditional knockout mice without the reporter gene following crossing with a 
FLP recombinase mouse. Finally, tm1c mice can be crossed with a cre expressing mouse to 
generate tm1b knockout mice without a reporter. 
 
In this study we obtained NTRK1 fl/fl and NGFR fl/fl mouse lines stemming from the tm1c line 
from Harwell UK as part of the IMPC. Hence they are conditional knockout models based on 
the presence of Cre recombinase. In the NTRK1 fl/fl mouse line the loxP sites flank exons 4-6. 




However, expression of a truncated form of the protein from exons 1-3 is possible. Exons 1-3 
of the TrkA protein encode part of the extracellular domain including 2 tyrosine protein kinase 
domains from the neurotrophic receptors and two of the four leucine rich repeat regions 
(Ensembl 2016b) As this truncated protein is non-ligand binding it would not be capable of 
interacting with endogenous NGF (Wiesmann et al. 1999). In addition to breeding of the 
mouse lines, the IMPC also publishes preliminary behavioural observations from tested mice 
(IMPC 2017e). Correlating with previous studies using NTRK1 knockout mice (Smeyne et al. 
1994), the tm1b version of gene knockout, where there is knockout from birth and the lacZ 
reporter present, there was evidence of pre-weaning lethality. A range of biochemical and 
behavioural tests were also run on the tm1b animals including monitoring blood chemistry, 
glucose tolerance, grip strength and open field tests however there was no significant 
difference observed compared to WT littermate controls. It is important to note that none of 
the tests used involved measuring of sensitivity to non-noxious or noxious stimuli and there is 
no data available for behavioural testing on tm1a or tm1c animals (IMPC 2017b).  The NGFR 
fl/fl tm1c mouse contains loxP sites flanking exon 2. Knockout of exon 2 ablates expression of 
the NGFR gene and the protein it is encoding, the low affinity p75 neurotrophin receptor 
(IMPC 2017d). Upstream of the loxP site, exon 1 remains. However it is unlikely that this would 
produce any truncated protein expression as exon 1 is mainly non-coding. Also, a potential 
truncated protein would not contain any of the main extracellular signalling regions (Ensembl 
2016a). Contrary with the literature on global p75 knockout mice where premature death at 
six months is observed (K. F. Lee et al. 1992; Bergmann et al. 1997), the IMPC behavioural data 
for the tm1b knockout of the NGFR gene (global knockout of NGFR gene and expression of the 
lacZ), shows pre-weaning lethality. In NGFR tm1b animals however, a number of other 
anatomical and behavioural deficits were found to be significantly altered compared to 




content, abnormal digit morphology and tremors (IMPC 2017a). There is currently no data 
available for NGFR tm1a or tm1c animals.  
3.1.2 The Cre-LoxP system is a useful tool for targeted knockout of floxed genes 
There have been a number of models developed to obtain conditional knockout mouse lines. 
Two in particular are currently in use; the FLP/FRT and the Cre/Lox-P system. However, there 
are new models emerging such as the Cre homologue Dre which recognises roxP sites (Sajgo et 
al. 2014). The Flippase recombinase (FLP) system involves cleavage of FRT sites by the 
bacteriophage enzyme FLP (Hofker and van Deursen 2011). The Cre recombinase is a 
bacteriophage P1 enzyme with both lytic and lysogenic phases in its life cycle (Hoess, Ziese, 
and Sternberg 1982; Leone et al. 2003) which catalyses recombination of DNA between loxP 
sites (Hoess, Ziese, and Sternberg 1982; Hoess, Wierzbicki, and Abremski 1986; Hofker and van 
Deursen 2011; S. Feil, Valtcheva, and Feil 2009). Four different lox (locus of crossing) sites have 
been identified, loxP, loxB, loxL and loxR , of which loxP was the most efficient due to 
symmetry and spacing between the sites (Hoess, Ziese, and Sternberg 1982) and has been 
widely used in later studies. LoxP sites are 34 bp long and consist of two homologous 13 bp 
regions which are inverted and separated by an 8 bp sequence (Hoess, Wierzbicki, and 
Abremski 1986). At normal body temperature of 37⁰C Cre recombinase is substantially more 
efficient than FLP recombinase, therefore for in vivo studies the Cre/LoxP system is preferred 
(R. Feil et al. 1997).  
3.1.3 Delivery of Cre recombinase using viral vectors 
One method used to deliver Cre recombinase to specific cell types include the use of viral 
vectors to package and deliver virally encoded Cre. Here, we describe the use of lenti virus and 




3.1.3.1 Lenti-virus  
Lenti virus (LV) delivered transgenes have the ability to integrate into both dividing and non-
dividing cells, are non-pathogenic and can be stably expressed over several months (Heldt and 
Ressler 2009). LV can also be used to house large capacity genetic material, including large 
genes such as neurotransmitters or neuropeptides, and has been widely used to deliver both 
cell markers such as GFP and Cre recombinase into cells (Heldt and Ressler 2009; Gompf et al. 
2015). 
In addition to delivering Cre, LV have been used to knockout genes using other methods such 
as the use of siRNA. Zhang et al describes how small interfering RNA against p75 were 
packaged into LV and used to transduce cultures of retinal pigment epithelial cells (RPE) to 
investigate the role of p75 in angiogenesis (J. Zhang et al. 2014).  Bertrand et al treated 
sympathetic neuron cultures with LV packaging miRNA against the receptor NRAGE, a potent 
activator of Jun kinase (JNK) and inducer of apoptosis which has been shown to be recruited to 
p75 and function as an adaptor protein between p75 and JNK. In this study LV mediated 
silencing of NRAGE was used to confirm observations using sympathetic neuron cultures from 
NRAGE knockout animals where they observed that NRAGE plays an important role in BDNF 
pro-apoptotic signalling via p75 in sympathetic neurons during development (Bertrand et al. 
2009). Taken together, these studies show that LV delivery of miRNA into cells is an effective 
method to induce gene knockout.  
LVs have also been used as a tool for in vivo studies: for example, Mason et al, injected LV into 
the DRG which resulted only in a handful of neurons expressing the LV encoded GFP marker, 
however there was evidence of transduction in non-neuronal cells suggesting that the LV was 
not specific enough for neuronal transduction (Mason et al. 2010). LV has been delivered in 
vivo using a range of different routes including intra-cranial injections into specific brain 




BDNF in the brain where among other LV vectors, LV encoding a truncated TrkB protein was 
bilaterally injected into rodent brains and animals were assessed for changes in memory 
consolidation (Heldt and Ressler 2009). LV delivery has also been used in vivo in combination 
with short hairpin RNA (shRNA) expression. For example, NGF is known to play a role in 
neurogenic inflammatory responses following allergen exposure and contribute to airway 
hyperresponsiveness (AHR). LV containing shRNA against NGF has been used to treat cultures 
of primary lung tissue and intratracheally to investigate inhibition of NGF as a novel 
therapeutic for AHR. Studies with this approach have shown that LV expressing sh-RNA against 
NGF attenuates lung inflammation and reduce hyperinnervation of the lung in AHR mouse 
models (Chen et al. 2014). Zuccaro et al designed shRNA against the NGF receptor p75 to be 
packaged into LV and injected it into the dentate gyrus of both brain hemispheres. They found 
p75 to be essential in governing the neuronal polarity and thus regulate the assembly of 
neuronal circuits in development of the adult hippocampus and cortical regions of the brain 
(Zuccaro et al. 2014). 
3.1.3.2 Adeno-associated viral vectors 
Adeno-associated viruses (AAVs) have been described as highly neurotrophic, non-pathogenic 
and efficient in delivering transgenes (Gompf et al. 2015; Mason et al. 2010), commonly used 
both in vitro and in vivo. AAVs are capable at packaging approximately 4.7-5.4 kilobases of 
genetic material (Gompf et al. 2015). There are nine different serotypes available which all 
have tropism for specific cell types. Mason et al investigated the different transduction profiles 
of AAV serotype 1-8 (AAV1-8) encoding GFP following direct injection into DRG. They found 
that AAV serotypes 1, 5 and 6 transduced the highest number of neurons in the DRG, (from 34-
49% of DRG neurons) but overall AAV5 was found to be the most efficient with both the 
number of neurons transduced and the time of onset of GFP marker expression (Mason et al. 




transduce neurons and astrocytes. However contrary to other AAV serotypes, AAV9 is able to 
cross the blood brain barrier. Intrathecal injection of AAV9 has been shown to be effective in 
transduction of sensory neurons with over 90% of L4 DRG neurons transduced (Schuster et al. 
2014).  
Viral vectors have been mainly used in combination with transgenic mouse lines, for example 
Madison et al describes the use of a number of AAV vectors expressing Cre, Flpe, Flpo and Dre 
which target loxP, FRT (both Flpo and Flpe) and Rox sites respectively. The aim was to evaluate 
the use of AAV in combination with transgenic mouse lines which express reporters following 
Cre, Flpe, Flpo or Dre activity. Flpe was confirmed to be the least efficient, whereas Cre activity 
was comparable to Flpo and Dre (Madisen et al. 2015). However, there is a confound that 
some cell specific primers are too weak to efficiently drive transcription of a GFP or RFP 
marker. Therefore, Gompf et al described a method using a dual AAV approach using 
transcranial injections of an AAV encoding Cre under the control of a cell specific promoter in 
combination with a second AAV which encodes an inversed GFP or RFP marker protein driven 
by a strong neuronal or general promoter. In the presence of Cre the gene is inverted and the 
marker is expressed.  This study found that weak cell specific promotor driving of Cre was 
sufficient to drive expression of Cre recombinase which then effectively drives expression of 
the marker protein from the second virus vector (Gompf et al. 2015). In addition to delivery of 
Cre recombinase, AAV9 has been used to target knockout of specific genes using short hairpin 
RNA (shRNA) For instance shRNA targeting TRPV1, which is known to be involved in 
neuropathic pain, packaged in an AAV9 vector is injected into mice to silence expression of 




3.1.4 Aim of the study 
The aim of this part of the study was to specifically knockout TrkA or p75 NGF receptors using 
NTRK1 fl/fl and NGFR fl/fl mouse lines. In this chapter, I describe the use of viral vectors to 
introduce Cre recombinase to DRG neurons. First, we optimised transduction of MACS purified 
cultures with a lenti Cre-GFP virus to knockout expression of either the TrkA receptor using 
DRG cultures from NTRK1 fl/fl or p75 receptor using cultures from NGFR fl/fl mice in vitro. 
Second, we used intrathecal injection of adeno-associated virus serotype 9 (AAV9) to knockout 
expression of the TrkA or the p75 receptors in NTRK1 fl/fl and NGFR fl/fl mice respectively. We 
characterise here the effectiveness of both methods to knockout the TrkA or p75 receptor at 
the protein and the RNA level. Furthermore, we show that Cre mediated knockout of TrkA or 
p75 result in vitro results in an effect on neurite outgrowth.   
3.2 Methods 
3.2.1 Animals 
All animals were housed in a designated facility and maintained in accordance with ASPA and 
Home Office regulations. Animals were kept in a 12hr light dark cycle and fed ad libitum. All 
animals were sacrificed using schedule 1. TdTomato-flox-STOP-flox mice (B6;129S6-
Gt(ROSA)26Sortm9(CAG-tdTomato)HzeI) originally provided by Jackson Laboratory were backcrossed to 
a C57Bl6 background on site (by colleague Dr Franziska Denk) and used in experiments to test 
if the lenti CreGFP virus was functional. All other animals used were NTRK1 fl/fl 
(Ntrk1tm1c(EUCOMM)Wtsi) and NGFR fl/fl (Ngfrtm1c(EUCOMM)Wtsi) transgenic mice obtained from the 
International Mouse Phenotype Consortium (IMPC) from the MRC Mammalian Genetics Unit 
at Harwell, both mouse strains were on a C57Bl6 background. Mice were obtained as 





Ear clips were collected from transgenic mice and digested in 450µl lysis buffer (50mM 
potassium chloride, 1.5mM magnesium chloride, 10mM Tris (pH 8.5), 0.45% Tergitol, 0.45% 
Tween-20) and 15µl of proteinase K (10mg/ml) at 55oC for 3 hours. Temperature was then 
increased to 95oC for 15 minutes. Following digestion samples were centrifuged at 7000rpm 
for 1 minute and supernatants stored at 4oC.  PCR was carried out in a 20µl reaction using 18µl 
of a standard mix (1.5µM 5xbuffer (7.5µM MgCl2) and 1.25 units GoTaq® DNA polymerase 
(Promega, M3175) 200nM dNTP mix (Promega, U1330) and 0.5µM oligonucleotide primers 
(Sigma Aldrich)) with 2ul DNA. PCR was run using the following programme: 95oC for 5 
minutes, 35 cycles of 95oC for 30 seconds, 58oC/60oC (NGFR fl/fl and NTRK1 fl/fl respectively) 
for 30 seconds, 72oC for 30 seconds then finally 72oC for 7 minutes. Samples were run on a 2% 
agarose gel with ethidium bromide for 60 minutes at 100V and visualised under a UV lamp. For 
NTRK1 fl/fl mice, WT bands were observed at 325 bp and mutant bands at 488 bp. For NGFR 
fl/fl mice, WT bands were observed at 114 bp and mutant bands at 328 bp.  





3.2.3 DRG culture 
As described in the methods section of chapter 2.2.2 with the exception that B27 medium was 




3.2.4 Magnetic assisted cell sorting (MACS) 
As described in the methods section of chapter 2.2.3. B27 medium with or without 10 ng/ml 
NGF treatment was used exclusively in this chapter. 
3.2.5 Lenti virus transduction in vitro  
DRG neurons were collected and processed for non-MACS and MACS purified cultures as 
previously described. Following the final centrifugation at 1000 rpm for 8 min, the cell pellet 
was re-suspended in 100µl of plating medium and cells were counted. Based on the cell count 
a certain volume of virus was added to the cell suspension for each multiplicity of infection 
(MOI) tested; since the MOI defines how many viral particles per neuron are present, 30 viral 
particles per neuron are added for MOI 30. We used a CMV-Cre-GFP lentivirus at a titre of 
1x10^8 CFU/ml (Cellomics Technology, PLV-10039). Cells were incubated with the virus for 20 
min at 37oC before they were plated onto PLL and matrigel coated coverslips as previously 
described for DRG and MACS purified DRG cultures. For RNA extraction, 4-well plates were 
coated directly (no coverslips used) with PLL and matrigel following the same protocol as for 
coverslips. Cultures were grown in B27 medium in the absence of NGF unless otherwise stated. 
Medium was changed after 24 hours and every subsequent 48 hours until fixation and staining.  
3.2.6 Immunocytochemistry 
As described in the methods section of chapter 2.2.5.   
The following primary antibodies were used for this chapter: 1:1000 anti-GFP chicken 
polyclonal (Abcam, ab13970) and 1:1000 anti-β-III tubulin mAb (Promega, G712A) except for 
AAV Cre-eGFP neurite outgrowth experiments where 1:1000 anti-β-III tubulin rabbit polyclonal 




The following secondary antibodies were used for this chapter: 1:1000 goat anti-chicken IgY 
(H+L) Alexa Fluor® 488 (ThermoFisher, A11039), 1:1000 donkey anti-mouse IgG (H+L) Alexa 
Fluor® 546 (ThermoFisher, A10036) and 1:1000 donkey anti-rabbit IgG (H+L) Alexa Fluor® 568 
(ThermoFisher, A10042). 
3.2.7 AAV9 virus injection  
Intrathecal (IT) administration of AAV9 Cre-eGFP virus was optimised and performed by 
another PhD student in the lab, Nikita Khovanov. Briefly, mice were anaesthetised with 
isofluorane and given 50µl of 0.5% analgesic carprive and 100µl of saline subcutaneously. A 3-4 
cm long area from the base of the neck was shaved. An incision of 1.5 cm length at the T13 
vertebrae was made and the muscle removed to expose the membrane between the 
vertebrae T12 and T13. A gauge 30 needle was then used to open the dura. A narrow cannula 
(diameter 0.02cm) preloaded with 5µl of AAV9 Cre-eGFP was inserted into the intrathecal 
space down the left hand side of the dorsal vein. Virus was administered at a rate of 1.2 
µl/min, then left for 2 min to equilibrate before the cannula was removed. The skin was closed 
using wound clips and animals were left to recover. After 10 days wound clips were removed. 
14 days post-surgery animals were sacrificed using schedule 1 and tissue collected fresh, 
without perfusion. 
3.2.8 Immunohistochemistry 
Mice were sacrificed and fresh tissue was collected. Both L4 DRGs were collected and fixed in 
2% PFA for 2 hours at 4⁰C before being washed three times for 20 mins in 1xPBS at 4⁰C. Tissue 
was then incubated in 30% sucrose for 24 hours at 4⁰C before being embedded in optimal 
cutting temperature (OCT) compound and rapidly frozen on a bed of dry ice and isopentane. 
Tissue was stored at -80⁰C before cutting on a cryostat. DRG sections were cut at 10µm 




The following primary antibodies were used: 1:1000 anti-GFP chicken polyclonal (Abcam, 
ab13970), 1:1000 anti-β-III tubulin rabbit polyclonal (Abcam, ab18207), 1:500 anti-p75 NGF 
receptor rabbit polyclonal (Abcam, ab8875) and 1:200 anti-TrkA goat polyclonal (R&D systems, 
AF1056).   
The following secondary antibodies were used: 1:1000 goat anti-chicken IgY (H+L) Alexa Fluor® 
488 (ThermoFisher, A11039), 1:1000 donkey anti-rabbit IgG (H+L) Alexa Fluor® 568 
(ThermoFisher, A10042) and 1:1000 chicken anti-goat IgG (H+L) Alexa Fluor® 488 
(ThermoFisher, A21467).  
Staining was performed as follows. Firstly, sections were left for 30 min at RT to equilibrate 
and the edges of the slide marked with a PAP pen to form a hydrophobic barrier. Sections 
were blocked in 10% normal donkey serum (NDS) (Abcam, ab1666643) in 0.2% PBS-Triton X-
100 (0.2% triton-100 and 0.1% sodium azide in 1xPBS) for 1 hour at RT. Blocking solution was 
then removed and replaced with primary antibody solution (antibody diluted in 0.2% PBS-
Triton X-100) and sections were left overnight at RT in a humidified chamber. Sections were 
then washed four times for 5 min in 1xPBS before a solution of secondary antibody (secondary 
antibody diluted in 0.2% PBS-Triton X-100) was added. Slides were incubated the secondary 
antibody solution for 2 hours at RT in a dark humidified chamber before being washed four 
times for 5min in 1xPBS. Sections were then mounted onto microscope slides using 
Fluoromount G with DAPI (eBioscience, 00-4959-52). 
3.2.9 RNA isolation and cDNA amplification post in vitro lentivirus treatment 
Following MACS purification control samples were collected directly by centrifugation (7000 
rpm for 6 mins). Cells were re-suspended in 500 µl RLT buffer with 5 of µl β-mercaptoethanol, 
vortexed for 30 seconds and then stored at -80⁰C. The RNA of samples treated with CMV-Cre-




and 500 µl of RLT buffer with 5 µl of β-mercaptoethanol was added directly to the well. Cells 
were scraped off and collected prior to vortexing and storing as above. Once all samples were 
collected, RNA was isolated using the Qiagen RNeasy Micro kit according to the manufacturer’s 
protocol from step 4 onwards (Qiagen, 74004). RNA quantity and quality was measured with 
the Agilent RNA 6000 pico kit for the bioanalyser (Agilent technologies, 5067-1535) using an 
Agilent2100 Bioanalyzer (Agilent, Santa Clara, CA).  
RNA was then reverse transcribed to cDNA and amplified using the QuantiTect® Whole 
Transcriptome kit (Qiagen, 207045). 150pg of RNA per sample was used to produce cDNA of a 
final concentration of 3 ng/µl following the manufacturer’s protocol.   
3.2.10 RNA isolation and cDNA amplification post IT AAV9 Cre-eGFP treatment 
Both L3 DRGs of one animal were collected and pooled in RNAse free tubes, snap frozen in 
liquid nitrogen and stored at -80⁰C. Prior to RNA isolation, tubes were kept on dry ice or in 
liquid nitrogen. DRGs were transferred to RNAse free 2ml flat bottomed tubes with 500 µl 
Qiazol (Qiagen, 79306) and tissue was homogenised using a hand held homogeniser in two 10 
second pulses. Once all the samples were homogenised, all of the samples were checked for 
un-homogenised tissue aggregates and re-homogenised if necessary. Samples were incubated 
for 5 mins at RT, meanwhile phase lock gel (PLG) columns were pre-spun at 12000 rpm for 2 
mins. Homogenates were added to the PLG columns and 100 µl of chloroform was added and 
the tubes were shaken for 15 seconds. Tubes were then incubated at RT for 3 mins followed by 
15 mins centrifugation at 12000 rpm at 4⁰C. The aqueous phase was then poured off into a 
fresh RNAse free tube and 1.5 volume of 70% Ethanol in DEPC (made fresh) was added and 
tubes inverted to mix. The solution was then transferred to RNAeasy spin columns 700 µl at a 
time and centrifuged for 1 min at 11000 rpm and the flow through discarded. This process was 




isolated using reagents from the RNAeasy micro kit (Qiagen, 74004) and following the 
manufacturer’s protocol from step 6 onwards, before the quantity and quality of RNA was 
measured using the Agilent RNA 6000 pico kit for the bioanalyser (Agilent technologies, 5067-
1535) using an Agilent2100 Bioanalyzer (Agilent, Santa Clara, CA). 
For reverse transcription, RNA was diluted in DEPC water to a final concentration of 250 ng/µl 
in a final volume of 12 µl. 1 µl of 50 mM random primers (Promega, C1181) and 1 µl of 10 mM 
dNTPs (Promega, U1330) were added to each reaction and placed in a thermocycler at 65⁰C 
for 5 mins. Samples were then cooled to 4⁰C for 1 min before 6 µl of a second mastermix was 
added for a final reaction volume of 20 µl (4 µl 5x first strand buffer, 1 µl 0.1 M DTT and 1 µl 
200 U/µl Superscript III RT (Life technologies, 18080-044)). Samples were placed in a 
thermocycler and the following programme was run: 25⁰C for 5 min, 50⁰C for 60 min, 70⁰C for 
15 min, 4⁰C until the programme was stopped at which point cDNA was stored at -20⁰C.  
3.2.11 RT-PCR 
3.2.11.1 Optimisation of RT-PCR primers for NTRK1 and NGFR 
Primers for NTRK1 and NGFR genes were designed using the Primer blast tool of Pubmed, 
purchased from Sigma Aldrich and then tested for efficiency against a standard tissue sample 
for efficiency. Primers were designed to target the appropriate gene at sites before, over, after 
and further downstream (end) from the loxP floxed sites. Briefly, tissue for a standard tissue 
sample was collected from a C57Bl WT mouse including small pieces of tissue (≤ 1 mm2) from 
heart, lung, brain, liver, kidney, bladder, muscle, DRG, spinal cord and sciatic nerve and snap 
frozen in liquid nitrogen. Tissue was dropped into a fresh RNAse 2ml flat bottomed tube 
containing 500 µl of Qiazol and homogenised using a hand held homogeniser in two 10 second 
pulses and re-homogenised if necessary. The samples were incubated for 5 mins at RT, 




Homogenates were added to the top of the PLG columns and 100 µl of chloroform was added. 
The tubes were shaken for 15 seconds and then left to incubate at RT for 3 mins. Tubes were 
then centrifuged for 15 mins at 12000 rpm at 4⁰C. The aqueous phase was then poured off into 
a fresh RNAse free tube and 1.5 volume of 100% Ethanol in DEPC (made fresh) was added to 
the tubes and inverted to mix. The solution was then transferred to RNAeasy spin columns 700 
µl at a time and centrifuged for 1 min at 11000 rpm and the flow through discarded. This 
process was repeated until all of the sample has been added to the column. From here the 
RNA was then isolated using reagents from the RNAeasy mini kit (Qiagen, 217004) and 
following the manufacturer’s protocol from step 11 onwards, before the quantity and quality 
of RNA was measured using the nanodrop.  
For reverse transcription of RNA to cDNA from tissue samples RNA was first diluted in DEPC 
water to a final concentration of 2.5 µg/µl in a final volume of 12 µl. 1 µl of 50 mM random 
primers (Promega, C1181) and 1 µl of 10 mM dNTPs (Promega, U1330) were added to each 
reaction and tubes were placed in a thermocycler at 65⁰C for 5 mins. Samples were then 
cooled to 4⁰C for 1 min before 6 µl of a second mastermix (4 µl 5x first strand buffer, 1 µl 0.1 M 
DTT and 1 µl 200 U/µl Superscript III RT (Life technologies, 18080-044)) was added for a final 
reaction volume of 20 µl. Samples were placed in a thermocycler and the following programme 
run: 25⁰C for 5 min, 50⁰C for 60 min, 70⁰C for 15 min then cool to 4⁰C, before cDNA was then 
stored at -20⁰C. To carry out the RT-PCR cDNA was diluted to 60 ng/µl, and then serially 
diluted to 30, 10, 3, 1, 0,3 and 0.1 ng/µl to assess the primer efficiency. For all reactions, a melt 
curve was calculated and the RT-PCR products were run on a 2% agarose gel to verify that the 
product size matched the predicted length and there was no non-specific binding and 
amplification.  
A summary of all tested primers for NTRK1 and NGFR can be found in Supplementary tables 




3.2.11.2 RT-PCR reaction 
Firstly, a mastermix for each primer pair was prepared, consisting of 5 µl of 2x Lightcycler480 
SYBR green I master (Roche, 04887352001), 3.5 µl of RNAse free water and 0.5 µl of 10 µM 
forward and reverse primer mix (Sigma Aldrich) per reaction. 9 µl of mastermix was then 
pipetted into a 384 well plate and 1 µl of cDNA was added to each well. The plate was then 
sealed and centrifuged in a plate spinner for 20 seconds before being placed into a Roche 
Lightcycler II RT-PCR machine. Plates were all run using the following programme: pre-
incubation at 95⁰C for 5 mins, then 45 cycles of amplification at 95⁰C, 60⁰C and 72⁰C for 10 
seconds each with a single acquisition after each 72⁰C incubation. A melt curve programme 
was run immediately after: 95⁰C for 5 sec before cooling to 65⁰C for 1 min and the 
temperature ramped up to 97⁰C with continuous acquisition. Samples were then cooled to 
4⁰C.  










3.2.12 Imaging and analysis  
Mosaic images were acquired at 200x using Carl Zeiss microscope and Axiovision software and 
neurite outgrowth assays were performed as described in the methods section of chapter 
2.2.7. 
For lenti viral CreGFP treatment, the number of cells remaining in culture post fixing was 
calculated using the cell counter plugin of Fiji. The percentage of neurons successfully 
transduced was measured as the percentage of neurons expressing GFP above control cells. 
This was calculated by first circling all cells imaged in Fiji and then measuring the amount of 
Fluorescence (measured as IntDen) in Fiji. For each of the control conditions the fluorescence 
intensity for all cells was measured and an average and standard deviation of fluorescence was 
calculated. The average was then added to two times the standard deviation and a 95% 
confidence interval (CI) for fluorescence was calculated, thus a baseline fluorescence 
accounting for 95% of control cells was set.  Neurons in culture treated with lenti virus 
expressing GFP above the respective 95% control threshold were said to be GFP positive and 
therefore successfully transduced with lenti virus and the percentage of GFP expressing 
neurons was calculated.  
Percentages of GFP, TrkA and p75 positive neurons post IT AAV9 Cre-eGFP was calculated by 
counting the number of cells expressing the marker of interest as a percentage of the total 
number of cells in the DRG section using the cell counter plugin of Fiji across a minimum of 3 
sections of both L4 DRG for each animal. 
Fold change from RT-PCR was calculated using the delta-delta Ct (Cq) normalised to the 




3.2.13 Statistics  
Graphs were plotted and statistical tests performed using GraphPad Prism 7 software.  
One-way ANOVA with Tukey multiple comparison test was performed for all analysis except 
for RT-PCR expression of NTRK1 and NGFR following lenti virus Cre-GFP treatment where a 
two-way ANOVA with Tukey multiple comparison test was performed.  Linear regression 
analysis was also performed to compare expression of GFP with TrkA or p75 expression in 
NTRK1 fl/fl and NGFR fl/fl mice treated with AAV9 Cre-eGFP virus. 
3.3 Results  
3.3.1 Validation of lenti virus as a tool for knockout of floxed genes 
Assessment of the transgenic mouse line will be reported in chapter 4, but we observed no 
alterations in DRG development. In this chapter, we investigate viral transduction of DRG, 
beginning with lenti virus. To investigate the effect of knock out of floxed genes in vitro we first 
optimised a method for transducing MACS purified cells using lenti viral treatment. DRG 
cultures without MACS purification from tdTomoto-flox-STOP-flox mice were treated with 
various multiplicity of infection (MOI) of a lenti virus encoding a Cre-GFP fusion protein (lenti 
Cre-GFP) and expression of tdTomato and GFP without antibody amplification was observed 
with all concentrations of viral particles showing effective transduction and the Cre 
recombinase to be functional (Fig 3.2a). For the treatment of MACS purified cells with lenti 
Cre-GFP virus different MOI and number of incubation days in vitro were used for optimisation 
and the percentage of cells expressing GFP were measured. The baseline level was set as the 
95% CI for the corresponding basal fluorescence for the MOI 0 control, and using this baseline 








Figure 3.2 Optimisation of lenti CreGFP transduction of MACS purified DRG neurons.   
a- Representative immunocytochemistry of non-MACS DRG cultures from tdTomato flox-STOP- 
flox mice treated with various MOI of lenti CreGFP. b- Representative ICC of optimal lenti 
CreGFP in MACS purified DRG culture, MOI 30 cultured for 3 days.  c- Control fluorescence from 
untreated cells used to calculate 95% CI of the fluorescence intensity/cell after 2, 3, 5 and 7 
days in culture (2d, 3d, 5d and 7d respectively) from each of the individual cultures (n). d- 
Number of cells surviving following treatment with varying MOI of lenti virus. e- Percentage of 
MACS purified neurons treated with varying MOI expressing GFP above the 95% CI threshold 
set from the control GFP expression. All n=2-3 independent cultures. 
 
measured. 64.3% ± 8.4% of cells expressed GFP after 2 days, 92.3% ± 2% after 3 days, 84.4% ± 
9.2% after 5 days and 83.2% ± 10.6% after 7 days (Fig 3.2b, c and e). The number of surviving 
cells was measured by counting the remaining cells in culture. It was found that there were 
fewer cells 5 and 7 days (average 28 ± 7 cells) in vitro compared to 2 and 3 days (average 68 ± 
27 cells). This correlated with a larger amount of cell debris observed after 5 and 7 days in 
culture (Fig 3.2d). Taken together we determined the optimal conditions for lenti Cre-GFP 
treatment were an MOI 30 for 3 days in vitro (Fig 3.2b).  
3.3.2 Lenti CreGFP treatment of NTRK1 fl/fl and NGFR fl/fl animals was not 
optimal for observing changes in neurite outgrowth 
To investigate potential differences in neurite outgrowth following lenti Cre-GFP mediated 
knockout of either TrkA using NTRK1 fl/fl mice or p75 using NGFR fl/fl mice respectively, DRGs 
were isolated and MACS purified from both strains. Cultures were treated with lenti Cre-GFP 




plating or after 1 or 2 days in culture, d0, d1 and d2 respectively) to investigate the effect of 
NGF on neurite outgrowth in either NGF receptor expressing or NGF receptor knock out cells.  
First we investigated the effect of NGF on neurite outgrowth following lenti Cre-GFP mediated 
knock out of TrkA in MACS purified cultures from NTRK1 fl/fl animals. In cultures from NTRK1 
fl/fl animals there was significant increase in neurite outgrowth between MOI 0 and 30 lenti 
CreGFP when treated with NGF after 2 days in vitro from 2658 ± 247 µm in control to 3840 ± 
82 µm in MOI 30 treated neurons (p= 0.0421). There was also a significant increase in neurite 
outgrowth between MACS purified neurons treated with a MOI 30 lenti CreGFP and NGF at the 
time of plating compared to treatment with NGF after 1 (p=0.0480) and 2 (p=0.0384) days in 
vitro, one-way ANOVA with Tukey post-hoc. NGF treatment at the time of plating and 
treatment of neurons with lenti CreGFP virus at MOI 30 resulted in overall neurite outgrowth 
of 2633 ± 386 µm, compared to 4038 µm when NGF treatment was added after 1 day in vitro 
and 3840 ± 32 µm when NGF was added after 2 days in vitro (Fig 3.3a and b). There were no 
significant differences between any other neurite outgrowth measures. In controls cultures 
treated with an MOI 0 there was average neurite outgrowth of 2679 ± 412 µm in the absence 
of NGF, 2824 ± 64 µm following NGF treatment at the time of plating, 3414 µm with NGF 
treatment after 1 day in vitro and finally neurons treated with MOI 30 in the absence of NGF 
showed an average neurite outgrowth of 3443 ± 150 µm. Additional neurite outgrowth 
measurements longest neurite (p=0.0172) and mean neurite length (p=0.0360) both showed a 
significant increase in outgrowth between MOI 0 and 30 treated MACS purified cultures 
treated with NGF after 2 days in vitro. However, other additional neurite outgrowth 
measurements like shortest neurite, mean neurite length, number of neurites per neurons, 
total length from longest branch and overall neurite outgrowth normalised to number of 
neurites all showed no significant differences following treatment with lenti CreGFP or NGF, 








Figure 3.3 Lenti CreGFP mediated KO of TrkA in MACS purified DRG from NTRK1 fl/fl mice 
does not reduce neuronal response to NGF. a- Representative immunocytochemistry of NTRK1 
fl/fl MACS purified cultures treated with NGF at 0, 1 or 2 days after treatment with lenti CreGFP 
at MOI 0 or 30. b- Quantification of neurite outgrowth 3 days post treatment with lenti CreGFP 
and NGF treatment at varying time points after virus treatment (MOI 0 NGF d2 vs MOI 30 NGF 
d2 p=0.0421, MOI 30 NGF d0 vs MOI 30 NGF d1 p=0.0480, MOI 30 NGF d0 vs MOI 30 NGF d2 
p=0.0384). One-way ANOVA, Tukey post hoc, n=2 individual cultures.  
 
MACS purified neurons from DRGs isolated from NGFR fl/fl animals and treated with lenti Cre-
GFP and NGF however showed no significant differences in total neurite outgrowth in vitro. For 
control neurons treated with MOI 0 the average neurite outgrowth in the absence of NGF was 
2625 ± 1072 µm, following NGF treatment at the time of plating 2770 ± 204 µm, following NGF 
treatment after 1 day in vitro 2510 ± 480 µm and 2 days in vitro 2967 µm. For MACS purified 
neurons treated with lenti Cre-GFP at a MOI 30 the average neurite outgrowth in the absence 
of NGF was 2508 ± 389 µm, following NGF treatment at the time of plating 3114 ± 162 µm, 
following NGF treatment after 1 day in vitro 2836 ± 637 µm and 2 days in vitro 3468 µm (Fig 
3.4a and b). Similarly, additional neurite outgrowth measurements longest, shortest, mean, 
number of neurites, total length from longest neurite branch and overall neurite outgrowth 
normalised to the number of neurites all showed no significant differences following lenti Cre-
GFP mediated knockout of p75 in NGFR fl/fl animals, one-way ANOVA with Tukey post-hoc 








Figure 3.4 Lenti CreGFP mediated KO of p75 in MACS purified DRG from NGFR fl/fl mice does 
not affect neuronal response to NGF. a- Representative ICC of NGFR fl/fl MACS purified 
cultures treated with NGF at 0, 1 or 2 days after treatment with lenti CreGFP at MOI 30. b- 
Quantification of neurite outgrowth 3 days post treatment with lenti CreGFP and NGF 
treatment at varying time points after virus treatment. None of the differences in neurite 
outgrowth were statistically significant. One-way ANOVA, Tukey post hoc, n=2 individual 
cultures. 
 
Next, we investigated the effectiveness of knockout of the NTRK1 and NGFR genes following 
treatment of MACS purified neurons with lenti Cre-GFP using RT-PCR. Investigations of neurite 
outgrowth following TrkA or p75 knockout from DRGs from NTRK1 fl/fl and NGFR fl/fl mice 
respectively showed no significant differences in neurite outgrowth. We hypothesised that this 
could be the result of insufficient gene knockdown or that we are observing a ceiling effect on 
outgrowth. To further investigate this, we analysed the gene expression for TrkA or p75 by RT-
PCR on a small numbers of MACS purified neurons from NTRK1 fl/fl and NGFR fl/fl mice treated 
with lenti CreGFP for up to 3 days in vitro in the absence of NGF.  We found that compared to 
control expression levels of untreated neurons isolated straight from the MACS column there 
was no significant change in expression of either the NTRK1 or the NGFR gene from purified 
neurons treated with lenti Cre-GFP over 1-3 days from cultures from both NTRK1 fl/fl 
(Supplementary Fig 3.3a) or NGFR fl/fl (Supplementary Fig 3.3b) mice, two-way ANOVA with 
Tukey post-hoc. This could suggest that there is indeed insufficient knockout of NTRK1 or NGFR 
following lenti Cre-GFP treatment. However, this could also be the result of degradation or a 
low concentration of RNA collected from MACS purified neurons. On the other hand, we found 




suitable for use with a cDNA amplification kit suggesting this is not the case (Supplementary 
Fig 3.3c and d). 
3.3.3 Intrathecal injection of AAV9 into NTRK1 fl/fl or NGFR fl/fl mice effectively 
knocks down expression of TrkA or p75 at the RNA and protein level 
Since knockout of TrkA and p75 using lenti CreGFP viral treatment in vitro was found not to be 
efficient we next used an adeno-associated virus (AAV) to achieve in vivo knockout of TrkA or 
p75. We used an AAV serotype 9, which has previously been shown in our group to effectively 
transduce DRG neurons when injected via a cannula intrathecally (IT). For example, we 
previously found that IT injection of AAV9 encoding eGFP protein effectively transduces 67.2% 
± 16.5% of lumbar DRG neurons, 13.7% ± 6.6% of thoracic DRG neurons and 60.6% ± 6.2% 
cervical DRG neurons (unpublished data from a PhD student in the lab, Nikita Khovanov).  
We injected AAV9 Cre-eGFP into NTRK1 fl/fl animals IT and quantified the percentage of GFP 
positive transduced neurons 2 and 4 weeks post AAV9 Cre-eGFP. We found 52.9% ± 10.3% of 
the DRG neurons to be GFP positive 2 weeks and 30.0% ± 15.1% GFP positive 4 weeks post 
AAV9 Cre-eGFP injections. This data is pooled from both L4 DRGs. Interestingly, there was a 
significant decrease in the number of GFP positive neurons from 2 to 4 weeks post injection, 
p=0.0372 one-way ANOVA with Tukey post-hoc (Fig 3.5a and b). Next, we stained the DRGs 
against TrkA and quantified its expression. This revealed that there was a significant decrease 
in TrkA expression from 38.5% ± 6.5% in un-injected WT DRGs to 15.0% ± 4.9% at 2 (p=0.0017) 
and 19.8% ± 6.8% at 4 (p=0.0092) weeks post AAV9 Cre-eGFP injection. This data is pooled 
from both L4 DRGs, one-way ANOVA with Tukey post-hoc (Fig 3.5a and c). Furthermore, we 
investigated if there was a difference in transduction between the left and right L4 DRG. 








Figure 3.5 Intrathecal injection of AAV9 Cre-eGFP into NTRK1 fl/fl animals reduces the 
protein expression of TrkA in the L4 DRG. a- Representative immunocytochemistry of GFP and 
TrkA expression in L4 DRG 2 and 4 weeks post AAV9 Cre-eGFP administration. WT controls 
tissue used was taken from C57Bl wildtype mice not treated with AAV9 Cre-eGFP.  b- 
Quantification of GFP (p=0.0372) and c TrkA (control vs 2 wk AAV9 Cre-eGFP p=0.0017, 4wk 
AAV9 Cre-eGFP p=0.0092) expression in L4 DRG following intrathecal AAV9 Cre-eGFP 
administration in NTRK1 fl/fl mice. One-way ANOVA with Tukey post-hoc, n=2-6 animals.  
 
unilateral transduction as assessed by GFP and TrkA expression (Supplementary Fig 3.4a and 
c).  
We then performed the same IT injections in NGFR fl/fl animals and observed again an 
increase in the expression of GFP to 39.0% ± 23.0 % and 16.3% ± 8.9% at 2 and 4 weeks post 
AAV9 Cre-eGFP injection respectively, pooled data from both L4 DRGs (Fig 3.6a and b). After 
staining for p75 we found a trend towards a reduction in the expression of p75 from 38.5% ± 
6.5% in control DRG to 27.1% ± 15.3% at 2 and 18.5% ± 11.8% at 4 weeks post AAV9 Cre-eGFP 
injection, however this data was not significant.  Data pooled from both L4 DRGs, one-way 
ANOVA with Tukey post-hoc (Fig 3.6a and c). As with the other animals, AAV9 Cre-eGFP 
injection into NGFR fl/fl mice also show a degree of unilateral transduction of virus between 
left and right L4 DRG as seen by GFP and p75 expression, but only in approximately 30% of 
mice injected (Supplementary Fig 3.4b and d).  
Correlation of GFP and TrkA or p75 expression in L4 DRG of NTKR1 fl/fl (R2= 0.1987, 95% CI -
0.3126 to -0.0102) or NGFR fl/fl (R2= 0.4284, 95% CI -0.6658 to -0.1813) mice 2 and 4 weeks 
post AAV9 Cre-eGFP injection showed a negative correlation between GFP and TrkA or p75 









Figure 3.6 Intrathecal injection of AAV9 Cre-eGFP into NGFR fl/fl animals trends towards a 
reduction in the protein expression of p75 in the L4 DRG. a- Representative 
immunocytochemistry of GFP and p75 expression in L4 DRG 2 and 4 weeks post AAV9 Cre-eGFP 
administration. Control tissue used here was taken from C57Bl mice not treated with AAV9 Cre-
eGFP.  b- Quantification of GFP and c p75 expression in L4 DRG following intrathecal AAV9 Cre-
eGFP administration in NGFR fl/fl mice. One-way ANOVA with Tukey post-hoc, all tests not 
significant, n=2-6 animals.  
 
observed laterality of GFP and TrkA/p75 expression between the left and right L4 DRG the 
trend for negative correlation between GFP and TrkA or p75 expression was maintained in 
both DRGs of NTRK1 fl/fl (left R2 = 0.1355, 95% CI -0.4343 to 0.1352 and right R2 =0.5018, 95% 
CI -0.4566 to -0.06482) and NGFR fl/fl (left R2 = 0.5046, 95% CI, -0.8389 to -0.08919 and right 
R2 = 0.2793, 95% CI -0.8423 to 0.113) animals (Supplementary Fig 3.4e and f).  
Finally, we performed RT-PCR to measure the relative knockdown of RNA transcript levels of 
NTRK1 and NGFR following IT AAV9 Cre-eGFP. Unexpectedly, in NTRK1 fl/fl animals treated 
with AAV9 Cre-eGFP there was a trend towards reduced expression but no significant 
difference in the expression level of NTRK1 gene normalised to GAPDH 2 and 4 weeks post IT 
AAV9 Cre-eGFP. Compared to control at 1.01 ± 0.24 there was a FC of 0.7 ± 0.35 2 weeks post 
AAV9 Cre-eGFP and 0.47 ± 0.05 4 weeks post AAV9 Cre-eGFP in NTRK1 expression. The level of 
NGFR expression in these animals remained unchanged. NGFR expression in controls was 1.00 
± 0.01 compared to 0.92 ± 0.12 2 weeks post AAV9 Cre-eGFP and 0.91 ± 0.12 4 weeks post 
AAV9 Cre-eGFP (Fig 3.7b). However, NGFR fl/fl animals showed a significant decrease in the 
expression of both NTRK1 (p=0.0350) and NGFR (p=0.0092) genes, normalised to GAPDH, 2 
weeks post AAV9 Cre-eGFP, one-way ANOVA with Tukey post-hoc. Expression of NTRK1 









Figure 3.7 Intrathecal injection of AAV9 Cre-eGFP into NTRK1 fl/fl and NGFR fl/fl animals 
reduces expression of NTRK1 and NGFR at the RNA level in whole DRG from NGFR fl/fl 
animals but not in NTRK1 fl/fl mice. a- Correlation of GFP expression and TrkA or p75 
expression in NTRK1 fl/fl (R2=0.1987) and NGFR fl/fl (R2=0.4284) mice treated with AAV9 Cre-
eGFP for 2 or 4 weeks respectively.  Expression of NTRK1 and NGFR displayed as a FC 
normalised to C57Bl wildtype mice not treated with AAV9 Cre-eGFP in b NTRK1 fl/fl animals 
treated with AAV9 Cre-eGFP for 2 and 4 weeks, all tests not significant, and c NGFR fl/fl (NTRK1 
p=0.0350, NGFR p= 0.0092) animals treated with AAV9 Cre-eGFP for 2 weeks. One-way ANOVA 
with Tukey post-hoc, n=2-6 animals.  
 
where expression of NGFR decreased from 1.01 ± 0.23 in WT controls to 0.14 ± 0.11 2 weeks 
post AAV9 Cre-eGFP (Fig 3.7c). This suggests that following knockout of NGFR, there is a 
downstream effect which results in a complementary decrease in NTRK1, which we discuss 
further below.  
3.3.4 Knockout of TrkA using IT injection of AAV9 Cre-eGFP results in a decreased 
response to NGF mediated neurite outgrowth in MACS purified neurons 
In order to test if the knockout of TrkA in neurons affects the neuronal response to NGF, 
NTRK1 fl/fl animals were IT injected with AAV9 Cre-eGFP and all DRGs extracted 2 weeks post 
AAV9 Cre-eGFP injection. DRGs were triturated and both non-MACS and MACS purified 
neurons were grown for 24 hours in the presence or absence of NGF. Cell somas expressing 
GFP were considered to be successfully transduced and TrkA knockout was assumed for these 
cells. Non-MACS purified cultures did not show any significant difference in neurite outgrowth 
in either AAV9 Cre-eGFP negative or positive neurons grown in the absence of NGF, as 





Figure 3.8 AAV9 Cre-eGFP mediated KO of NTRK1 reduces MACS purified neuronal response 
to NGF in vitro. a- Representative ICC of non-MACS and MACS purified neurons from NTRK1 
fl/fl mice two weeks post intrathecal injection with AAV9 Cre-eGFP.  Quantification of neurite 
outgrowth following administration of 10ng/ml NGF of b non-MACS purified and c MACS 
purified neurons (p=0.0002). One-way ANOVA with Tukey post-hoc, n=3 individual cultures, 2 





compared to 387 ± 125 µm in AAV9 Cre-eGFP positive neurons.  Furthermore, non-MACS 
purified cultures grown in the presence of NGF also showed no significant difference in neurite 
outgrowth, where the average neurite outgrowth in AAV9 Cre-eGFP negative neuron was 1094 
± 352 µm and Cre-eGFP positive neurons was 514 ± 251 µm (Fig 3.8a and b). This observation 
was also true for MACS purified cultures from IT injected animals grown in the absence of NGF, 
where there was no significant difference between an average neurite outgrowth of 20 ± 15 
µm in AAV9 Cre-eGFP negative neurons compared to 16 ± 9 µm in AAV9 Cre-eGFP positive 
neurons (Fig 3.8a and c). However, in MACS purified cultures plated in the presence of NGF, 
there was a significant decrease in neurite outgrowth in MACS purified neurons following the 
knock-out of TrkA, p=0.0002, one-way ANOVA with Tukey post-hoc. AAV9 Cre-eGFP negative 
neurons showed an average neurite outgrowth of 552 ± 118 µm where AAV9 Cre-eGFP 
positive and therefore TrkA KO neurons showed an average neurite outgrowth of 109 ± 64 µm 
(Fig 3.8a and c). This same pattern for neurite outgrowth holds true for all other neurite 
outgrowth parameters, where there is a significant decrease in MACS purified neurons in GFP 
positive, TrkA KO, neurons treated with NGF compared to GFP negative controls 
(Supplementary Fig 3.5 and 3.6).  
3.3.5 Knockout of p75 using IT injection of AAV9 Cre-eGFP results in a decreased 
response to NGF mediated neurite outgrowth in both non-MACS and MACS 
purified neuronal cultures 
Similar to NTRK1 fl/fl animals, NGFR fl/fl animals were given IT injection of AAV9 Cre-eGFP and 
2 weeks later all DRGs were collected. DRG cultures of both non-MACS and MACS purified 
neurons were treated with and without NGF and the effect of p75 knock out on neurite 
outgrowth was measured after 24 hours in vitro. Cell soma with a GFP positive nucleus were 




purified cultures there was no significant difference in the neurite outgrowth of both AAV9 
Cre-eGFP negative and positive neurons grown in the absence of NGF, from an average overall 
neurite outgrowth of 2739 ± 380 µm in AAV9 Cre-eGFP negative neurons to 1077 ± 203 µm in 
AAV9 Cre-eGFP positive neurons. However, following NGF treatment we observed a significant 
decrease in the neurite outgrowth in non-MACS purified cultures. Non-MACS AAV9 Cre-eGFP 
positive p75 KO neurons showed an average neurite outgrowth of 2241 ± 260 µm compared to 
5214 ± 1798 µm in AAV9 Cre-eGFP negative controls, p=0.0190, one-way ANOVA with Tukey 
post-hoc (Fig 3.9a and b). Similar to non-MACS there was no significant difference between 
AAV9 Cre-eGFP negative and positive neurons in MACS purified neurons cultured in the 
absence of NGF, from an average neurite outgrowth of 68 ± 54 µm in AAV9 Cre-eGFP negative 
neurons to 59 ± 48 µm in AAV9 Cre-eGFP positive neurons. However, comparable to non-
MACS purified cultures there was a significant decrease in NGF mediated neurite outgrowth in 
MACS purified neurons with AAV9 Cre-eGFP positive neurons with p75 knockout showing an 
average neurite outgrowth of 301 ± 125 µm compared to 989 ± 327 µm in AAV9 Cre-eGFP 
negative controls, p=0.0066 one-way ANOVA with Tukey post-hoc (Fig 3.9a and c). This 
observation of a significant decrease in NGF mediated neurite outgrowth following knockout 
of p75 in both non-MACS and MACS cultures was also found in other neurite outgrowth 
parameters (Supplementary Fig 3.7 and 3.8). The only exception to this being in MACS purified 
neurons treated with NGF where there was no significant difference in the length of the 
shortest neurite between the AAV9 Cre-eGFP negative controls and AAV9 Cre-eGFP positive 
neurons, one-way ANOVA with Tukey post-hoc (Supplementary Fig 3.8). Interestingly, in non-
MACS purified neurons plated in the absence of NGF there was a significant decrease in the 
longest neurite (p=0.0026), mean neurite length (p=0.0478), number of neurites per neuron 
(p=0.0075) and the total length from the longest branch (p=0.0410), one-way ANOVA with 




difference in the total neurite outgrowth of neurons, these other neurite outgrowth 
parameters suggest that there may be a difference in the neurite outgrowth of p75 knockout 
neurons, even in the absence of NGF. 
 
Figure 3.9 AAV9 Cre-eGFP mediated KO of NGFR reduces MACS purified neuronal response to 
NGF in vitro. a- Representative ICC of non-MACS and MACS purified neurons from NGFR fl/fl 




outgrowth following administration of 10ng/ml NGF of b non-MACS purified (p=0.0190) and c 
MACS purified neurons (p=0.0066). One-way ANOVA with Tukey post-hoc, n=3 individual 
cultures, 2 mice pooled per culture.  
 
3.4 Discussion  
3.4.1 Lenti Cre-GFP viral mediated knockout of TrkA or p75 in vitro is not 
successful  
To investigate the effect of knockout of either TrkA or p75 in vitro we decided to isolate DRG 
neurons from NTRK1 fl/fl and NGFR fl/fl mice respectively and optimise a culture protocol to 
introduce Cre recombinase to neurons using a lenti viral vector. Firstly, we tested the 
transduction efficiency of several lenti viruses encoding Cre-GFP fusion protein in non-MACS 
purified neurons isolated from WT C57Bl mice. Cultures were grown in BS medium and treated 
with lenti virus at varying MOI directly in the medium for up to 5 days. Cells were daily 
monitored for the expression of GFP in the neuronal cell somas. Transduction and expression 
of Cre-GFP is usually observed from 24-48 hours in culture (Millington et al. 2009; Denning et 
al. 2013).  
The first lenti-viral vector tested was purchased from Amsbio (LVP576) which encoded Cre 
recombinase with a GFP-puromycin selection marker under the CAG promoter. After 2 days in 
culture no expression of GFP was observed, therefore to test if this was due to a defective 
virus or due to a weak signal from GFP this virus was tested in non-MACS purified cultures 
isolated from TdTomato mice. These particular TdTomato mice contained a TdTomato-flox-
STOP-flox cassette where there is a translational stop upstream of the TdTomato gene flanked 




there is expression of the TdTomato protein. Treatment of non-MACS purified cultures from 
TdTomato mice with Amsbio lenti Cre-GFP however failed to induce expression of the 
TdTomato signal in addition to a failure to observe signal from the GFP marker suggesting that 
the purchased vector was not functional for our purpose. We repeated this experiment with a 
new virus from a different batch however the result was the same.  
Testing of a different lenti Cre-GFP from Cellomics Technology which encodes a Cre-GFP fusion 
protein under the control of the CMV promoter in non-MACS purified DRG cultures from 
C57Bl6 WT mice however showed expression of GFP in neuronal cell somas after 2 days in 
culture. To increase the number of neurons expressing GFP we optimised our protocol. Instead 
of adding the lenti virus directly to the plating medium we pre-incubated the virus with the cell 
suspension before plating. Cultures from TdTomato mice after 2 days in culture incubated with 
the virus showed expression of both GFP and TdTomato marker proteins from all MOI of virus 
showing that there was effective transduction of virus in a higher proportion of cells compared 
to the previous method of viral transduction and proved the Cre recombinase protein was 
active. 
In order to optimise the transduction of MACS purified DRG cultures with lenti Cre-GFP, we 
tested a number of different MOI ranging from 20-50 for 2-5 days in MACS purified cultures. 
We observed that there was the highest percentage of transduced cells using a MOI 20 or 30 
for 3 days or a MOI 50 for 3, 5 and 7 days. However, in cultures grown with the virus for 5 and 
7 days or treated with MOI 50 lenti virus there was a larger amount of debris present in the 
culture suggesting that in these cultures there was cell death likely due to toxic exposure to 
the lenti virus. We concluded from this that either MOI 20 for 3 days or MOI 30 for 3 days is 
the optimal incubation time for the transduction of MACS purified neurons. For all subsequent 
experiments we decided to use a MOI 30 for 3 days in MACS purified cultures to allow maximal 




floxed gene. However, it shall be noted that when we evaluated the cultures after fixation, we 
found a greater number of cells on average remaining in cultures treated with lenti Cre-GFP at 
MOI 20 for 3 days. 
For our RT-PCR experiments we designed and tested RT-PCR primers upstream, over and 
downstream of the floxed regions of the NTRK1 gene in order to investigate if there was 
complete KO of the floxed gene, or if there was partial transcription of mRNA for both the 
NTRK1 fl/fl and NGFR fl/fl cells following exposure to Cre recombinase. However, only one of 
the tested primer pairs were efficient (Supplementary table 3.1 and 3.2). RT-PCR analysis of 
the NTRK1 and NGFR expression following lenti Cre-GFP mediated knockout in NTRK1 fl/fl or 
the NGFR fl/fl cell cultures showed no difference in the expression of either gene after 
treatment with MOI 30 for 1-3 days. We ensured that the quality of the RNA was high by 
testing it with an Agilent bioanalyser. As expected there was some cell loss in samples 
collected after 3 days in culture compared to control samples untreated with lenti Cre-GFP 
collected straight off the MACS LD column. Despite the reduction in the number of cells with 
the increased number of days in culture there was still sufficient amount of RNA for 
amplification, using the limit of the amplification capacity of this commercial kit (Quantitect 
whole transcriptome kit, Qiagen). However, this amplification method has since been shown in 
the lab to not sensitively amplify small amounts of RNA at this limit compared to other more 
specialised amplification kits (Repli-g WTA single cell amplification kit, Qiagen kit, data not 
shown, performed by post-doctoral researcher Dr Damini Tewari). In conclusion, we are not 
sure whether the lack of change in the expression of the NTRK1 or the NGFR genes following 
lenti Cre-GFP mediated knock out is the result of improper amplification of RNA. This could be 
tested by repeating this experiment the now identified better kit for RNA amplification and 




Another explanation for the failure of gene knockout might be that 3 days in culture with the 
lenti virus was not sufficient. Typically it can take 1-2 days for transduction and expression of 
viral genes which could result in a lag time between expression of the Cre recombinase and the 
knock out of the gene. However, we based our time points on the expression of TdTomato in 
the TdTomato-flox-STOP-flox strain that showed knockout of the stop cassette. Also, our 
experiments showed that cultures incubated with the virus for more than three days were less 
viable.  Although our pilot experiments showed that knockout should have occurred after 3 
days in culture the RNA stability is unknown. Therefore, we might be measuring stable RNA 
rather than newly expressed RNA. Furthermore, even if there was gene knockout after 
incubation with the virus for three days, at this point we don’t know if this had resulted 
already in protein knockout. The turnover rate of the two proteins are not known to us.  Any 
residual protein in the cell and stored in vesicles (Lessmann, Gottmann, and Malcangio 2003) 
could still be functional and account for the similar neurite outgrowth in control and knockout 
cells.  
Despite there being no knockout in NTRK1 or NGFR as measured by RT-PCR, due to a number 
of reasons mentioned above there was reason to not fully trust this result. Therefore, we 
investigated further the neuronal response to NGF following of knock out of either the TrkA 
receptor using MACS purified cultures from NTRK1 fl/fl mice or the p75 receptor from MACS 
purified cultures from NGFR fl/fl mice. We treated MACS purified cultures with NGF either at 
the time of isolation and start of culturing in combination with lenti Cre-GFP or after 1 or 2 
days in culture with the lenti Cre-GFP. There was no significant difference, except for those 
mentioned below, in neurite outgrowth following application of NGF at any time point in both 
cultures from both NTRK1 fl/fl and NGFR fl/fl mice. In NTRK1 fl/fl mice there was a significant 
increase in neurite outgrowth following in cultures treated with NGF 1 and 2 days after plating 




neurons were able to respond better to NGF than when plated in NGF throughout the 3 days 
left in culture. Additionally, this observation could be the result of interference between NGF 
and the virus which could result in inhibition of NGF signalling. Similarly, addition of virus to 
MACS purified cells could induce cellular stress and therefore neurons would not respond to 
NGF as predicted. Another explanation might be that after TrkA knockout there is a 
compensatory mechanism upregulating p75 expression, which then mediates the NGF effect, 
however we were not able to confirm this on RNA level using RT-PCR.  
In MACS purified cultures from NGFR fl/fl mice treated with NGF and lenti Cre-GFP to knockout 
the p75 receptor there were no significant differences in neurite outgrowth between either 
the knockout or controls, or between cultures treated with NGF at different times points (0, 1 
or 2 days). We observed in control (no virus treatment) cultures from both NTRK1 fl/fl and 
NGFR fl/fl mouse strains that the MACS purified neurons showed no significant difference in 
neurite outgrowth between cultures treated with NGF for the entire 3 day duration of the 
experiment or untreated controls. In the previous chapter (chapter 2) we described that 
differences in neurite outgrowth assays were observed after 1 day in culture (Fig 2.6). 
Investigating neurite outgrowth after NTRK1 or NGFR knockout and NGF treatment did not 
reveal any NGF induced differences at the time of plating, 1 or 2 days after treatment. This 
might suggest that the neurons themselves secrete enough neurotrophins to sustain and 
saturate neurite outgrowth. 
In summary, our conclusion from this series of somewhat frustrating experiments was: delivery 
of the Cre recombinase to the floxed neurons via lenti virus is not the right approach since the 
knockout takes too long and the cells are not healthy anymore by the time of successful 




3.4.2 IT injection of AAV9 Cre-eGFP was effective in knocking out expression of 
floxed genes but there was variation in the transduction patterns 
After finding that transduction of MACS purified cultures from NTRK1 fl/fl and NGFR fl/fl mice 
was ineffective we decided to use an in vivo approach. We used intrathecal (IT) injections with 
an AAV9 Cre-eGFP into NTRK1 fl/fl and NGFR fl/fl mice to knockout expression of TrkA and p75 
respectively. IT injections with AAV9 is a well-established technique in the lab. We used an IT 
cannula to inject AAV9 into the intrathecal space using a method developed by a PhD student 
in the lab, Nikita Khovanov. All injections in this study were performed by Nikita Khovanov.  
Firstly, we measured the effectiveness of the knockout of the TrkA and the p75 mice in the 
respective floxed mouse lines. We observed that in the both NTRK1 fl/fl and NGFR fl/fl mice 
injected with AAV9 Cre-eGFP there was expression of GFP 2 and 4 weeks after injection with 
AAV9 Cre-eGFP. Interestingly, we observed that after 4 weeks there were less transfected cells 
and lower GFP expression compared to 2 weeks. We found this trend in both mouse lines, but 
in the NTRK1 fl/fl mice it reached significance. This observation is counter-intuitive. However, 
it has been found that overexpression of GFP in some cases is toxic for cells, especially when 
highly expressed (H. S. Liu et al. 1999). This phenomenon could explain the reduced efficiency 
after 4 weeks, however we did not detect any evidence of cell death in our 4 week samples (L4 
DRG sections). The loss in the signal of GFP could be the result of the Cre-eGFP fusion protein 
being degraded after active cleavage of the loxP sites in the gene of interest by the Cre 
recombinase-GFP fusion protein (Schulz et al. 2007), however as the virus would continue to 
produce the Cre-eGFP fusion protein in transfected cells this is unlikely. Next, we verified 
knockout of TrkA by staining for the protein in NTRK1 fl/fl L4 DRG neurons injected with AAV9 
Cre-eGFP. We found in both time points a comparable reduction in the percentage of TrkA 




assessed by expression there is only about 60% transduction efficiency at the peak of 
transduction 2 weeks after injection. Similar to NTRK1 fl/fl mice, expression of the GFP marker 
protein in L4 DRGs from NGFR fl/fl mice treated with AAV9 Cre-eGFP correlated with a 
decrease in the percentage of neurons expressing the p75 receptor compared to control levels, 
however this was not significant. Contrary to the NTRK1 fl/fl mice there was a further decrease 
in the expression of p75 after 4 weeks incubation with AAV9 Cre-eGFP compared to 2 weeks 
after injection despite there being a decreased number of neurons expressing the GFP marker 
protein 4 weeks after injection. The reason for this discrepancy in knockout between NTRK1 
fl/fl and NGFR fl/fl animals 2 and 4 weeks after IT injection of AAV9 Cre-eGFP is likely the result 
of large variation in the cannula placement during the injection, which in some animals results 
in unilateral transduction as observed in this study. As only 30% of NGFR fl/fl animals 
(compared to 91% of NTRK1 fl/fl animals) show a side bias in transduction and the percentage 
of cells expressing p75 are calculated across both L4 DRG, a higher proportion of cells overall 
could be transduced in NGFR fl/fl animals which resulted in this further decrease in p75 
expression.  
In both NTRK1 fl/fl and NGFR fl/fl mouse strains we observed a negative correlation between 
the percentage of cells expressing GFP and the percentage of cells expressing either TrkA or 
p75 from the respective knockout mouse. This indicates that as the percentage of neurons 
expressing of GFP increased, indicating successfully transduction, the percentage of neurons 
expressing the protein of interest decreased suggesting successful knockout of the targeted 
gene. TrkA and p75 NGF receptors are known to be only expressed in certain populations of 
neurons (Chapter 1.1) (Aloe et al. 2012; Richner et al. 2014). We observed the same when we 
stained sections of L4 DRGs from WT mice without IT injection and found that only 40% of 
neurons expressed of TrkA or p75. We established that there is only 60% transduction of DRG. 




can also assume that a proportion of the cells not transduced will also be positive or negative 
for TrkA or p75. This therefore may account for the incomplete knockout of either TrkA or p75 
following IT injection of AAV9 Cre-eGFP. However, a decrease in the expression of either the 
TrkA or the p75 receptor with an increase in the expression of GFP shows that there is no 
preferential transduction of certain neurons, there is at least partial transduction of the 
neurons of interest. Furthermore, work by a PhD in the lab Nikita Khovanov has shown that 
there is no preferential transduction of specific neurons in regards to cell size as he has 
observed that there was an equal level of transduction across small, medium and large 
diameter neurons (data not shown). 
We then used RT-PCR to confirm knockout of genes in whole DRGs taken from floxed animals 
IT injected with AAV9 Cre-eGFP.  We measured the expression of both NTRK1 and NGFR gene 
expression in injected NTRK1 fl/fl animals. Interestingly, we found that despite a trend towards 
a decrease in expression there was no significant decrease in the expression of NTRK1 either 2 
or 4 weeks after injection. This is likely due to RNA being extracted from whole L3 DRG pooled 
from both sides and therefore these samples contain a mix of neuronal and non-neuronal cells. 
In addition we only expect a proportion of neurons to be transduced with AAV9 Cre-eGFP and 
therefore be knockout for TrkA. We also measured the expression of NGFR 2 and 4 weeks after 
injection and observed no significant difference compared to whole DRGs from WT C57Bl 
animals which were not injected, which is again likely the result of the confounds of a mixed 
sample from whole DRGs as mentioned above. It should also be noted that these changes in 
gene expression from NTRK1 fl/fl animals were only calculated using 2 independent samples 
since a third sample failed in the isolation process as there was insufficient material to convert 
to cDNA. Therefore, without a third sample no statistics can be performed from this 
experiment. Following investigation of NTRK1 fl/fl animals we then measured the change in 




injection there was a significant decrease in the expression of NGFR confirming that AAV9 Cre-
eGFP mediated knockout of the p75 gene was effective. Interestingly, we also observed a 
significant decrease in the expression of the TrkA gene NTRK1 in these animals. The p75 
receptor has been identified to control apoptosis, but in combination with TrkA it has also 
been shown to contribute to growth and survival of neurons. This loss in both receptors could 
be the result of neuronal death following knock out of the NGFR gene, however as previously 
mentioned there is no evidence for a loss in the number of neurons in L4 DRG used for 
immunohistochemistry however, this could be further confirmed indirectly by measuring the 
cell size distribution of the remaining neurons to see if there is loss of a particular population 
of neurons. The decrease in the expression of the NTRK1 gene could be directly related to the 
loss of the NGFR gene and therefore could be regarded as a downstream effect following 
knockout of p75. It should also be noted that there is no data for gene expression of NTRK1 or 
NGFR genes 4 weeks after IT injection. This was due to a failure to isolate sufficient RNA from 
whole DRG in these samples and therefore would need to be repeated with a second cohort of 
animals in the future. For the future, more experimental replicates will be needed. However, 
we also propose to change the method used to isolate the cells in order to improve the 
assessment of changes in RNA expression. Following collection and dissociation of DRGs from 
IT injected neurons, transduced neurons should be isolated using FACS and RNA isolated from 
these neurons. Non-transduced cells without a GFP tag could be collected and used as an 
internal control, however, this would also contain non-neuronal cells which would dilute the 
expression of the gene of interest. One solution would be to use MACS purification to isolate 
neurons prior to FACS isolation, however, this would limit the GFP neurons to contain only 





3.4.3 MACS purified neurons following knockout of either the TrkA or the p75 
receptor using IT injection of AAV9 Cre-eGFP are irresponsive to NGF treatment 
in culture 
In order to determine if knockout of either the TrkA or p75 NGF receptors has an effect on the 
neuronal response to NGF we cultured non-MACS and MACS purified neurons from NTRK1 fl/fl 
and NGFR fl/fl mice2 weeks after IT injection of AAV9 Cre-eGFP. We made the assumption that 
all GFP expressing neurons were positively transduced and knockout for the gene of interest. 
Non-GFP expressing cells were used as internal controls for WT neurons. Cultures isolated 
from AAV9 injected NTRK1 fl/fl animals and MACS purified showed a significant decrease in 
the neurite outgrowth following NGF treatment in neurons with knockout of TrkA compared to 
controls suggesting that TrkA is essential for NGF mediated neurite outgrowth in pure neurons. 
However, non-MACS purified treated with NGF showed a trend towards a decrease in neurite 
outgrowth, however, the difference was not significant. This could be due to non-MACS 
cultures secreting factors such as neurotrophins which can induce neurite outgrowth through 
signalling via other growth factor receptors e.g. BDNF. In cultures isolated from injected NGFR 
fl/fl animals and MACS purified we found that neurons treated with NGF show a significant 
decrease in neurite outgrowth following knockout of p75 compared to controls similar to 
MACS purified cultures with knockout of TrkA treated with NGF. Interestingly, non-MACS 
cultures treated with NGF also showed a significant decrease in neurite outgrowth in neurons 
with knockout of p75 compared to controls. This suggests that p75 is essential for NGF 
mediated growth in culture. Taken together these results where both knockout of TrkA or p75 
in neurons results in a decrease in neurite outgrowth is contradictory to the common belief 
that alone TrkA signals growth or survival of neurons where p75 signals apoptosis of cells as 
both receptors appear to play a role in neuronal growth response to NGF (Capsoni and 




receptor for NGF, BDNF and NT-3. It could be that the significant decrease in neurite 
outgrowth in non-MACS purified cultures from NGFR fl/fl animals compared to NTRK1 fl/fl is 
the result of a loss in not only NGF signalling but also BDNF and NT-3 signalling. BDNF and NT-3 
are secreted from neuronal and non-neuronal cells (Richner et al. 2014; Lessmann, Gottmann, 
and Malcangio 2003). In the MACS purified cultures however it is likely that the decrease in 
neurite outgrowth is sole effect of the knockout of p75 on NGF signalling as in these cultures 
there are predominately small diameter nociceptors, known to be approximately 50% 
peptidergic nociceptors which express the TrkA receptor. TrkB (receptor for BDNF) is mainly 
expressed by medium diameter neurons and TrkC (receptor for NT-3) is expressed mainly by 
large diameter neurons (Richner et al. 2014). As previously described (chapter 2.4), medium 
and large diameter neurons are absent from MACS purified cultures and MACS purified 
cultures exhibit a lag in neurite outgrowth due to the lack of supportive factors secreted from 
non-neuronal cells. Therefore, we can assume that the increase in neurite outgrowth in MACS 
purified control cells treated with NGF compared to neurons cultured in the absence of NGF is 
the result of NGF mediated neurite outgrowth. As a result, the decrease in MACS purified cells 
with knockout of p75 cultured in the presence of NGF is the result of an insensitivity of 
neurons to NGF mediated by a loss in p75.  
3.4.4 Future directions for AAV9 Cre-eGFP mediated knockout of TrkA or p75  
We tried to knockout NTRK1 or NGFR by isolating and MACS purifying neurons from NTRK1 fl/fl 
and NGFR fl/fl mouse strains and treating them with lenti Cre-GFP virus to introduce Cre 
recombinase and achieve knockout of TrkA and p75 gene respectively in vitro. However, we 
concluded from the results that this method is not suitable for our study. Therefore, we chose 
to use AAV9 Cre-eGFP injected IT to effectively transduce DRG neurons in vivo. However, we 
observed that there was a varying degree of unilateral transduction as assessed by expression 




bias in the L4 DRG in 91% of animals (10 out of the 11 animals injected), however, only 
approximately 30% of NGFR fl/fl showed unilateral preference for transduction. The unilateral 
nature of the injection is likely the result of the cannula placement during the injection. In 
order to avoid damage to the spinal cord, the cannula is inserted on the left-hand side of the 
spinal cord, rather than the midline. Due to the observed bias in the NTRK1 fl/fl DRGs, the 
injection of the NGFR fl/fl animals was slightly altered as the end was pointed towards the 
midline during injection. The improvement of the injection resulted in only 30% animals 
showing any bias. This is considerably better than 91% achieved before, however, it is not yet 
ideal since the aim is to have 0% bias. Any bias would complicate any behavioural experiments 
for obvious reasons and normalisation to the degree of knockout of left or right would have to 
be performed. However, if a behavioural effect was observed, or not, various degrees of 
transduction could elucidate if there was any kind of dose response.  
In order to perform behavioural experiments, it would be beneficial to have better controls for 
the study. The control used in our study used WT C57Bl mice (brought in from Harlan, UK) 
which were not injected with any AAV9. We chose this control as the transgenic mice are all 
bred onto the same C57Bl background. Ideally, this study would have used littermate controls  
that were WT for the floxed alleles. However, the number of available animals was limited due 
to breeding constraints. Therefore, we opted to use commercially supplied control animals in 
this pilot experiment to determine if using an AAV9 viral vector resulted in any significant 
knockout of either the NTRK1 or the NGFR gene from NTRK1 fl/fl and NGFR fl/fl animals 
respectively. In order to further validate this model, particularly for use in behavioural 
experiments, a number of additional controls groups should be needed included, such as naïve 
mice or sham groups, saline injected, injected with an AAV9 GFP control virus and finally the 
AAV9 Cre-eGFP injected group. These controls would shed light on any effect caused by the 




the floxed allele itself. Such in-depth analysis of the model was outside of the scope of this 
thesis due to animal and time constraints.  
In this study we used non-MACS and MACS purified cultures from AAV9 Cre-eGFP injected and 
measured neurite outgrowth response to 24 hours of NGF treatment. It is important to note 
that there are confounds to the neurite outgrowth method used in this study that could be 
improved in the future. Following IT injection of AAV9 Cre-eGFP there is incomplete 
transduction of DRG neurons which were then MACS purified and used for cultures. As these 
cultures contain a mix of peptidergic and non-peptidergic neurons it is therefore it is 
reasonable to assume that for example in the case of cultures from NTRK1 fl/fl animals a 
proportion of the GFP negative neurons analysed for neurite outgrowth are peptidergic and 
TrkA positive internal controls. However, there would also be a subset of these neurons which 
are non-peptidergic and therefore neurons which would not express TrkA and are unsuitable 
as controls. Similarly, a proportion of the GFP positive neurons would be peptidergic neurons 
which are the targeted KO neurons for TrkA where other neurons would be non-peptidergic 
neurons which would not express TrkA and confound the results of this study. Therefore, in 
the future it would be advisable to counterstain these cultures for both a non-peptidergic 
marker such as Ret or IB4 in addition to a counterstain for either TrkA or p75 positive neurons 
for cultures from NTRK1 fl/fl and NGFR fl/fl mice respectively. In this case neurons that are 
stained positive for either TrkA or p75 and negative for GFP would be used as control neurons 
where neurons which are positive for GFP and negative for the non-peptidergic marker would 
be analysed as KO neurons in the neurite outgrowth assay. 
Other assays that could be used to measure a potential effect of the knockout of the TrkA or 
p75 receptor. These include calcium imaging and patch clamping of GFP negative and positive 
neurons. In calcium imaging NGF has been used as a sensitising agent for neurons. Bonnington 




gradually desensitised the neuronal response to the stimulus as seen by a decreased calcium 
influx.  However, when they performed five applications of capsaicin and then added NGF to 
the culture, a sixth application of capsaicin then produced a response similar to the first 
application of the stimulant suggesting that the NGF had acted to sensitise the neurons to the 
stimulus (Bonnington and McNaughton 2003). We used the calcium imaging method described 
in Bonnington et al in MACS purified DRG cultures from adult mice however we were not able 
to reproduce the described results. In our hands only approximately 10% of neurons became 
re-sensitised by repeated capsaicin and NGF treatment (data not shown). Potential 
explanations why we were not able to reproduce the published data might be that we used 
adult DRG cultures as opposed to embryonic cultures or that we used MACS purified cultures 
as opposed to whole DRG cultures. Another important difference to note is that the 
Bonnington et al study cultured DRG neurons in the presence of NGF as embryonic neuronal 
cultures require NGF for survival and therefore this pre-exposure to NGF may have primed 
cells for this response. Since we are interested the response of cells to NGF following the KO of 
either the NTRK1 or NGFR gene from floxed animals, we chose not to use any pre-incubation 
with NGF in these cultures. However, for the future pre-sensitisation of our cells to NGF could 
be performed and the assay repeated. Another approach, as mentioned above, would be 
patch clamping, a method used to investigate and characterise the biophysical properties of 
neurons. We could employ it to further characterise our MACS purified knockout cells. 
Tsantoulas et al used patch clamping in DRG cultures 6-8 days after culturing cells in 
microfluidic chambers where the cell soma and axons are cultured in separate compartments. 
In this study cell somas were patched and current was constantly measured in the cell soma 
following pulses of electrical stimulation to the axonal compartment. Using micropipettes, 
patch clamping also allows application of pharmacological agents such as lidocaine or 




Performing patch clamping on our knockout cells could identify if NGF stimulation of TrkA or 
p75 knockout cells results in a diminished firing pattern and would prove that NGF stimulation 
is essential for the electrophysical potential of pure DRG neurons following application of 
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Supplementary figure 3.1 Additional neurite outgrowth measurements of MACS purified DRG 
neurons isolated from NTRK1 fl/fl mice treated with lenti CreGFP at MOI 30 for 3 days. a- 
Longest (p=0.0172), b shortest and c mean neurite length (p=0.0360), d number of neurites, e 
total neurite outgrowth from longest branch and f overall neurite outgrowth normalised to 





Supplementary figure 3.2 Additional neurite outgrowth measurements of MACS purified DRG 
neurons isolated from NGFR fl/fl mice treated with lenti CreGFP at MOI 30 for 3 days. a- 
Longest, b shortest and c mean neurite length, d number of neurites, e total neurite outgrowth 

















Supplementary figure 3.3 No significant difference in the expression of NTRK1 or NGFR 
following lenti CreGFP treatment of DRGs isolated from NTRK1 fl/fl or NGFR fl/fl mice and 
MACS purified. Relative expression of GAPDH, NTRK1 and NGFR as shown by Cq values 
following lenti CreGFP treatment at MOI 0 or 30 for 0, 1, 2 or 3 days in vitro for a NTRK1 fl/fl 
and b NGFR fl/fl mice. RNA concentration c and RIN value d of RNA used. Two-way ANOVA with 











Supplementary figure 3.4 AAV9 Cre-eGFP intrathecal injections display some unilateral 
transduction patterns. a- Percentage of cells expressing TrkA in the left and right L4 DRG 2 and 
4 weeks post AAV9 Cre-eGFP injection in NTRK1 fl/fl mice. b- percentage of cells expressing p75 
in the left and right L4 DRG 2 and 4 weeks post AAV9 Cre-eGFP injection in NGFR fl/fl mice. c 




Cre-eGFP injection in c NTRK1 fl/fl and d NGFR fl/fl mice. Correlation of GFP and TrkA or p75 
expression in e NTRK1 fl/fl and f NGFR fl/fl mice respectively from left and right L4 DRG 2 and 4 
weeks post AAV9 Cre-eGFP. Solid lines show linear regression and dotted lines show 95% CI. 
NTRK1 fl/fl left R2=0.1355 and right R2=0.5018. NGFR fl/fl left R2=0.5046 and right R2=0.2793. 









Supplementary figure 3.5 Additional neurite outgrowth measurements for non-MACS 
purified DRG neurons 2 weeks post intrathecal AAV9 Cre-eGFP in NTRK1 fl/fl mice. a- 
Longest, b shortest and c mean neurite length, d number of neurites, e total neurite outgrowth 
from longest branch and f overall neurite outgrowth normalised to number of neurites. All 









Supplementary figure 3.6 Additional neurite outgrowth measurements for MACS purified 
DRG neurons 2 weeks post intrathecal AAV9 Cre-eGFP in NTRK1 fl/fl mice. a- Longest 
(p=0.0008), b shortest (p<0.0001) and c mean neurite length (p=0.0002), d number of neurites 
(p=0.0068), e total neurite outgrowth from longest branch (p=0.0002) and f overall neurite 
outgrowth normalised to number of neurites (p=0.0005). One-way ANOVA with Tukey post hoc, 








Supplementary figure 3.7 Additional neurite outgrowth measurements for non-MACS 
purified DRG neurons 2 weeks post intrathecal AAV9 Cre-eGFP in NGFR fl/fl mice. a- Longest 
(No NGF p=0.0026 and NGF p=0.0006), b shortest (p=0.0252) and c mean neurite length (No 
NGF p=0.0478 and NGF p=0.0055), d number of neurites (No NGF p=0.0075 and p=0.0312), e 
total neurite outgrowth from longest branch (No NGF p=0.0410 and NGF p=0.0077) and f 
overall neurite outgrowth normalised to number of neurites (p=0.0035). One-way ANOVA with 








Supplementary figure 3.8 Additional neurite outgrowth measurements for MACS purified 
DRG neurons 2 weeks post intrathecal AAV9 Cre-eGFP in NGFR fl/fl mice. a- Longest 
(p=0.0146), b shortest and c mean neurite length (p=0.0332), d number of neurites (p=0.0073), 
e total neurite outgrowth from longest branch (p=0.0041) and f overall neurite outgrowth 




















Chapter 4: Generation of a new 
conditional knockout mouse line for 
TrkA and p75 
4.1 Introduction 
In the previous chapter (chapter 3), we used both NTRK1 fl/fl and NGFR fl/fl mouse lines in 
combination with viral vectors expressing Cre recombinase to induce knockout of NTRK1 and 
NGFR genes, which encode the NGF receptors TrkA and p75, respectively. We used a lenti Cre-
GFP virus in vitro and IT injection of an AAV9 Cre-eGFP in vivo to deliver Cre recombinase. 
However, both of these methods were found to have disadvantages.  Therefore, we decided to 
use another approach to generate TrkA and p75 knockout. We bred these floxed lines with a 
mouse line encoding tamoxifen-inducible Cre recombinase under the Advillin promoter which 
is only expressed in sensory and sympathetic neurons. This allows allow both spatial and 
temporal control of the gene knockout in animals, thus allowing us to bypass the 
developmental impact of early knockout of either NGF receptor or its ligand NGF observed in 
global knockout mice (Chapter 1.2)(Crowley et al. 1994; Smeyne et al. 1994; K. F. Lee et al. 




4.1.1 Generation of spatial-temporal controlled transgenic lines  
4.1.1.1 Spatially controlled conditional knockout lines 
As previously described the Cre-loxP system has been identified as an invaluable tool for using 
temporal and spatial control of gene expression and functional genomics (Chapter 3.1.2) 
(Branda and Dymecki 2004). Brown et al. generated knockout mouse lines using zinc-finger 
nucleases (ZFNs) delivered using pronuclear microinjections into fertilised rat eggs. They used 
2 pairs of ZFNs targeted against 2 specific genes where each pair of ZFNs cleaved an intron 
flanking the region of the exon of interest and inserted a loxP site. Generation of a second 
transgenic mouse expressing Cre fused to an internal ribosomal entry site (IRES) cassette under 
the control of an endogenous promoter, where the IRES cassette allows separate transcription 
of the Cre after translation of the gene upstream of the insertion site, i.e. the promoter gene 
of the Cre. In this study IRES-Cre was injected by pronuclear injection into a fertilised egg as 
part of a donor plasmid in combination with a pair of ZFN which promotes insertion of the 
IRES-Cre immediately after the translational stop of the tyrosine hydroxylase (th) gene, 
therefore placing the Cre under the control of the th promoter. Newly generated floxed and 
Cre mouse lines were then crossed and tissue specific knockout was observed of the floxed 
genes (A. J. Brown et al. 2013).  
4.1.1.2 Temporally controlled conditional knockout lines  
Following success using spatial restriction placing the Cre gene expression under the control of 
specific promoters, studies were performed to place the Cre gene under temporal control 
following fusion of the Cre gene with the hormone binding oestrogen receptor (ER). In order to 
prevent activation of the Cre recombinase by endogenous oestrogen Feil et al reported how 
targeted triple mutations in the ligand binding domain (LBD) of the ER resulted in ligand 




(E2). They found that using either the G400V/M543A/L544A or G400V/L539A/L540A triple 
mutation by site directed recombination of the human ER fused to the Cre recombinase from 
bacteriophage P1 resulted in ligand specific activation from synthetic oestrogen only, such as 
4-hydroxytamoxifen (OHT) and ICI 182,780 (ICI) respectively (R. Feil et al. 1997). Hayashi et al 
describes how they bred a new Cre-ERTM mouse line, also insensitive to endogenous oestrogen 
but generating by mutating a different site in the LBD of the ER and under the control of the β-
actin promoter, where Cre recombinase can be ubiquitously expressed in all cells, induced by 
tamoxifen. It has further been shown that Cre expression can effectively be activated with 
tamoxifen treatment in utero or postpartum or with the active metabolite of tamoxifen 4OH-
TM in vitro (Hayashi and McMahon 2002). In parallel, Metzger et al generated a Cre-ERT 
transgenic mouse line by inducing a point mutation in the LBD of ER resulting in Gly521Arg 
mutation. This mutated Cre was expressed under the control of the CMV promoter, which is 
expressed in several tissues. These mice were then crossed into a floxed RXRα mouse line and 
the Cre activated by tamoxifen injection. Subsequent expression  as measured using RT-PCR of 
the affected tissues showed successful downregulation of RXRα after tamoxifen treatment 
(Metzger and Chambon 2001). Cre-ERT mice were bred with an ACZL lacZ reporter line, which 
carries a CMV enhancer β-actin promoter-loxP- chloramphenicol acetyltransferase (CAT) 
cassette-loxP-lacZ cassette, whereby the lacZ reporter is only expressed following Cre 
mediated excision of the CAT cassette. It was observed that at later time points following 
tamoxifen injection lacZ expressing cells in the tail migrated from the granular layer into the 
cornified layer of the epidermis. This suggests that in this model there was no tamoxifen 
mediated excision of the CAT cassette in the proliferative basal keratinocytes of the epidermis 
as the lacZ reporter was lost over time as the epidermis was renewed. Therefore, it is 




Cre recombinase is active in progenitor cells repeated treatment of tamoxifen is required 
(Metzger and Chambon 2001). 
It has been found that the triple mutation G400V/M543A/L544A in the LBD of the ER described 
above in the CreERT2 mouse is three to four fold more sensitive to OHT in F9 cells compared to 
Cre-ERT. It has therefore been hypothesised that this mutation is more potent in mice too (R. 
Feil et al. 1997; Metzger and Chambon 2001; Leone et al. 2003). This Cre-ERT2 containing this 
triple mutation in the ER has since been used in a number of studies, including neuroscientific 
studies by fusing Cre-ERT2 to a cell line specific promoter (S. Feil, Valtcheva, and Feil 2009). For 
example, a study by Leone et al used the Cre-ERT2 line to generate novel mouse lines for 
targeted gene ablation in oligodendrocytes and Schwann cells, the myelinating glial cells of the 
nervous system. First, they inserted CreERT2 into a proteolipid protein (PLP) regulatory region 
which is sufficient to direct specific transgene expression in oligodendrocytes and Schwann 
cells (PLP-CreERT2). They also inserted CreERT2 under the control of the P0 promoter driving 
the connexin32 gene to generate a Schwann cell specific inducible Cre line (P0Cx-CreERT2). 
Characterisation of these lines revealed that they result in cell specific knockouts across both 
the CNS and the PNS (Leone et al. 2003). A sensory and sympathetic neuron specific Cre mouse 
line using the CreERT2 has also been developed. Lau et al generated an Advillin-CreERT2 line, 
where Advillin is an actin-binding protein of the gelsolin family which is expressed in sensory 
and sympathetic neurons. A bacterial artificial chromosome (BAC) was used to generate this 
line. It contained part of exon 2 of the Advillin gene which contains an ATG start codon. The 
CreERT2 was fused to this ATG start codon of the Advillin gene. This BAC was then injected into 
embryos using pronuclear injection and offspring were screened to test the number of copies 
of BAC inherited. They found here that the generated mouse line contained 10 copies of the 




4.1.2 Delivery methods of tamoxifen to Cre-ER transgenic mouse lines 
There have been several treatment regimens described for treatment of floxed mice with 
tamoxifen, a drug which is metabolised into the active metabolite OHT (S. Feil, Valtcheva, and 
Feil 2009). Feil et al 2009 summarises different methods which have been used to induce gene 
knockout in animals using tamoxifen. This includes in utero methods where pregnant females 
have been given i.p. doses of tamoxifen at 1 mg at E12.5, oral doses of 3-4 mg at E8.5-11.5, 
oral doses of 5-10 mg for up to 3 days at E12.5-13.5 or i.p. injection of OHT directly of 1 mg for 
3 days at E12.5-14.5. Postnatal delivery of tamoxifen has also been shown to be successful via 
different routes. i.p. injection of 1mg tamoxifen for 5 consecutive days in lactating mothers 
where the tamoxifen is passed pups indirectly via milk from the mother or directly to the pup 
by i.p. injection of 0.25-1 mg tamoxifen for 5 consecutive days, oral delivery or intragastric 
injection of 0.05-0.1 mg for 3 consecutive days or topical skin exposure to 0.05-1 mg OHT for 3 
consecutive days. Adult treatment with tamoxifen also includes a range of doses and routes. 
This includes 0.01-1 mg OHT or tamoxifen i.p. for 5 consecutive days, oral 1 mg tamoxifen for 5 
consecutive days in 5 week old mice or 1-5 mg oral tamoxifen for 5 days in 4-8 week old mice 
(S. Feil, Valtcheva, and Feil 2009). Differences in treatment methods vary according to the age 
of mice and the target tissue. However, there is no standard method even within these 
parameters. There is evidence that high doses of tamoxifen in utero can result in failure for 
embryos to develop to term as has been found with Cre-ERTM mice (Hayashi and McMahon 
2002). Having said that, there was no difference in expression from tamoxifen injections from 
0.5-3 mg although higher doses induced faster recombination (Hayashi and McMahon 2002). 
Kinetics of the efficiency of Cre-ERT following treatment of tamoxifen was investigated by 
crossing Cre-ERT mice this line with an ACZL reporter mouse which expressed lacZ in the 
presence of Cre as described above (chapter 4.1.1.2), which can be visualised using β-




and compared to controls. Expression of β-galactosidase was observed 2 to 3 days after 
tamoxifen treatment in the granular layer of the tail (Metzger and Chambon 2001). Crossing of 
the PGP-CreERT2 and P0Cx-CreERT2 oligodendrocyte and Schwann cell specific Cre mouse 
lines with a R26R reporter line which contains a loxP-STOP-loxP lacZ site, was used to generate 
a reporter line to test the specificity of the Cre line, where lacZ is transcribed following the 
activation of Cre. For cells within the nervous system five days of consecutive injections of 1 
mg tamoxifen in 8 week old mice was found to be sufficient to achieve knockout in the lines in 
the CNS. However, for effective transduction of the PNS it was found that twice daily injections 
of 1 mg tamoxifen for 5 consecutive days was required (Leone et al. 2003). Lau et al also used 
2 mg tamoxifen injections for 5 consecutive days to induce Cre expression in AdvCreERT2 mice 
crossed with a Rosa26LacZ reporter mouse where lacZ expression was observed in sensory 
neurons (Lau et al. 2011). Recently, a study has been published which for the first time 
investigated the toxic effects of tamoxifen in mice. In the Atf3-CreERT2 mouse line the 
CreERT2 was under the control of Atf3, a marker of cellular stress. This line was bred with a 
TdTomato reporter line where the presence of active Cre recombinase results in the 
expression of the TdTomato marker protein. This study found that tamoxifen alone resulted in 
expression of TdTomato in areas of the brain such as the olfactory bulb and the dentate gyrus 
in addition to peripheral sensory neurons. Further investigation suggests that upregulation of 
this stress associated marker was the result of tamoxifen mediated inhibition of cholesterol 
epoxide hydrolase (ChEH). However, expression was mitigated by dissolving tamoxifen in 
wheat germ oil which is rich in vitamin E compared to the commonly used sunflower oil, with a 
treatment regime of 75 mg/kg (1.5 mg) i.p for 3 consecutive days (Denk et al. 2015).  
4.1.3 Aim of the study 
The aim of this part of the study was to generate a knockout mouse line that allows spatial and 




fl/fl mouse lines with an AdvCreERT2 (Lau et al. 2011) line we aimed to generate conditional 
inducible knockout lines for both NGF receptors. Conditional knockout of the NTRK1 and NGFR 
genes will be restricted to cells expressing the Advillin gene by using a Cre mouse line that 
expresses Cre under the control of the Advillin promoter. Since the Advillin gene is expressed 
in sensory and sympathetic neurons there is spatial control of gene knockout. Fusion of Cre 
recombinase to a mutated ER (ERT2) results in the Cre recombinase remaining inactive and 
bound to heat shock protein 90 (HSP90) except in the presence of tamoxifen, where binding of 
tamoxifen to the LBD results in confirmation change of the Cre protein and the HSP90 is 
released and active Cre then moves to the nucleus where it recognises and cleaves LoxP sites 
(Leone et al. 2003).  This therefore allows temporal control of gene knockout. Once the NTRK1 
fl/fl; AdvCreERT2 and NGFR fl/fl; AdvCreERT2 mouse lines were generated the second aim of 
this part of the study was to use tamoxifen (TMX) to induce knockout of the NTRK1 and NGFR 
genes respectively in Cre positive mice, characterise the effectiveness of the knockout at the 
RNA and protein level, and investigate the adult phenotype following gene knockout.  
4.2 Methods 
4.2.1 Animals 
All animals were housed in a designated facility and maintained in accordance with ASPA and 
Home Office regulations. Animals were kept in a 12hr light dark cycle and fed ad libitum. All 
animals were sacrificed using schedule 1. NTRK1 fl/fl (Ntrk1tm1c(EUCOMM)Wtsi ) and NGFR fl/fl 
(Ngfrtm1c(EUCOMM)Wtsi) transgenic mice obtained from the International Mouse Phenotype 
Consortium (IMPC) from Harwell, previously described in chapter 3.1.1 were crossed with 
Advillin CreERT2 (AdvCreERT2) transgenic mice (kindly provided by Prof John Wood, UCL). 
AdvCreERT2 mice were backcrossed into the C57Bl6 background for 5 generations prior to 




generated using pronuclear injection of a BAC containing the fused Advillin and CreERT2 gene 
where there is insertion of the BAC into the genome at several sites and therefore these mice 
are hemizygous and defined as either Cre negative or Cre positive based on genotype. There is 
no homozygous or heterozygous AdvCreERT2. Homozygous NTRK1 fl/fl and NGFR fl/fl mice 
were crossed with hemizygous AdvCreERT2 mice. The resulting heterozygous NTRK1 +/fl or 
NGFR +/fl AdvCreERT2 positive mice were then crossed in order to generate homozygous 
NTRK1 fl/fl or NGFR fl/fl; AdvCreERT2 positive mice respectively. All animals were sacrificed 
according to Schedule 1 procedure.  
4.2.2 Genotyping 
As described in the methods section of chapter 3.2.2.  
Progeny from the crossings of NTRK1 fl/fl and NGFR fl/fl mice with AdvCreERT2 were 
genotyped using the specific primers for the floxed allele of NTRK1 or NGFR (as described in 
chapter 3.2.2) in addition to two sets of primers for the AdvCreERT2 inheritance in separate 
PCR reactions. For the AdvCre primers, WT bands were observed at 480 bp and mutant bands 
at 180 bp. For the CreERT2 primers a mutant band was observed at 435 bp.  
The AdvCreERT2 founder colony was also crossed with another floxed line LIFR fl/fl 
(Lifrtm1c(EUCOMM)Hmgu) from the International Mouse Phenotype Consortium (IMPC) from Harwell, 
details of the number of mice FD and inheritance of the Cre gene are included in Fig 4.2. 
Similar to the NTRK1 fl/fl and NGFR fl/fl lines LIFR fl/fl mice contain a loxP flanked region of a 
critical region of the gene for the lif receptor which can be excised and expression knocked out 















4.2.3 Tamoxifen dosing  
Tamoxifen was prepared as follows: 0.195g of tamoxifen (Sigma, T5648) was dissolved in 2ml 
of 100% ethanol. Solution was vortexed until the tamoxifen was dissolved and diluted in 23ml 
of wheat germ oil resulting in a final tamoxifen concentration of 7.8 µg/µl. The wheat germ oil 
was placed on a shaker at RT and left until it was well mixed, typically 15-20 min. It was then 
aliquoted and stored at 4⁰C for up to 3 days or stored at -20⁰C for up to 3 months. Adult mice 
9-12 and 19 week old were intraperitoneally (i.p.) injected with tamoxifen at 75 mg/kg i.p. for 
3 consecutive days.  
4.2.4 Immunohistochemistry 
As described in the methods section of chapter 3.2.8. 
Using the cryostat sections of lumbar spinal cord around the L3 to L5 region were cut to a 




hind-paws was collected. However, in this study we only measured the number of 
intraepidermal nerve fibres (IENF) in the left paw for each animal. Contrary to DRG and spinal 
cord sections, plantar skin was also collected onto gelatine coated slides. Briefly, gelatine 
coated slides were prepared by distilled water by dissolving 1.5g of Gelatine type A (Sigma, 
G2500) and 0.25g chromium potassium sulphate (Sigma, 34636) in 500 ml distilled water 
heated to 60⁰C. The solution was then cooled to 40-50⁰C and racks of slides dipped twice to 
coat. Slides were then covered and left in a dust free environment overnight to dry before use. 
The following primary antibodies were used for this chapter: 1:200 anti-TrkA goat polyclonal 
(R&D systems, AF1056), 1:1000 anti-β-III tubulin rabbit polyclonal (Abcam, ab18207), 1:500 
anti-p75 NGF receptor rabbit polyclonal (Abcam, ab8875), 1:500 anti-PGP 9.5 rabbit polyclonal 
(Ultraclone, RA95101) and 1:1000 anti-NeuN rabbit mAb (cell signalling, 12943). 
The following secondary antibodies were used for this chapter: 1:1000 Chicken anti-goat IgG 
(H+L) Alexa Fluor® 488 (ThermoFisher, A21467), 1:1000 donkey anti-rabbit IgG (H+L) Alexa 
Fluor® 488 (ThermoFisher, A21206), 1:1000 donkey anti-rabbit IgG (H+L) Alexa Fluor® 568 
(ThermoFisher, A10042) and 1:1000 donkey anti-mouse IgG (H+L) Alexa Fluor® 488 
(ThermoFisher, A21202).  
4.2.5 RT-PCR  
As described in the methods section of chapter 3.2.11. 
4.2.6 RNA sequencing  
L2, 3 and 5 DRGs from both sides of the spinal cord were collected from NTRK1 fl/fl littermate 
controls and NTRK1 fl/fl; AdvCreERT2 mice 4 weeks after i.p. injection with tamoxifen. At the 
time of injection mice were 12-19 weeks of age. DRGs were triturated and MACS purified as 




purified neurons were lysed and RNA was isolated and purified as described in the methods 
section of chapter 3 (chapter 3.2.9) except that the quantity and quality of RNA was measured 
using the Agilent RNA 6000 pico kit (Agilent technologies, 5067-1535) and measured using the 
Agilent2100 Bioanalyzer (Agilent, Santa Clara, CA). Once confirmed that there was sufficient 
RNA and the RIN for each sample was above 8, samples were transferred to a 96 well plate and 
sent off to high throughput genomics at the Oxford genomics centre, University of Oxford, for 
RNA sequencing. Samples were run on an Illumina HiSeq4000 platform. Analysis was 
performed using the online bioinformatics software the galaxy project with the Tuxedo suit. 
Files were re-aligned and mapped back to the genome using TopHat2. Fragments per kilobase 
per million (FPKM) was then estimated using Cufflinks and then the differential expression 
measured using CuffDiff (Thakur et al. 2014; Michalovova et al. 2015). Data was then sorted 
according to unadjusted p value with a first cut-off of p ≤ 0.0001. When the data was split into 
males and females it was observed that there was a larger number of differentially regulated 
genes in males alone compared to males and females combined. However, with the first cut-
off for p values in the males only NTRK1 expression was not included in the differentially 
regulated genes between WT and CKO animals. Applying a second cut-off of p ≤ 0.001 included 
the NTRK1 gene in the list of genes differentially regulated (total 184 genes). This second cut-
off was also applied to data for males and females combined and a list of 63 differentially 
expressed genes obtained. Data was then sorted according to log2 fold change to arrange data 
based on the number of genes up and down regulated. Heat maps were plotted for 
differentially regulated genes for males and females combined and males only using FPKM 
values.  
4.2.7 Behavioural tests 
Thermal hypersensitivity was measured using the static hot plate test (Hunskaar, Berge, and 




the plate, and a timer started. The time taken for the mouse to respond as seen by a flicking, 
licking or biting behaviour of the hind paw was measured. We used a 40 second cut-off where 
any animal that failed to respond within 40 seconds was removed from the hot plate to 
prevent injury. This test was performed at either 2 or 4 weeks post the first tamoxifen injection 
for two separate cohorts of NTRK1 fl/fl mice where for the 2 week cohort 4 control and 4 
knockout animals were used and for the 4 week cohort 7 control and 7 knockout animals were 
used. For NGFR fl/fl animals a single cohort of animals was tested on the static hot plate after 2 
weeks where 4 control animals and 3 knockout animals were used.  
Mechanical hypersensitivity was measured using Von Frey hairs using the SUDO up down 
method (Bonin, Bories, and De Koninck 2014). Briefly, mice were introduced to the test boxes 
and acclimatised for 45 minutes to acclimatise prior to testing. All mice were first tested on the 
left hind paw with the 0.6g Von Frey hair. Hairs were placed into the centre of the paw twice 
to assure the response was accurate. A positive response to the hair was defined as a flicking 
or licking of the hind paw. In case of a positive response the subsequent hair used for testing 
was a lower weight, for non-responders the weight of the Von Frey hair was increased by one 
level for the subsequent round of testing. Once all animals were tested with the first hair on 
the left paw, the right paw was tested with the first hair before proceeding to the left paw for 
the second hair. The testing alternated between the left and right hind paws for all animals 
until 5 responses had been measured for each paw. All animals were given 3 baseline 
measurements over 3 subsequent days 1 week prior to tamoxifen treatment. The test was 
then repeated 1, 2, 3 and 4 weeks post the first tamoxifen injection. The 50% threshold for 
withdrawal was then calculated for each paw for all animals (Chaplan, SR, Bach, FW, Pogrel, 




4.2.8 Imaging and analysis  
Images of immunohistochemistry were obtained as described in the methods section of 
chapter 2.2.7. A minimum of 3 sections of a L4 DRG or lumbar spinal cord was imaged per 
animal.  
Expression of TrkA or p75 in the L4 DRG was measured using the cell counter plugin of Fiji. The 
cell size distribution was measured by circling the cell soma and calculating the Feret diameter 
from the area using Fiji.  
Expression of TrkA in the spinal cord was measured by circling the area of both superficial 
dorsal horns in control and conditional knockout animals. The relative fluorescence was 
measured, normalised to the area circled and an average calculated for both superficial dorsal 
horns per section. Within each section a similar sized region of both ventral horns was circled 
and fluorescence was normalised to that area and an average background level of fluorescence 
was obtained from both ventral horns. The expression of TrkA in the dorsal horn as measured 
by the fluorescent signal was then normalised to the corresponding ventral horn control for 
each section. An average level of fluorescence was calculated from the 3 sections of each of 
the 4 control animals imaged and all data was normalised to this average to calculate the FC in 
expression in the conditional knockout animals.  
Intraepidermal nerve fibre (IENF) density was calculated by counting the fibres staining 
positive for PGP 9.5, a marker for axons and small nerve fibres in peripheral tissue. The 
number of PGP 9.5 positive fibres in the intraepidermal space was counted from 5 sections of 
left hind paw plantar skin per animal. Fibres that branched prior to crossing into the 
intraepidermal space were counted as separate fibres, however all branches inside the 
intraepidermal space were counted as one fibre. The number of fibres was then normalised to 




FC was calculated using the delta delta CT value normalised to GAPDH for RT-PCR.  
4.2.9 Statistics  
Graphs were plotted and statistical tests performed using GraphPad Prism 7 software.  
For immunohistochemistry, expression of TrkA in the L4 DRG of NTRK1 fl/fl; AdvCreERT2 mice 
was tested using a one-way ANOVA with Sidak’s multiple comparison test. However, for 
testing a potential change in TrkA expression in the spinal cord or p75 expression in L4 DRGs in 
the NGFR fl/fl; AdvCreERT2 mice a two-tailed unpaired student t-test was used. Changes in cell 
size distribution in both the NTRK1 and the NGFR fl/fl; AdvCreERT2 was measured using a two-
way ANOVA with Sidak’s multiple comparison test. Finally, for measuring changes in the IENF, 
a one-way ANOVA with Tukey multiple comparison test was used for NTRK1 fl/fl; AdvCreERT2 
mice and a two-tailed unpaired student t-test for NGFR fl/fl; AdvCreERT2 mice.  
Two-tailed unpaired student t-tests were also used to measure any significant differences in 
gene expression from all RT-PCR experiments and changes in thermal hypersensitivity using 
the static hot plate. Two-way ANOVA with Tukey post-hoc test was used to assess changes in 
mechanical hypersensitivity using Von Frey hairs. 
4.3 Results 
4.3.1 Breeding a new line of conditional TrkA or p75 knockout animals 
In order to investigate the role of TrkA and p75 in vivo we bred inducible conditional knockout 
mice for TrkA (NTRK1) and p75 (NGFR) KO. We crossed NTRK1 fl/fl and NGFR fl/fl mice with 
AdvCreERT2 transgenic mice to obtain homozygous NTRK1 fl/fl or NGFR fl/fl and AdvCreERT2 
positive animals (Fig 4.1). In our experiments, we used littermate controls that were 





Figure 4.1 Breeding plan of transgenic mice. Examples of the breeding plans for crossing the 
NTRK1 fl/fl or the NGFR fl/fl mice with hemizygous AdvCreERT2 from either a a homozygous or 




The breeding of these various lines proved to be problematic. A number of AdvCreERT2 
positive mice were found dead (FD) for unknown reasons. Even more animals were FD when 
carrying a floxed allele in addition to the gene for Cre recombinase. The following percentages 
of Cre positive or negative mice FD from the total number of Cre positive or negative animals 
in the colony have been identified. For the AdvCreERT (A1645) 13.2% of animals FD were 
positive and 1.2% negative, for the LIFR fl/fl; AdvCreERT2 (A1831) 41.2% were positive and 
2.4% negative, for the NGFR fl/fl; AdvCreERT2 (A1832) 88.9% were positive and 3.8% negative 
and finally for NTRK1 fl/fl; AdvCreERT2 (A1833) 76.2% were positive and 6.1% negative. The 
total percentage of mice FD from the total number of mice in the colony however was not 
found to be high. For the AdvCreERT2 5% of animals were FD, 10.8% from the LIFR fl/fl; 
AdvCreERT2, 16.4% from the NGFR fl/fl; AdvCreERT2 and 13.6% from NTRK1 fl/fl; AdvCreERT2, 
data taken up until the end of July 2016 (Fig 4.2a). It should be noted that LIFR fl/fl; 
AdvCreERT2 which are conditional knockout for the lif receptor are not used directly in this 
study but they were an additional colony crossed with the AdvCreERT2 line under my care and 
exhibited similar sign of breeding issues. Therefore, I have incorporate breeding data from this 
line into this study. 
We then investigated if there were any environmental factors that had an impact on sudden 
death of animals in a given month. When split into months, it became apparent that there was 
a peak in death occurrence between November 2015 and February 2016, and then again 
between March and May 2016 in the NGFR fl/fl; AdvCreERT2 and NTRK1 fl/fl; AdvCreERT2 
colonies particularly (Fig 4.2b). Investigating the age of death revealed a wide age range at the 
time of death. The average age of male mice FD from the AdvCreERT2 line was 152 ± 98 days, 
from the LIFR fl/fl; AdvCreERT2 line 168 ± 68 days for males and 85 ± 39 days for females, from 








Figure 4.2 Breeding of transgenic animals was slow and there unexplained deaths a- 
Percentage and number of mice which were found dead (FD) across various lines. These include 
A1645 AdvCreERT2 founder line (green), A1831 LIFR fl/fl; AdvCreERT2 cross (blue), A1832 NGFR 
fl/fl; AdvCreERT2 cross (red) and A1833 NTRK1 fl/fl; AdvCreERT2 cross (purple). b- Number of 
mice that were FD split into the month of death. c- Ages of the mice FD for each of the various 
transgenic mouse lines separated into males and females. d- Percentage of mice FD split into 
males and females. e- Percentage of mice inheriting the AdvCreERT2 gene split into males and 
females. f- Inheritance of the AdvCreERT2 across various transgenic animals (average 30.7% ± 
5.6%) from different breeding strategies.  All this data collected from July 2015 until July 2016.  
 
NTRK1 fl/fl; AdvCreERT2 line 112 ± 48 for males and 109 ± 53 days for females (Fig 4.2c). To 
evaluate if there is a gender difference, the percentage of male and female mice FD was 
calculated for each of the transgenic lines. We found that for the AdvCreERT2 line 100% of the 
mice FD were males, from the LIFR fl/fl; AdvCreERT2 62.5% were male and 37.5% female, from 
the NGFR fl/fl; AdvCreERT2 line 36.4% were male and 63.6% female and from the NTRK1 fl/fl; 
AdvCreERT2 42.5% were male and 57.5% female (Fig 4.2d).   
Genotyping for the Cre recombinase gene of new born litters revealed that the distribution 
was not occurring according to Mendelian law. We then investigated if the Cre gene 
inheritance had a gender preference. We therefore calculated the percentage of males and 
females inheriting the AdvCreERT2 gene across the four transgenic colonies. Of the number of 
mice having the Cre gene from the AdvCreERT2 line 61.5% were male and 38.5% female, from 
the LIFR fl/fl; AdvCreERT2 line 57.9% were male and 42.1% female, from the NGFR fl/fl; 
AdvCreERT2 line 42.1% were male and 57.9% female and lastly from the NTRK1 fl/fl; 
AdvCreERT2 line 52.9% were male and 47.1% female (Fig 4.2e). Finally, we calculated the 




number of mice and found that across each of the lines – irrespective of the genotypes of the 
parents- there was on average 30.7% ± 5.6% of the progeny to be Cre positive (Fig 4.2f). 
4.3.2 Conditional KO of TrkA in vivo results in a decrease in RNA transcript and 
protein expression 
In order to KO TrkA in vivo, adult NTRK1 fl/fl; AdvCreERT2 and NTRK1 fl/fl littermates were 
injected with 75mg/kg tamoxifen (TMX) for 3 days consecutively and tissue was collected 2 or 
4 weeks post the first injection. We first confirmed the KO of TrkA by measuring the level of 
TrkA expression in the L4 DRG.  
From experience in the group it is known that TrkA antibodies need very specific conditions to 
be efficient so we tested different antibodies in vitro and in wildtype tissue first before moving 
into tissue from transgenic mice. A range of different antibody concentrations and fixing 
methods were trialled until an optimal staining protocol and antibody was found 
(Supplementary Table 4.1).  
We decided to use the R&D antibody and stained tissue from NTRK1 fl/fl and NTRK1 fl/fl; 
AdvCreERT2 animals given i.p. injection of TMX at 9-19 weeks of age where TMX mediated 
activation of Advillin Cre in NTRK1 fl/fl; AdvCreERT2 animals knockout TrkA expression in 
sensory neurons. Both L4 DRG was collected and used for immunohistochemistry and both L3 
DRG collected for RT-PCR 2 or 4 weeks after injection with TMX. Sections of lumbar cord were 
also collected from animals 2 weeks after TMX injection. Compared to NTRK1 fl/fl littermates a 
significant decrease in TrkA protein levels was observed in NTRK1 fl/fl; AdvCreERT2 animals 
both 2 (p=0.0017) and 4 (p<0.0001) weeks post-TMX, one-way ANOVA with Sidak’s post-hoc 
test. At 2 weeks post TMX there was a decrease from 19.8% ± 11.9% in NTRK1 fl/fl to 0.6% ± 
0.4% TrkA expression in L4 DRG in NTRK1 fl/fl; AdvCreERT2 mice. At 4 weeks post TMX there 





Figure 4.3 Expression of TrkA was reduced in NTRK1 fl/fl; AdvCreERT2 mice 2 and 4 weeks 
post tamoxifen injection. a- Representative immunohistochemistry of TrkA expression in an L4 




TMX. b- Quantification of TrkA expression in a L4 DRG in NTRK1 fl/fl and NTRK1 fl/fl; 
AdvCreERT2 CKO mice 2 and 4 weeks post IP TMX (2wks p=0.0017 and 4 weeks p<0.0001). One-
way ANOVA with Sidak’s post-hoc, n=3-5 animals. 
 
NTRK1 fl/fl; AdvCreERT2 mice (Fig 4.3). RT-PCR on whole L3 DRG from NTRK1 fl/fl; AdvCreERT2 
mice also showed a significant decrease in NTRK1 mRNA expression normalised to GAPDH 
compared to NTRK1 fl/fl littermate both 2 (p=0.0006) and 4 (p=0.0456) weeks post TMX, two-
tailed unpaired student t-test. There was a decrease from 1.02 ± 0.25 in NTRK1 fl/fl to 0.17 ± 
0.06 fold change at 2 weeks post TMX in NTRK1 fl/fl; AdvCreERT2 mice and a decrease from 
1.11 ± 0.49 in NTRK1 fl/fl to 0.5 ± 0.31 fold change at 4 weeks post TMX in NTRK1 fl/fl; 
AdvCreERT2 mice. Next, we investigated if the knockout of NTRK1 affects the expression level 
of NGFR. There was no significant difference in NGFR expression normalised to GAPDH 2 
weeks (1.01 ± 0.11 in NTRK1 fl/fl to 0.93 ± 0.48 in NTRK1 fl/fl; AdvCreERT2 mice) and 4 weeks 
(1.14 ± 0.65 in NTRK1 fl/fl to 1.40 ± 0.72 in NTRK1 fl/fl; AdvCreERT2 mice) post TMX injection 
(Fig 4.4a).  
We measured TrkA expression in the superficial lamina of the dorsal horn of the spinal cord to 
investigate if knockout of NTRK1 in sensory neurons correlated to reduced TrkA expression in 
sensory neuron terminals projecting into the cord. We observed a significant decrease in the 
expression of TrkA based on fluorescence intensity normalised to the background staining of 
the ventral cord from 1.05 ± 0.16 in NTRK1 fl/fll littermates to 0.92 ± 0.10 in NTRK1 fl/fl; 







Figure 4.4 Tamoxifen injections in NTRK1 fl/fl; AdvCreERT2 mice results in reduced NTRK1 
RNA levels in the DRG and TrkA protein expression in the lumbar spinal cord. a- Fold change 
(FC) of NTRK1 and NGFR expression normalised to GAPDH levels and NTRK1 fl/fl control in 




tailed unpaired student t-test, n=4-5. b- Representative immunohistochemistry of lumbar spinal 
cord dorsal horn from NTRK1 fl/fl and NTRK1 fl/fl; AdvCreERT2 mice 2 weeks post i.p. TMX. 
Stained with TrkA and pan-neuronal marker NeuN and c- quantification of TrkA expression 
(p=0.0228). Two tailed unpaired student t-test, n=4 animals (average from left and right dorsal 
horn from 3 sections, each normalised to background).  
 
4.3.3 There are no changes in peripheral skin innervation or cell size distribution 
of DRG neurons following knock out of TrkA in vivo 
From previous studies investigating the effects of a global TrkA KO, changes have been 
observed in the periphery including differences in plantar skin innervation and a loss of small 
diameter neurons in the DRGs (Crowley et al. 1994; Smeyne et al. 1994).  Therefore, following 
TMX mediated KO of TrkA, we investigated if there were any gross anatomical differences in 
skin innervation. We therefore measured the intraepidermal nerve fibre (IENF) density in the 
plantar skin of the hind paw by counting the number of sensory fibres crossing in the 
intraepidermal space as visualised by PGP 9.5 staining (Lauria et al. 2005). We observed no 
significant difference between the number of IENF normalised to NTRK1 fl/fl littermates either 
2 or 4 week post-TMX in NTRK1 fl/fl; AdvCreERT2 mice, one-way ANOVA with Tukey post-hoc 
test. There was a fold change in the number of IENF from 1.00 ± 0.12 in NTRK1 fl/fl compared 
to 1.10 ± 0.12 in NTRK1 fl/fl; AdvCreERT2 2 weeks post TMX and a fold change from 1.00 ± 0.23 
in NTRK1 fl/fl to 1.29 ± 0.62 in NTRK1 fl/fl; AdvCreERT2 animals 4 weeks post TMX, one-way 
ANOVA with Tukey multiple comparison (Fig 4.5a and b). Next, we measured the cell size 
distribution of neurons in the L4 DRG by measuring the cell diameter of neurons in sections. 
There was no significant difference between the NTRK1 fl/fl; AdvCreERT2 and NTRK1 fl/fl 2 and 





Figure 4.5 KO of TrkA does not result in any changes in IENF, cell size distribution in the L4 
DRG or have any behavioural effect in the naïve animal. a- Representative 




mice 2 weeks post IP TMX. Stained with pan-neuronal marker PGP 9.5. b- Quantification of 
IENF/mm in NTRK1 fl/fl; AdvCreERT2 animals 2 and 4 weeks post TMX, represented as a fold 
change normalised to NTRK1 fl/fl controls. One-way ANOVA with Tukey post-hoc, n=4-5. Cell 
size distribution of L4 DRG in NTRK1 fl/fl and NTRK1 fl/fl; AdvCreERT2 animals c 2 and d 4 
weeks post TMX. No significant difference observed, two-way ANOVA with Sidak’s multiple 
comparison, n=4-5.  e- static hot plate and f von Frey behavioural assessments of thermal and 
mechanical hypersensitivity respectively in NTRK1 fl/fl; AdvCreERT2 animals 2 and 4 weeks post 
TMX, n=4-7. Static hot plate all tests not significant, two tailed unpaired student t-test.  Von 
Frey test showed all tests not significant, two way ANOVA with Tukey post-hoc test. 
 
4.3.4 Knock out of TrkA in vivo has no effect on thermal or mechanical thresholds 
in the naïve mouse 
Previous studies using global TrkA KO mice showed a hyposensitivity to thermal and 
mechanical stimuli (Crowley et al. 1994). Therefore, we tested NTRK1 fl/fl; AdvCreERT2 mice 2 
and 4 weeks post TMX for thermal and mechanical hyposensitivity in the naïve state. In this 
study the naïve state refers to the absence of any inflammatory or neuropathic pain model 
being used following injection with TMX in order to investigate the effect of knockout of the 
NTRK1 gene alone. We used the static hot plate to test thermal hyposensitivity by placing 
animals onto a plate pre-warmed to 52⁰C and measuring the time taken for the animal to 
respond (latency to withdraw) by flicking, licking or biting of the hind-paw. We found no 
significant difference in the latency to withdraw between NTRK1 fl/fl; AdvCreERT2 or NTRK1 
fl/fl littermates either 2 or 4 weeks post TMX, two-tailed unpaired students t-test. At 2 weeks 
post TMX NTRK1 fl/fl showed a latency of 18.1 ± 2.0 seconds compared to 18.0 ± 5.4 seconds 




16.2 ± 2.8 seconds compared to 18.7 ± 2.7 seconds in NTRK1 fl/fl; AdvCreERT2 mice (Fig 4.5e). 
We also carried out Von Frey behavioural test to assess mechanical hyposensitivity where 
animal threshold to mechanical stimuli was tested using different weight filaments applied to 
the hind-paw using the SUDO Von Frey up down method (Bonin, Bories, and De Koninck 2014).  
We observed no significant difference in the 50% withdrawal threshold up to 4 weeks post 
TMX compared to baseline. There was also no difference between left and right hind paws in 
either the NTRK1 fl/fl or NTRK1 fl/fl; AdvCreERT2 mice, two-way ANOVA with Tukey post-hoc 
(Fig 4.5f).  
4.3.5 RNA sequencing reveals a number of differentially regulated genes 
following KO of TrkA in vivo in the naïve animal 
Since there are no functional differences or changes in the plantar skin innervation between 
NTRK1 fl/fl; AdvCreERT2 and NTRK1 fl/fl littermates 2 or 4 weeks post TMX we further 
investigated the phenotype of our KO animals by investigating their transcriptional profiles. of 
the animals. Both L2, 3 and 5 lumbar DRGs of were collected from age matched 16 week old 





Figure 4.6 – RNA sequencing of DRGs isolated and MACS purified from NTRK1 fl/fl and NTRK1 
fl/fl; AdvCreERT2 animals 4 weeks post TMX shows differential transcriptional profiles in 
naïve animals. a- RNA concentration and RIN of the sequenced samples. b- Venn diagram 




females or males alone. c- Heat map showing expression of the genes identified from combined 
analysis of males and females.  
 
DRGs were triturated and MACS purified before RNA was isolated and purified. Firstly, the RNA 
was screened for quantity and quality (Fig 4.6a) before it was sent for RNA sequencing to 
Oxford genomics centre, University of Oxford. We received the data from the high throughput 
facility in the Oxford genomics centre and then realigned the data to the mouse genome and 
normalised to calculate the FPKM (fragments per kilobase of transcript per million fragments 
mapped) for each gene sequenced. Data was analysed using online bioinformatics tool the 
Galaxy project with the Tuxedo suit, where the sequence was aligned using the TopHat 
algorithm, the FPKM calculated using Cufflinks and then finally differences in the expression 
between samples from NTRK1 fl/fl and NTRK1 fl/fl; AdvCreERT2 animals using CuffDiff.  
Analysis of all collected samples revealed a total of 63 genes, 33 upregulated and 30 
downregulated, significantly regulated between NTRK1 fl/fl and NTRK1 fl/fl; AdvCreERT2 mice 
(Fig 4.6b and c). Considering there might be a gender effect between the samples, we next 
excluded the two female samples. Analysis of the male samples by themselves revealed 184 
genes (160 upregulated and 24 downregulated), regulated between NTRK1 fl/fl; AdvCreERT2 
and NTRK1 fl/fl animals (Fig 4.6b and Fig 4.7). Comparing the mixed and the male only analysis 
showed only 39 differentially regulated genes common to both males and females and males 
alone, where 24 genes were specific to the males and females and 145 genes were specific to 








Figure 4.7 – RNA sequencing on NTRK1 fl/fl and NTRK1 fl/fl; AdvCreERT2 animals 4 weeks 
post TMX shows differential transcriptional profiles in naïve male animals. a- Heat map from 
RNA sequencing showing expression of the genes identified in analysis of male animals. 
 
4.3.6 Conditional KO of p75 in vivo results in a decrease in p75 protein and RNA 
transcript levels 
We next characterised the effect of p75 knockout in NGFR fl/fl; AdvCreERT2 animals. Adult 
NGFR fl/fl; AdvCreERT2 and NGFR fl/fl littermates were i.p. injected with TMX for 3 days and L3 
and L4 DRGs were collected 2 weeks after the first injection for RNA and immunohistochemical 
analysis respectively. A significant decrease in the expression of p75 in the L4 DRG was 
observed in NGFR fl/fl; AdvCreERT2 animals compared to NGFR fl/fl 2 weeks post TMX as 
assessed by immunohistochemistry staining of L4 DRG sections for p75 expression in neurons, 
p<0.0001 two-tailed unpaired student t-test. We quantified the p75 staining and found the 
percentage p75 positive neurons in NGFR fl/fl mice in L4 DRG was 53.1% ± 6.5% compared to 
1.7% ± 0.5% in NGFR fl/fl; AdvCreERT2 mice 2 weeks post TMX (Fig 4.8a and b). Similarly, there 
was a significant decrease in the expression of NGFR gene normalised to GAPDH. There was a 
decrease from 1.02 ± 0.22 in NGFR fl/fl to 0.49 ± 0.05 fold change in NGFR fl/fl; AdvCreERT2 
mice 2 weeks post TMX, p=0.0101 two-tailed unpaired student t-test. We then investigated if 
the KO of NGFR gene affected the expression of the NTRK1 gene. There was no significant 
difference in the expression of NTRK1 normalised to GAPDH where the fold change in NGFR 
fl/fl animals was 1.04 ± 0.34 compared to 0.92 ± 0.05 in NGFR fl/fl; AdvCreERT2 2 weeks post 





Figure 4.8 – Two weeks post tamoxifen injection there is reduction of p75 at the RNA and 
protein level in NGFR fl/fl; AdvCreERT2 animals. a- Representative immunohistochemistry of a 
L4 DRG from NGFR fl/fl and NGFR fl/fl AdvCreERT2 mice 2 weeks post TMX. Stained for p75 and 
pan-neuronal marker β-III tubulin. b- Quantification of p75 expression 2 weeks post TMX 
(p<0.0001), two tailed unpaired student t-test, n=3-4. c- Expression of NTRK1 and NGFR 
(p=0.0101) 2 weeks post TMX in NGFR fl/fl and NGFR fl/fl; AdvCreERT2 animals. Levels of 
NTRK1 and NGFR expression were normalised to GAPDH expression before normalisation to 





4.3.7 There are no changes in peripheral skin innervation or cell size distribution 
of DRG neurons following knock out of p75 in vivo 
Comparable to TrkA global knockout mice, p75 global knockout mice exhibit loss in peripheral 
innervation compared to controls (Bergmann et al. 1997; K. F. Lee et al. 1992). Therefore, we 
investigated the effect of p75 knockout in advillin positive neurons on IENF density in plantar 







Figure 4.9 KO of p75 does not result in changes in IENF, cell size distribution in the L4 DRG or 
have any behavioural effect in the naïve animal. a- Representative IHC of hind paw plantar 
skin of NGFR fl/fl and NGFR fl/fl; AdvCre ERT2 mice 2 weeks post i.p. TMX. Stained with pan-
neuronal marker PGP 9.5. b- Quantification of IENF/mm in NGFR fl/fl; AdvCreERT2 animals 2 
weeks post TMX. Two-tailed unpaired student t-test, n=3-4. c- Cell size distribution in L4 DRG in 
NGFR fl/fl and NGFR fl/fl; AdvCreERT2 animals 2 weeks post TMX (p=0.0181). Two-way ANOVA 
with Sidak’s post-hoc, n=3-4.  d- static hot plate assessment of thermal hypersensitivity in NGFR 
fl/fl; AdvCreERT2 animals 2 weeks post TMX. Static hot plate not significant, two tailed 
unpaired student t-test, n=3-4. 
 
the intraepidermal space. We observed no significant difference between NGFR fl/fl (35.5 ± 5.3 
IENF/mm) littermates and NGFR fl/fl; AdvCreERT2 (29.4 ± 2.6 IENF/mm) mice 2 weeks post 
TMX, two-tailed unpaired student t-test (Fig 4.9a and b). As global KO for p75 have shown 
differences in the cell size distribution in DRG we then measured the cell size distribution in 
the L4 DRG and found no significant difference between NGFR fl/fl; AdvCreERT2 mice and 
NGFR fl/fl, with the exception of a significant decrease in the number of neurons with a cell 
soma diameter of 25µm, p=0.0181 two-way ANOVA with Sidak’s post-hoc test (Fig 4.9c).  
4.3.8 Knockout of TrkA in vivo has no effect on thermal threshold in the naïve 
mouse 
Global p75 knockout animals have also been previously shown to be thermal hyposensitive 
(Bergmann et al. 1997; K. F. Lee et al. 1992). Therefore, we tested the hind paw of NGFR fl/fl; 
AdvCreERT2 mice on the static hot plate, where animals were placed onto a hot plate set to 




However, there was no significant difference between the latency to respond of NGFR fl/fl 
(23.8 ± 6.2 seconds) and NGFR fl/fl; AdvCreERT2 (25.0 ± 4.6 seconds) mice 2 weeks post TMX in 
naïve mice, two-tailed unpaired student t-test (Fig 4.9d). In this study the naïve mouse is 
described as an animal which has not been used in any neuropathic or inflammatory models 
following TMX mediated NGFR knockout.   
4.4 Discussion 
4.4.1 We generated new transgenic mouse lines to investigate the effect of 
knockout of the NGF receptors TrkA and p75 
In the past several studies have investigated the effect of the global knockout of components 
of the NGF signalling pathway, including knockout of TrkA, p75 and NGF. In each of these 
knockout models animals exhibited insensitivity to noxious stimuli which was attributed to 
improper development of peripheral nerve fibres, as NGF is essential for the survival of 
sensory neurons until post-natal day 14 (Bennett et al. 1996; Lallemend and Ernfors 2012). In 
this study we wanted to avoid the effects of this early knockout of the NGF receptors. We 
therefore bred two new tamoxifen inducible transgenic mouse lines for the TrkA and p75 
receptor. However, it turned out that these mouse lines had lower survival rates than 
anticipated. A significant number of animals that were positive for the Cre and the floxed gene 
were found dead for unknown reasons. Further investigation showed that there was no 
correlation between gender or age in animals found dead. This suggests that observed 
spontaneous death was not linked to the increased oestrogen levels in females or other sex 
linked differences nor linked to any specific developmental stage based on the age of animals. 
We observed two different peak times in the year that for increased spontaneous deaths. The 
peak from November 2015 until February 2016 correlated with the move of the colonies from 




from March to May 2016 correlated with building works that took place to repair a service lift 
in the animal unit close to the holding room. Given that a significant percentage of the dead 
animals were positive for Cre and the floxed allele across the different AdvCre lines this could 
indicate that the double positive animals were more sensitive to stress or there could be 
“leakiness” of the Cre expression. However, global knockout lines for TrkA and p75 did not 
survive past weaning in the case of TrkA knockouts, or past 6 months in p75 knockout animals 
and exhibit an noticeable phenotype in relation to size and appearance of knockout animals 
compared to littermate controls (K. F. Lee et al. 1992; Bergmann et al. 1997; Smeyne et al. 
1994). Therefore, it is unlikely that knockout of either receptor in the adult following activation 
of a “leaky” Cre would abruptly lead to death in these animals as mice appear physically 
normal. In the original study which generated and characterised the AdvCreERT2 mice less 
than 1% of cells were seen to have spontaneous Cre activation in control mice (Lau et al. 
2011). One method to restrict the leakiness is to control the breeding of animals where you 
avoid the use of brother sister breeding pairs and limit the inheritance of the Cre recombinase 
to Cre positive males not females (Egan et al. 2007; Jackson Laboratory 2007; Heffner et al. 
2012). In this study, we adhered to these rules where possible and used no brother sister 
breeding pairs, however, due to a limited number of available Cre positive animals from issues 
described in inheritance of the Cre and unexplained deaths some breeding pairs used Cre 
positive female mice. In order to test if any leakiness of Cre occurred in our animals we crossed 
the AdvCreERT2 mouse line with the TdTomato flox-STOP-flox reporter mouse with the aim to 
observe the expression of the TdTomato marker protein in both control and tamoxifen 
injected animals. This mouse line would reveal if there was TdTomato expression in non-
tamoxifen injected animals and therefore indicate that our animals were indeed leaky. It 
would also shed light on which tissues express the TdTomato reporter protein in the tamoxifen 




we have not yet clarified this in our hands because breeding of these mice proved slow and 
due to time constraints it was not possible to breed a cohort of animals to perform 
experiments within this study. On the other hand this Cre mouse line has been previously used 
in the lab in combination with a floxed line for HDAC4, which as with TrkA and NGF, global 
knockout also results in underdeveloped animals which do not survive past weaning. However,  
there were no reports of unexplained deaths in these animals following crossing with 
AdvCreERT2 (Crow et al. 2015) suggesting that this Cre line has not exhibited these issues 
previously. However, in this earlier another batch of AdvCreERT2 mice from the same supplier 
was used generate the founder colony which unfortunately was not available in this study to 
cross with NTRK1 fl/fl and NGFR fl/fl animals. Therefore, we cannot exclude the fact that the 
first batch of animals was slightly different to the second batch used here and that this 
difference might be causing the experienced higher mortality. Another explanation could be 
linked to the method of inheritance of the AdvCreERT2 gene. As described previously, the 
AdvCreERT2 mouse line was generated using a BAC which inserts at random sites in the 
genome (Lau et al. 2011). It is therefore possible in some animals it inserted the AdvCreERT2 
gene into a critical part of the genome disrupting essential genes, however, if this was the case 
we would expect to see a higher number of unexplained deaths as all inheriting Cre in a 
specific site would be affected, unless a particular combination of Cre insertion sites into 
essential genes is required. In order to test this hypothesis of random insertion sites, whole 
genome sequencing would be necessary however this is beyond the scope of this thesis. 
Additionally, there are some reports from BSU staff of animals that were found dead showing 
evidence of seizures prior to death which could also be the causative factor for a number of 




4.4.2 Knockout of TrkA and p75 using the generated conditional knockout lines 
was successful at the RNA and protein level 
We have first shown the successful knockout of TrkA in NTRK1 fl/fl; AdvCreERT2 and p75 in 
NGFR fl/fl; AdvCreERT2 animals i.p. injected with TMX at the RNA and the protein level. At 2 
and 4 weeks after TMX injection into NTRK1 fl/fl; AdvCreERT2 animals there was a significant 
reduction in the percentage of TrkA positive neurons in the L4 DRG and superficial dorsal horn 
of the lumbar spinal cord 2 weeks following TMX injection, as assessed by 
immunohistochemistry. Taken together this suggests that 2 weeks after TMX maximal 
knockout of the NTRK1 gene occurred and existing TrkA in the cell membrane has been turned 
over and intracellular stores depleted as assessed on the protein level, where TrkA turnover is 
dependent on activation by NGF followed by internalisation of the receptor and ubiquitin 
mediated degradation of TrkA (Geetha, Jiang, and Wooten 2005; Makkerh et al. 2005; Arévalo 
et al. 2006). We invested a fair amount of time and resources into the optimisation of the TrkA 
antibody staining, however, we were not successful until we used the antibody sold by R&D, 
which has been used for the staining presented in this study. As mentioned previously (chapter 
4.3.2) the loxP sites of the NTRK1 gene is located downstream of exons 1-3, which encode part 
of the extracellular region of the TrkA protein. It is therefore possible that knockout animals 
expressed a truncated TrkA protein. If this was the case this truncated version, although 
unlikely to be able to bind the ligand NGF and act as a scavenger receptor, it may still bind TrkA 
antibody and confound the results of TrkA staining. All of the TrkA antibodies tested in this 
study contain epitopes against a part of either the extracellular or the intracellular domain of 
the TrkA receptor. The TrkA antibody used in this study recognises an epitope at the start of 
the extracellular domain from amino acids 33 to 418 which overlaps with the TrkA region of 
any potential truncated protein from exon 1-3. We conclude that L4 DRGs from TMX injected 




TrkA staining and there is no evidence for the expression of a truncated form of TrkA (Fig 4.3). 
There is also evidence of a significant reduction in TrkA expression in the superficial dorsal 
horn of the lumbar spinal cord from TMX injected NTRK1 fl/fl; AdvCreERT2 animals showing 
there is loss of TrkA protein from the terminals in addition to the soma (Fig 4.4). Similarly, to 
the NTRK1 fl/fl; AdvCreERT2 animals, in NGFR fl/fl; AdvCreERT2 animals 2 weeks after TMX 
injection we observed an ablation in the percentage of neurons expressing the p75 receptor as 
assessed by immunohistochemistry. Contrary to the TrkA knockout mouse line the critical 
region of the NGFR gene in the p75 is exon 2 and there is no truncated protein predicted 
following excision of exon 2. Due to insufficient animals and time limitations we only measured 
knockout of p75 after 2 weeks after TMX injection.  
RT-PCR performed on the RNA of whole DRG from both the NTRK1 fl/fl; AdvCreERT2 and NGFR 
fl/fl; AdvCreERT2 animals confirmed that there was a reduction in the NTRK1 gene expression 
and NGFR gene expression respectively following TMX injection, whereas the expression in the 
non-targeted receptor did not change. Therefore, we exclude the presence of a compensatory 
mechanism between the two NGF receptors in both mouse lines tested. Even though at the 
protein level we found an ablation of the protein of interest in both mouse lines, the RNA 
expression shows only a partial, though significant, decrease. However, this does not reflect a 
true partial decrease in the gene of interest in the sensory neurons, but rather stems from the 
fact that we isolated RNA from whole DRG which also include numerous glial cells (Richner et 
al. 2014), in addition to the gene of interest only expressed on a subset of sensory neurons. 
However, even though there was a partial decrease in both mouse lines it has been found that 
the NGFR gene but not the NTRK1 gene is expressed in non-neuronal cells (chapter 1.1) 
(Gosselin et al. 2014; Lavin et al. 2014; Mo et al. 2015). Recombination of the loxP sites of the 
NTRK1 gene results in a deletion of exons 4-6, therefore exon 1-3 are still transcribed and 




targeted to different sections of the NTRK1 transcript (chapter 3.2.11). In this study however, 
we used primers targeted to exons downstream of the floxed exons 4-6, therefore, as these 
primers do not bind exons 1-3 it is unlikely that the partial knockout of NTRK1 gene expression 
observed here is the result of partial mRNA transcript. Another approach would be to MACS 
purify DRG from injected animals and isolate the RNA from these neurons enriched cultures 
and measure expression of the NTRK1 and NGFR genes (chapter 3.2.9). Alternatively, in situ 
hybridisation could be used as a more sensitive technique to stain sections from DRGs from 
TMX injected NTRK1 fl/fl; AdvCreERT2 or NGFR fl/fl; AdvCreERT2 animals to investigate RNA 
transcript levels of the NTRK1 and NGFR genes respectively in neurons. However, the decrease 
in the percentage of neurons positive for the TrkA or p75 receptor protein suggests that there 
is effective knockout of the gene of interest, only limited by the detection limit of the 
antibodies that were used to detect TrkA and p75.  
4.4.3 We found no changes in peripheral skin innervation or cell size distribution 
of neurons in NTRK1 and NGFR KO animals 
Studies investigating changes in global KO of NGF or the NGF receptors TrkA or p75 showed KO 
of either the ligand or the receptor to result in a decrease innervation of peripheral skin and a 
decrease in the total number of neurons and overall size of DRG, with a shift towards medium 
and large diameter neurons following a loss in small diameter neurons (Crowley et al. 1994; 
Smeyne et al. 1994; K. F. Lee et al. 1992; Bergmann et al. 1997). It is known that NGF is 
required for survival of sensory and sympathetic neurons during development and therefore 
the above mentioned anatomical changes in the animals are most likely the result of the 
knockout of NGF signalling during a critical point in development (Crowley et al. 1994; Smeyne 
et al. 1994; K. F. Lee et al. 1992; Bergmann et al. 1997). In order to bypass these 




anatomical changes in adult NTRK1 fl/fl; AdvCreERT2 or NGFR fl/fl; AdvCreERT2 animals 
injected with TMX we measured the innervation of plantar skin of the hindpaw and cell size 
distribution within the DRG. However, compared to controls there was no significant 
difference in plantar skin innervation in either NTRK1 fl/fl; AdvCreERT2 or NGFR fl/fl; 
AdvCreERT2 knockout animals. We also observed no significant difference in the cell size 
distribution of DRG between control and knockout animals. Even though we did not measure 
the total number of neurons in the L4 DRGs there was no gross differences in the size of DRG 
during collection. Overall, from these preliminary experiments we concluded that knockout of 
either NGF receptor in the adult mouse did not result in any gross anatomical differences in 
the peripheral nervous system, supporting the current belief that while NGF is essential during 
development for the formation and survival of sensory neurons, this is not the case in the 
adult system (Patel et al. 2003).  
4.4.4 There are no behavioural changes in thermal or mechanical sensitivity in 
either TrkA or p75 knockout animals 
In addition to the decreased innervation of the plantar skin and loss of small diameter neurons 
in the DRG, global knockout mice for NGF, TrkA and p75 exhibit a hyposensitivity to thermal 
and mechanical stimuli as mentioned previously (chapter 1.2)(Crowley et al. 1994; K. F. Lee et 
al. 1992; Bergmann et al. 1997; Smeyne et al. 1994). It is believed that this hyposensitivity is 
the direct result of the loss of the sensory neurons in global KO animals following the loss of 
NGF signalling during development. In the adult however, there is increasing evidence for a 
role of NGF in pain (chapter 1.4), supported by a number of clinical trials using anti-NGF 
antibodies which have shown a significant reduction in pain, particularly in osteoarthritis 




Since there in no role for NGF signalling in the adult mouse reported except following injury or 
inflammation, we hypothesised that in the adult mouse knockout of either the TrkA or the p75 
alone would not exhibit no differences in pain related behaviour. Therefore, to characterise 
this mouse we investigated how the loss of either the TrkA or p75 receptor alone affected 
mouse behavioural response to mechanical and thermal stimuli in a pilot study using a small 
number of either NTRK1 fl/fl; AdvCreERT2 or NGFR fl/fl; AdvCreERT2 against Cre negative 
littermate controls injected with TMX to see if there was any change in the “naïve” state. In 
this study, we refer to the naïve mouse as an animal which had not been tested using any 
inflammatory or neuropathic pain model. In an initial pilot with both NTRK1 and NGFR KO 
animal lines a small cohort of knockout and control animals was used to measure thermal 
sensitivity using the static hot plate test 2 weeks after TMX injection. We found that in both 
NTRK1 fl/fl; AdvCreERT2 and NGFR fl/fl; AdvCreERT2 animals there was no significant 
difference in the latency to respond between knockout and control animals. We did not 
perform any other behavioural tests with the NGFR fl/fl; AdvCreERT2 line due to limitations in 
the number of animals available for experiments. Since we were able to obtain a second, 
larger cohort of NTRK1 fl/fl; AdvCreERT2 animals. We tested them for mechanical sensitivity 
using Von Frey hairs for 4 weeks after TMX injection, at which point they were also tested 
again for thermal sensitivity using the static hot plate. The aim of testing this second cohort 
was to investigate the effect of a longer period of TrkA knockout, allowing all the pre-formed 
protein to be turned over and the complete knockout to become effective. Again, we observed 
no evidence for thermal or mechanical hypersensitivity of knockout animals compared to 
controls. The initial plan for this study was to test animals for up to 6 weeks after TMX 
injection, however due to several unexplained deaths in this cohort of animals and the risk of 
not having enough animals survive the end of the study we chose to shorten the post TMX 




before, we assumed that the dying animals post TMX injection were also Cre positive floxed 
animals. This was later confirmed, through genotyping of earclips taken after the study, to be 
true. Except for these behavioural tests we did not perform any other tests, however we 
observed no obvious phenotype in these animals. In this study we carried tests for the most 
likely behavioural deficits suggested from studies using global knockout lines. However, to fully 
characterise these animals a broader range of tests was required, for example cold plate for 
cold thermal sensitivity (Brenner et al. 2015; Brenner, Golden, and Gereau IV 2012), open field 
test to investigate the anxiety general locomotion (Carola et al. 2002) and rotarod to test 
motor impairment (Shiotsuki et al. 2010). Unfortunately, this was outside of the scope of this 
thesis. A longer study characterising the effect of p75 knockout in adult animals would also be 
interesting to perform, however, as previously mentioned it was not possible to obtain the 
necessary number of animals within the scope of this thesis. In general, working with 
conditional knockout mouse lines has the disadvantage that larger numbers of animals are 
needed to obtain the correct genotype for testing behavioural outcomes of the knockout. In 
our case, this was even more aggravated by the fact that Cre positive floxed animals had a 
higher mortality rate. Furthermore, we observed that the inheritance of the Cre gene following 
crossing of the AdvCreERT2 and floxed animals did not follow Mendelian law. Overall only 30% 
of the offspring were Cre positive, resulting in higher numbers of breeding pairs needed in 
studies for behavioural testing. These circumstances forced us to pool animals from a wider 
age range than normally aimed for, from 9-19 weeks across cohorts. Where possible we age-
matched animals between control and knockout animal groups. We believe that these rather 
large age ranges within the experiment may have a confounding effect on the result from this 
study. Animals from 12-24 weeks are considered adult animals (NIF 2010). Since the youngest 
animals of our study were 9 weeks old when TMX was injected and therefore still adolescent 




is reasonable to believe that age may have been a confounding element in the study. In 
addition, our behavioural cohorts were mixed genders, which could have been a further 
confounding element to this study. To avoid this larger animal colonies would have to be bred. 
Overall, we found in this study with the animal numbers that were available to us that KO of 
either the TrkA or p75 alone did not result in any mechanical or thermal hypersensitivity at the 
time point post TMX injection that we tested. 
As mentioned above there is evidence for a role of NGF in pain in the adult (chapter 1.4). 
Phase II and III clinical trials involving treatment with anti-NGF antibodies have shown a 
decrease in pain in a number of different pain conditions including osteoarthritis, lower back 
pain and diabetic polyneuropathy and bladder pain syndrome (Lane et al. 2010; Bannwarth 
and Kostine 2014; Capsoni and Cattaneo 2006; Aloe et al. 2012). To test for a pain phenotype 
in our NTRK1 fl/fl; AdvCreERT2 or NGFR fl/fl; AdvCreERT2 mouse lines, animals could be 
challenged in inflammatory and neuropathic pain models. Previously in preclinical models, 
studies using where animals were exposed to inflammatory models such as CFA injection into 
the hind-paw, injections of anti-NGF reversed the onset of thermal and mechanical 
hypersensitivity (Andreev et al. 1995; Lewin, Ritter, and Mendell 1993; McMahon et al. 1995; 
Woolf et al. 1994). Therefore, we hypothesis that in animals with KO of either the TrkA or the 
p75 receptor prior to exposure to inflammatory or neuropathic pain models after TMX 
injection there will be a reduction in the pain phenotype for example in behavioural tests 
measuring thermal or mechanical sensitivity in knockout animals compared to controls. 
Animals could be tested using inflammatory pain models such as injection of complete Freud’s 
adjuvant (CFA) into the hind-paw (Fehrenbacher, Vasko, and Duarte 2015), neuropathic pain 
models such as sciatic nerve ligation (SNL) (Yalcin et al. 2014; Malmberg and Basbaum 1998) or 




Pest 2017). Together, these experiments will further shed light on the role of NGF signalling in 
neurons in the context of pain following neuron specific knockout of the NGF receptors.  
4.4.5 RNA sequencing of NTRK1 KO animals shows changes in gene expression 
Next we performed RNA sequencing analysis on RNA isolated from MACS purified L2, 3 and 5 
DRG of  NTRK1 fl/fl; AdvCreERT2 animals, 4 weeks after TMX injection. Our preliminary analysis 
showed that 63 genes were differentially regulated in samples where genders were mixed 
compared to 184 differentially expressed genes in males. This suggests an influence on the 
gender on the adaptation to the knockout of the TrkA receptor via TMX injection. For example, 
the females might have been more susceptible to tamoxifen compared to males which could 
be assessed by comparing differences in gene expression in males and females across the 
knockout (TMX injected Cre positive NTRK1 floxed animals) and the control groups (TMX 
injected Cre negative NTRK1 floxed animals) used in this experiment. However, the mixed 
group did not consist of equal males and females, but rather consisted of 6 males and 2 
females, so this hypothesis of a gender difference could not be tested. For example, recently 
there is increasing evidence that there are gender specific mechanisms in pain sensation, 
where a study by Sorge et al observed that compared to males, microglia in female mice are 
not required for the development of mechanical hypersensitivity in chronic pain. Instead 
female mice exhibit an increase in the number of T cells suggesting that in female mice chronic 
pain is likely the result of a mechanism involving the adaptive immunity (Sorge et al. 2015). 
However, animals used in this study were age matched, 19 weeks at the time of injection, and 
taken from the cohort used for thermal and mechanical hypersensitivity described above 
where there was no difference observed in behaviour which could explain gender differences 
observed from the RNA sequencing. Gene comparison between the mixed and male only 
group has shown that only 39 genes were differentially expressed. These genes have a high 




differentially expressed we also performed protein-protein interaction analysis using the 
online software STRING. This software identifies protein networks which the differentially 
expressed genes could be part of. However, we found that there were no significant networks 
of proteins regulated in TrkA KO animals. Further analysis could include grouping genes into 
protein functionality could also be a useful tool to identify the range of regulated genes, for 
example the number of genes either upregulated or downregulated that code for transcription 
factors vs signalling molecules vs structural proteins. This data set harbours a high potential to 
identify novel gene that are part of the NGF signalling pathway. However, in-depth analysis of 
this dataset was beyond the scope of this thesis. In the future, potential novel genes also 
require validation by PCR and recurrence in a separate cohort of animals.  
We first investigated NTRK1 gene expression in samples from NTRK1 fl/fl; AdvCreERT2 animals 
compared to controls. Reassuringly, we found NTRK1 in both analyses (male and females 
mixed and males only) to be significantly decreased in knockout animals. However, in the 
mixed group the p value was p<10-5 and in the male group it was p<10-3. This suggests that in 
the male group there was residual NTRK1 RNA. There are several different explanations for 
this. First, there could be residual mRNA left in the cells which has not been degraded. Second, 
as mentioned previously (chapter 3.1.1), the loxP sites are positioned downstream of exon 1-3, 
around exons 4-6, which might result in a truncated RNA fragment. We tested this by further 
analysing the alignment of the results from the RNA sequencing to the genome using the 
Galaxy software. However, we found that a significant proportion of the fragments for TrkA 
sequenced to be downstream of the floxed region, which makes this hypothesis unlikely. 
Furthermore, the TrkA RNA is similar in sequence to the other Trk receptors TrkB and TrkC. The 
realignment algorithm used post RNA sequencing deals with transcripts of areas common to 
several proteins, such as protein kinase domains, in the following ways. The total number of 




that some of the reads assigned to TrkA in these animals could in fact be from other similar 
proteins, such as TrkB or TrkC. Finally, we received the AdvCreERT2 mouse line as a generous 
gift from John Wood, University College London. It has been reported that due to the 
hemizygous nature of these mice the inheritance of the transgene is not stable (Jax 2017), 
which is in line with the findings of this study of only 30% inheritance (Fig 4.2). This fact 
suggests that each generation shall be screened for the number of copies of the AdvCreERT2 
gene in each animal (Jax 2017). There might be a dose response in the efficiency of gene 
knockout correlating to the number of AdvCreERT2 copies.  In the original publication 
characterising this Cre mouse line, copy number was assessed by comparing the intensity of 
bands on southern blots taken from wildtype and mutant mice (Lau et al. 2011), however copy 
number can also be assessed using qRT-PCR (Luo et al. 2014).  
However, preliminary data from the analyses has shown a couple of interesting genes with 
different expression patterns. These include Cdk4, cyclin dependent kinase 4, which is involved 
in cell cycle regulation and is used as a target in cancer. Interestingly it has also been found to 
have a role in spinal cord injury (Yang et al. 2014; J Wu et al. 2014; Junfang Wu et al. 2013). 
March9, membrane-associated ring finger (C3HC4) 9, which is a membrane-bound E3 ubiquitin 
ligase which targets the internalisation of several membrane glycoproteins (Hör et al. 2009; 
Hoer, Smith, and Lehner 2007; Jahnke, Trowsdale, and Kelly 2013) and Vamp8, vesicle 
associate membrane protein 8, which encodes an integral membrane protein belonging to the 
synaptobrevin/ VAMP subfamily of soluble N-ethylmaleimde-sensitive factor attachment 
protein receptors (SNAREs) which is involved in the fusion of vesicles with the presynaptic 
membrane (Marshall et al. 2015; Behrendorff et al. 2011).  
The big drawback of this analysis is that with the exception of CGRP (p< 10-3) we did not 
observe any changes following NTRK1 KO in the gene expression of known proteins 




Dubin and Patapoutian 2010; A. Patapoutian, Tate, and Woolf 2009). However, as these genes 
are commonly believed to be pain related genes it is not surprising that we do not observe 









Supplementary table 4.1 Details of the different TrkA antibodies tested using 














Chapter 5: General discussion  
5.1 Main conclusions of the study  
NGF has been identified to have a role in the development of the sensory and sympathetic 
nervous system (K. F. Lee et al. 1992; Bergmann et al. 1997; Crowley et al. 1994; Smeyne et al. 
1994). In adulthood on the other side there is evidence for a role for NGF in pain (Andreev et 
al. 1995; Lewin, Ritter, and Mendell 1993; Bennett et al. 1998; McMahon et al. 1995; Woolf et 
al. 1994). It has been shown that NGF is important for peripheral and central sensitisation in 
addition to hyperinnervation of tissues in the development of pain (Kelleher, Tewari, and 
McMahon 2016; Dubin and Patapoutian 2010; A. Patapoutian, Tate, and Woolf 2009; Kerr et 
al. 1999; Michael et al. 1997; Jimenez-Andrade et al. 2011). Preclinical rodent models and 
phase II and III clinical trials using anti-NGF therapies have shown success in the alleviation of 
pain (Lane et al. 2010; Bannwarth and Kostine 2014; Aloe et al. 2012; Capsoni and Cattaneo 
2006), however, studies using global knockout mouse lines for either NGF or its receptors TrkA 
and p75 to investigate the role of NGF in pain have failed to address the precise role of NGF in 
pain. Global knockouts do exhibit hyposensitivity to thermal and mechanical stimuli, however 
these defects are attributed to the effects of loss of NGF during development rather than to its 
role in the adult animal (Crowley et al. 1994; Levi-montalcini 1987).  
The aim of this study was to investigate unanswered questions concerning the mechanism of 
action of NGF in pain. First, we aimed to answer if NGF binds directly to neurons or exhibits its 
effects indirectly via non-neuronal cells, which have been shown to express receptors for NGF 
(Richner et al. 2014; Thakur et al. 2014; Usoskin et al. 2014; Aloe et al. 2012; Gosselin et al. 




characterised a method of purifying neuronal cultures using MACS purification of adult DRGs. 
Second, we set out to identify the main receptor for NGF in pain between TrkA and p75. We 
therefore obtained knockout mouse lines, NTRK1 fl/fl and NGFR f/fl, in which critical regions in 
the NTRK1 gene for TrkA and the NGFR gene for p75 are floxed and conditional knockout is 
induced through the action of Cre.  We used both lenti and adeno-associated viruses to 
characterise their efficiency for Cre mediated excision of floxed genes and in parallel bred a 
novel inducible conditional knockout mouse line for these NGF receptors by crossing the floxed 
lines with an Advillin-CreERT2 mouse line to generate sensory neuron specific knockout 
animals under the control of tamoxifen.  
We described in this study that MACS purification is an effective method in purifying viable 
DRG neurons to a greater level of purity and using a less labour intensive and faster protocol 
than previous methods used including immunopanning and FACS. However, we also identified 
a disadvantage of this method since there is a loss of medium and large diameter neurons. 
Large diameter neurons consist of low threshold, myelinated, mechanoreceptors sensitive to 
non-noxious stimuli with a role in proprioception and fine touch, whereas medium diameter 
neurons include medium threshold thinly myelinated fibres such as Aδ fibres (Hudspith, 
Siddall, and Munglani 2006; Richner et al. 2014). This project investigated the role of NGF in 
pain and therefore focuses on primary afferent nociceptors which include small diameter high 
threshold, unmyelinated C-fibres – specifically peptidergic nociceptors - and small-medium 
diameter myelinated Aδ  fibres, which both express TrkA and p75 receptors (Hudspith, Siddall, 
and Munglani 2006; Richner et al. 2014). Therefore, for this study, the use of MACS 
purification is suitable. Through the characterisation and optimisation of this method we 
developed a protocol with which pure neurons can be isolated and used to test the direct 
effect of factors such as elements of the inflammatory soup secreted in pain, for example NGF, 




cultures where an indirect effect via non-neuronal cells may be observed. We have achieved 
the first aim of the project to develop a method to study the direct effect of NGF on neurons.  
The second question was to investigate whether NGF in pain signals mainly through the TrkA 
or the p75 receptor. To address this, we used transgenic mouse lines with LoxP flanked regions 
of either the NTRK1 gene for TrkA or NGFR gene for p75. We employed two different viral 
approaches to knockout these genes and we generated a new mouse line for conditional 
tamoxifen dependent knockout of TrkA or p75 in sensory neurons. We determined in this 
study that the treatment of MACS purified cultures with lenti Cre-GFP virus was not optimal 
for knockout of either the TrkA or the p75 NGF receptors. We observed that after three days in 
culture, the optimal time determined for efficient transduction of cells and therefore knockout 
of the floxed gene of interest, a ceiling effect in neuronal response to NGF was observed, as 
measured using a neurite outgrowth assay. We found no difference in neurite outgrowth 
between no NGF controls and cultures treated with NGF suggesting that after 3 days the levels 
of NGF had reached saturation following secretion from neuronal cells, resulting in insensitivity 
of the neurite outgrowth assay to observe any differences in early NGF treatment of cultures. 
Therefore, we chose to use an alternative method of viral transduction using IT delivery of 
AAV9 Cre-eGFP to knockout TrkA and p75 in floxed mice in vivo prior to culturing MACS 
purified neurons from DRG. We found that AAV9 mediated knockout of both the TrkA and the 
p75 receptor was successful on the protein level however at the RNA level the knockout of the 
NTRK1 gene was not as clear. There was a trend towards a reduction in the expression of the 
NTRK1 gene in NTRK1 fl/fl animals 2 or 4 weeks after AAV9 Cre-eGFP injection, and no change 
in the expression of the NGFR gene. This suggests that knockout of TrkA in these animals did 
not result in any compensatory upregulation in p75. It is important to note that only a small 
sample size was used to measure gene expression changes by RT-PCR. It would therefore be 




fl/fl animals there was a significant reduction in the expression of both the NTRK1 and NGFR 
genes 2 weeks after injection of AAV9 Cre-eGFP. This suggests that following the knockout of 
p75 there is a mechanism activated that leads to a decrease in NTRK1 expression. However, in 
this study we also characterised the knockout of p75 receptor using a novel conditional mouse 
model by crossing NGFR fl/fl mice with an AdvCreERT2 mouse line, where knockout of the 
floxed gene in sensory neurons is controlled by tamoxifen. Two weeks after tamoxifen 
treatment of NGFR fl/fl; AdvCreERT2 mice we observed a significant decrease in the 
percentage of neurons expressing p75 neurons (as assessed by immunohistochemistry), 
corresponding with a significant decrease in the expression of the NGFR gene at the RNA level 
using RT-PCR. However, in this model we did not observe a decrease in NTRK1 expression (as 
has been observed in neurons isolated from NGFR fl/fl mice injected with AAV9 Cre-eGFP).  
This conflicting result could be firstly the result of a decreased statistical power in the AAV 
mediated knockout compared to the transgenic mouse model. This could be tested by 
increasing the number of samples tested. Or secondarily due to the route of knockout. The 
adeno-associated viral particles could have a side effect. This could be investigated we think by 
including controls such as AAV9 eGFP without Cre expression in floxed animals or AAV9 Cre-
eGFP in WT animals. Thirdly, treatment with tamoxifen could have also resulted in side effects. 
This could be addressed using tamoxifen injections in WT animals.  
Expression of the NTRK1 and NGFR genes and percentage of neurons positive for TrkA protein 
was also assessed in NTRK1 fl/fl; AdvCreERT2 mice treated with tamoxifen. Compared to 
NTRK1 fl/fl animals injected with AAV9 Cre-eGFP where the percentage of cells expressing TrkA 
was measured in L4 DRG sections, there was a comparable reduction in the percentage of 
neurons positive for TrkA protein following tamoxifen. There was also no change in the 
expression of the NGFR gene. However, contrary to the AAV9 model in vivo we found a 




We concluded that knockout of floxed genes using either AAV9 mediated Cre delivery or in 
vivo Cre recombinase activated by tamoxifen results in successful in knockout on the protein 
level and the RNA level. However, there are confounds to both methods. Using the viral 
approach with intrathecal delivery exposes animals to a surgical procedure and there is the risk 
of spinal cord damage during this process. There is also the issue of high variability of 
transduction both between animals and within animals, as we observed that there is a degree 
of bias to laterality in transduction making this method unsuitable for behavioural studies. 
However, by using the GFP marker protein, this model is useful when using cells in cultures 
since each experiment has its own internal controls. On the other hand, the novel inducible 
condition knockout lines for the NTRK1 and NGFR genes bred in this study have demonstrated 
to be difficult to breed due to the occurrence of abnormally high numbers of unexplained 
deaths. This results in costlier and more time-consuming situations than expected. However, in 
these animals there is the benefit of both spatial and temporal control of gene knockout. 
Despite the AAV serotype 9 showing neural trophism there is a chance of transfection of other 
cell types whereas the AdvCreERT2 is limited to Advillin expressing sensory and sympathetic 
neurons, giving tighter spatial control. Temporal control using tamoxifen allows the knockout 
to be timed to a specific developmental stage or point in an experiment i.e. before or after 
inducing a neuropathic pain injury using a model such as sciatic nerve ligation.  
In this thesis we also did some pilot studies on the functional and behavioural impact of TrkA 
and p75 knockout in sensory neurons. Our in vitro experiments on TrkA or p75 knockout 
neurons (gene ablation via AAV9 Cre-eGFP IT injections in vivo) showed a decreased response 
to NGF in knockout cells, as measured by neurite outgrowth. This suggests that even in the 
adult system, despite neurons being independent of NGF for survival, they are responsive to 
neurotrophins, such as NGF, for regeneration of neurites following axotomy – as dissection of 




in the inflammatory soup following inflammation or injury, has a role in both sensitisation of 
neurons but also in repair and axon guidance. It has been shown that in axotomy models, 
following the cut-off of retrograde transport of NGF from the periphery, apoptosis of neurons 
was observed supporting the role for NGF in survival of neurons (Levi-montalcini 1987). 
Therefore, decreased sensitivity to NGF in vitro following knockout of either the TrkA or p75 
receptor may result in decreased repair and regeneration of neurons in vivo following 
axotomy. In our conditional knockout strains that we generated we found that contrary to 
studies using global knockout mice we observed no change in peripheral skin innervation of 
the hind-paw or changes in the cell size distribution in DRGs. Deficiencies in the peripheral 
nervous system in global knockout mice for either NGF or the NGF receptors result in 
hyposensitivity to mechanical and thermal stimuli, however, in both the NTRK1 fl/fl; 
AdvCreERT2 and NGFR fl/fl; AdvCreERT2 animals there is no change in thermal sensitivity as 
measured using the static hot plate two weeks after induction of knockout via tamoxifen 
injections. A second cohort of NTRK1 fl/fl; AdvCreERT2 animals was used to assess mechanical 
and thermal sensitivity four weeks after tamoxifen treatment however no change both tests 
was observed as measured using the static hot plate or Von Frey hairs respectively. Due to 
time constraints and the unavailability of animals the mechanical sensitivity of NGFR fl/fl; 
AdvCreERT2 animals was not assessed in this study. To fully characterise the effect of TrkA or 
p75 knockout more extensive behavioural testing and detailed investigation of anatomical 
changes needs to be performed as detailed below. To date, we did not see any gross changes 
in behaviour or anatomy in the animals tested. Overall, we have established and characterised 
in this study two methods for generating neuron targeted knockout of NGF receptors. This 
allows us to investigate the role of NGF in sensory neurons and to answer the question if NGF 





5.2 Future directions  
We characterised MACS purified cultures and observed that despite a lag in neurite outgrowth 
after 24 hours, after 48 hours MACS purified neurons began to grow neurites. Treatment of 
neurons with conditioned medium taken from non-MACS purified cultures resulted in a 
significant increase in neurite outgrowth of MACS purified cells after 24 hours. In addition to 
NGF, conditional media from non-MACS purified cultures contains a number of other factors 
such as growth factors and members of the neurotrophin family such as BDNF and NT-3. To 
dissect the effect of NGF vs these other growth factors it is helpful to block NGF binding to 
TrkA, with a TrkA conjugated to IgG, and measuring the residual neurite outgrowth effect. 
Furthermore, the amount of other factors present in the conditional medium can be measured 
by ELISA. MACS purified cultures from wildtype mice or conditional knockout mice can be used 
in combination with the NGF inhibitors to further investigate changes in NGF signalling through 
the TrkA or the p75 receptor in vitro. As previously described activation of TrkA or p75 activate 
a number of different signalling pathways where TrkA signals via molecules such as MAPK, ERK 
and Ras, and p75NTR via JNK and c-Jun (Wilma J Friedman 2010; Bertrand et al. 2009), 
respectively. The complexity of NGF signalling has led to the hypothesis that the large degree 
of redundancy may result in different cell types preferentially using one downstream signalling 
pathways over another (Friedman and Greene, 1999). Therefore, using cultures from 
conditional knockout animals may provide further insight into the signalling pathways used 
following NGF signalling in pain. These experiments can be carried out following stimulation of 
cultures with both NGF and proNGF (the precursor to mature NGF). How pure neuron cultures 
alone respond to stimuli compared to non-MACS sorted cultures containing non-neuronal SGC 
will give an idea of how non-neuronal cells may modulate NGF signalling. This will be especially 




non-neuronal cells will retain expression of NGF receptors in non-MACS cultures such as TrkA 
on mast cells and p75NTR on SGCs.  
MACS purification of DRG neurons has been shown to be effective in generating pure cultures 
of mainly small diameter neurons, which is a confound for studies investigating receptors or 
ion channels expressed on large diameter neurons.  For the study of neurons expressing the 
TrkA or p75 receptors, MACS purification is useful as TrkA for example is expressed on the 
small diameter peptidergic C fibres. However, in cultures of small diameter neurons there is 
also the presence of the small diameter non-peptidergic C fibres. Therefore, in MACS purified 
cultures taken from NTRK1 fl/fl or NGFR fl/fl animals injected IT with AAV9 Cre-eGFP a 
percentage of the GFP positive neurons might actually not be knockout for either the NTRK1 or 
NGFR gene but could in fact be non-peptidergic neurons which do not express the gene of 
interest. Similarly, some of the control cells used might not express the gene of interest for the 
same reason. This could be avoided by counterstaining neurons against markers of non-
peptidergic neurons such as IB4. It could also be useful in the future to further optimise the 
MACS purification protocol to isolate specifically p75 or TrkA expressing neurons. This would 
be achieved by running neurons thorough a second MACS column with a second batch of 
antibodies. In this way, the first step in the purification would be to use the non-neuronal 
antibody cocktail described in this study which tags all of the non-neuronal cells resulting in 
these cells being retained in the MACS LD column. A second sort using either antibodies 
against the p75 receptor or the TrkA receptor, or perhaps a combination of both, could then 
be used to tag all neurons expressing these receptors, which could then be sorted from the cell 
suspension and retained in the MACS column following a second sort. Of course, this protocol 
could not be used for generating MACS purified cultures following NTRK1 or NGFR knockout 
either via AAV9 Cre-eGFP injection to deliver Cre or tamoxifen injection to activate Cre as 




to specifically sort TrkA or p75 positive neurons from WT DRG could be used as an alternative 
method to confirm the effect of knocking out either NGF receptor in cultures of MACS purified 
DRG from either AAV9 or tamoxifen treated animals, through the use of specific receptor 
antagonists in these WT cultures. MACS sorting for p75 positive neurons has already been used 
as previously described, (chapter 2.4.1) (T.-V. V Nguyen et al. 2014) however, as this study has 
highlighted there have been issues optimising conditions for antibodies against the TrkA 
receptor however we identified a TrkA antibody that was suitable for staining TrkA in sections 
of L4 DRG. So, this antibody might be a candidate for such an approach.  
As described in the previous chapter (chapter 3.4.4) MACS purified cultures isolated from 
NTRK1 fl/fl and NGFR fl/fl animals injected with AAV9 Cre-eGFP could be further investigated 
for functional changes using calcium imaging and patch clamping. Detailed investigation using 
these methods can be performed by plating MACS purified cultures into microfluidic chambers 
to separate the cell body from the axons in different compartments. Using this technique, 
neurons are plated into a compartmental chamber where axons can grow across to a second 
chamber separated by microgrooves several days after plating. These microgrooves have a 
diameter large enough for axons to pass through however, they are too small for the cell 
bodies to pass through. Maintaining a higher volume of liquid on one side of the device allows 
movement of liquids from one compartment to the other by osmosis, creating effective 
separation of the two compartments (Tsantoulas et al. 2013). Using this setup separate 
treatments can be given to both the soma and axonal compartments, and the effect can be 
measured using both calcium imaging and patch clamping techniques. However, one confound 
of using the microfluidic technique with MACS purified cultures is that we discovered in this 
study that MACS purified neurons are difficult to adhere to either plastic plates or glass 
coverslips. In this study we use a thin coating of matrigel to aid adhesion of purified neurons to 




matrigel forms a gel like layer and when used with the microfluidic chamber would prevent a 
tight seal being formed between the microfluidic chamber and the glass coverslip – which is 
critical in separating the compartments between the soma and axons. In addition to this, it is 
possible that matrigel could block the small microgrooves in the microfluidic chambers and 
retard the growth of axons from the soma chamber to the axonal chamber. As matrigel is a 
component of the extracellular matrix it has been used previously to resuspend cells before 
plating, thus allowing plating of cells within a matrix that is growth permissive (Bapat et al. 
2016; Wyatt et al. 2011; Delree et al. 1989). Therefore, matrigel does not directly inhibit the 
growth of neurites in the dish or through the microgroove channels, however, it would prevent 
the passage of liquid though the channels. In order to direct the growth of neurites through 
the microgrooves, growth factors such as NGF are commonly added to the axonal 
compartment, matrigel blockage of the microgrooves would block the movement of liquids 
across the osmotic gradient in the microfluidic chamber, in addition to blocking the 
chemotractive signal by growth factors. This could be overcome by trialling the use of other 
adhesive compounds like fibronectin, which has not been tested as an adhesive for MACS 
purified neurons in this study. However, the need to use NGF or a similar substrate to direct 
neurite growth prior to experiments is another confound that despite benefits may make the 
use of microfluidic chambers unsuitable to investigate the effect of NGF following knockout of 
either the TrkA or the p75 receptor.  
One method for validating findings from calcium imaging and patch clamping experiments 
using DRGs isolated from NTRK1 fl/fl or NGFR fl/fl animals injected with AAV9 Cre-eGFP would 
be to repeated these experiments using DRGs isolated from NTRK1 fl/fl; AdvCreERT2 or NGFR 
fl/fl; AdvCreERT2 Cre positive animals injected with tamoxifen.  
In addition to in vitro experiments using both the AAV9 and tamoxifen mediated knockout of 




following knockout. Using both models we noticed no gross anatomical changes, and 
confirmed knockout of the gene of interest at both the RNA and the protein level. 
Furthermore, Cre positive animals treated with tamoxifen showed no change in the cell size 
distribution of DRGs or innervation of the plantar skin of the hind-paw compared to global 
knockout studies suggesting that TrkA or p75 knockout in the adult mouse has no impact on 
survival of neurons. This could be confirmed by staining DRG sections for markers of different 
subpopulations of neurons including NF200 for large diameter neurons, IB4 for small diameter 
non-peptidergic C fibres and CGRP for peptidergic C fibres. Further to this other anatomical 
changes such as further investigation of fibres innervating peripheral skin and changes in the 
spinal cord could be performed. For example, in this study we did not investigate the effect of 
the knockout of p75 in the lumbar spinal cord in NGFR fl/fl; AdvCreERT2 Cre positive animals 
treated with tamoxifen. Another approach would be to confirm skin innervation and cell size 
distribution in tissue from NTRK1 fl/fl or NGFR fl/fl mice injected IT with AAV9 Cre-eGFP. 
It appears there is no change in expression of the complementary NGF receptors (i.e. no 
change in the expression of NGFR gene following targeted knockout of NTRK1 gene or vice 
versa) as measured at the RNA level following knockout of either the TrkA or the p75 receptors 
except for NGFR fl/fl mice 2 weeks after AAV9 injection where a decrease in both NTRK1 and 
NGFR gene expression was measured. However, the protein levels have not yet been 
investigated in regards to compensation of the complementary receptor. Therefore, one 
aspect to investigate in the future is to perform immunostaining and measure the percentage 
of neurons expressing p75 in NTRK1 knockout mice and the percentage of TrkA expressing 
neurons in NGFR knockout animals using both AAV9 and tamoxifen mediated gene knockout 





There are also interesting approaches to further investigate the functional and behavioural 
impact following knockout of either the TrkA or the p75 receptor to determine if one or both 
receptors are involved in NGF signalling in pain. 
As already discussed (chapter 3.4.4), risk of spinal cord damage and variability in transduction 
following IT injection of AAV9 Cre-eGFP results in this model to be suboptimal for behavioural 
experiments. We therefore propose to use the generated conditional knockout strain for these 
experiments. Using this model has the benefit of temporal control where tamoxifen can be 
administered prior to, during or after behavioural testing. In combination with pain models this 
can be used to measure the impact of knockout of NGF signalling via either NGF receptor prior 
to pain, in the induction phase of pain, during the development of pain to investigate the role 
of NGF in the establishment and maintenance of peripheral or central sensitisation, or after 
pain to investigate a role for NGF in the resolution of pain. To fully characterise the effect 
following knockout of the TrkA or the p75 receptor, thermal sensitivity using the ramping 
hotplate or Hargreeves tail flick test to hot stimuli or testing using the cold plate or the 
acetone test to cold stimuli could be performed in addition to the tests that were performed in 
this study. Anxiety can be measured using the open field test which can also be used to 
investigate any motor impairments, in addition to the rotarod test to test for any off-target 
effects. Once any changes in the knockout animals have been identified it would be interesting 
to test these animals in inflammatory and neuropathic pain models. As described in chapter 
1.4, preclinical models have been used where rodents injected with complete Freud’s adjuvant 
(CFA) into the hind-paw, which induces inflammation as a model of inflammatory pain. In the 
naïve animal, following CFA treatment the resulting inflammation results in thermal sensitivity 
of these animals. However, following treatment with a TrkA-IgG or anti-NGF monoclonal 
antibody in CFA treated animals, no change in thermal sensitivity was observed suggesting that 




1995; Lewin, Ritter, and Mendell 1993; Woolf et al. 1994; McMahon et al. 1995). We 
hypothesis that following knockout of either the TrkA or the p75 receptors we should see 
similar responses in inflammatory pain models, such as CFA treatment, where loss of NGF 
signalling stops the development of inflammatory pain.  
While behavioural testing confirms the involvement of NGF in the development of pain – 
namely peripheral and central sensitisation – the downstream molecular changes in the 
neuron are unknown. Therefore, in addition to validating our findings from the RNA 
sequencing performed on NTRK1 fl/fl; AdvCreERT2 Cre positive animals treated with 
tamoxifen, samples for RNA sequencing after induction of an inflammatory or neuropathic 
pain injury should also be collected to perform RNA sequencing to investigate changes in 
common downstream molecular signalling pathways. As mentioned previously, both the TrkA 
and the p75 receptors signal through several common signalling pathways in the cell, for 
example MAPK, ERK etc. (Kiris et al. 2014; Pezet and McMahon 2006; Capsoni et al. 2011; 
Capsoni and Cattaneo 2006; K. F. Lee et al. 1992). RNA sequencing could therefore be used to 
determine if NGF signalling in neurons is mediated by a particular pathway important for pain 
signalling. Once this is known it could be investigated whether knockout of one of the NGF 
receptors regulates this pathway or if a different pathway becomes active. This would also 
provide insight into how NGF signalling regulates downstream changes of known pain-related 
genes. For instance, it is known that NGF signalling results in rapid transcription of pain related 
genes such as VEGF, BDNF, TRPV1, substance P and CGRP, but RNA sequencing could highlight 
novel pain-related genes or signalling pathways previously overlooked (Pezet and McMahon 
2006; Dubin and Patapoutian 2010; A. Patapoutian, Tate, and Woolf 2009). This in depth 
investigation might lead to the identification of novel pain-related genes, which could later be 




In conclusion, we have characterised in this study two methods of specific knockout of TrkA 
and p75 in neurons which can be used to answer questions surrounding the role of NGF in 
pain. In addition to the pain models described above, these transgenic animals can be used for 
a number of different disease models. For example, NGF has been linked to arthritis which can 
be studied using the MIA model of arthritis (Rahman and Dickenson 2015; Sun, Beier, and Pest 
2017). Diabetic polyneuropathy which can be studied using a diabetic mouse model such as 
the streptozotocin- induced diabetes (Shaqura et al. 2014) or investigating the role of p75 in 
suppressing angiogenesis of the retina as seen in diabetes (J. Zhang et al. 2014). Finally, NGF 
has a role in allergic airway hyperresponsiveness which can be studied using an allergic asthma 
model (Chen et al. 2014), in addition to studying neuroimmune interactions such as 
macrophage-neuron interactions. Furthermore, there is the potential to use the NTRK1 fl/fl 
and NGFR fl/fl mouse lines in combination with other Cre lines in the future. Feil et al, 
describes a list of commercially available Cre mouse lines currently available, however few of 
them are CreERT2 and therefore tamoxifen controlled, but as the LoxP/Cre system is being 
more and more recognised as a powerful tool for creating transgenic mouse lines more 
conditional Cre lines will be produced with time (S. Feil, Valtcheva, and Feil 2009). It might be 
possible in the future to generate more inducible knockout mice for TrkA or p75 targeted to 
other cells of interest, for example astrocytes, oligodendrocytes or Schwann cells (S. Feil, 
Valtcheva, and Feil 2009). Similarly, by crossing the NTRK1 fl/fl and NGFR fl/fl mouse lines with 
each other it is possible to generate a double knockout mouse to investigate complete 
knockout of NGF signalling. 
Preclinical studies and phase II and III clinical trials relating pain and NGF have been highly 
effective in the reduction of pain. The use of the anti-NGF monoclonal antibody tanezumab in 
osteoarthritis for example has been shown to result in more than a 30% reduction in pain 




compound which produces a significant reduction in pain (Lane et al. 2010). Anti-NGF 
therapies are thought to be a potent novel therapy against pain which outperforms current 
pain treatments without having the harmful side effects that have been observed with current 
treatments, such as addiction to opioid treatments. However, as previously described (chapter 
1.5) clinical trials with monoclonal anti-NGF antibodies potentially serious side effects, such as 
osteonecrosis, have been observed leading to a hold of these clinical trials from 2012 until 
2016 when they recommenced after the potential causes of the side effects were uncovered. 
The FDA hold on anti-NGF (Hertz and Fields 2012; Holmes 2012) has delayed the progression 
of this novel treatment, however, the positive effects cannot be denied and it underpins a 
need for further investigation of NGF as a key player in pain. This study contributes to these 
investigations by developing a conditional and inducible knockout model for the TrkA and p75 
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